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Abstract 
Medicinal inorganic chemistry is a vibrant offspring research area of bioinorganic chemistry-
an interface between inorganic chemistry (coordination chemistry, organometallics and 
reaction mechanism) and medicine discipHnes. There is tremendous development in the field 
of bioinorganic medicinal chemistry both in terms of classes of compounds studied as well as 
breadth of applications in hurrian medicine ranging from potent therapeutics against cancer, 
HIV, and malaria, antibiotics and diagnostic agents aS/adiopharmaceuticaIs. After 44 years of 
Bamett Rosenberg's v, discjDvery of cis-diammin'edichloroplatinum(ll), cisplatin- an 
archetypical inorganic antitliiTiioi';'dr-«g! clinically'in use for treating solid malignancies (viz., 
ovarian, testicular, head and neck cancers); diagnostic and therapeutic applications of metal 
complexes have significantly expanded beyond the use of platinum complexes in anticancer 
chemotherapy owing to muhifactorial (acquired and intrinsic) resistance and severe toxicity 
issues of platinum complexes. Therefore, the quest for more efficacious non-platinum 
metallo-drugs with less systemic toxicity and tumor resistance has emerged. 
DNA- an inherently chiral molecule is the most likely molecular receptor for most of the 
cancer chemotherapeutic agents; many metal complexes exert their antitumor effects through 
binding to DNA. In order to understand the mechanism of action of DNA targeting drugs, the 
investigation of interaction of DNA with complexes becomes mandatory. Since, single 
enantiopure drugs have proven to be better drug candidates by exhibiting fewer side effects, 
are safer and more potent than the racemate drugs. Therefore, much attention is paid to design 
and construction of chiral metal complexes as they play a profound role in their interactions 
with DNA as they have the potential to demonstrate both enantioselectivity and 
stereoselectivity with their chiral target-DNA at the molecular level. Among the various 
features governing the binding modes with DNA (covalently or non-covalently by 
intercalation, groove binding or external electrostatic binding), the most significant is the 
"molecular shape" of the interacting metal complex, in addition to ligand modifications in 
geometry, size, hydrophobicity, planarity and hydrogen bonding interaction which leads to 
subtle or to spectacular changes in the binding modes, binding affinity and to a different 
cleavage effect. A large number of transition metal complexes because of their redox 
properties, have been found to promote DNA cleavage which is an outstanding criteria for the 
development of metallo-drugs as chemotherapeutic agents. 
The pharmacological efficacy of metal complexes depends on the nature of the metal ions and 
the ligands. For the inorganic compounds, the metal serves as structural center for organizing 
the organic ligands in the biologically relevant chemical space while the ligand framework 
plays significant role in metal-based pharmaceuticals via alteration in the biological 
properties by modifying reactivity or substitution inertness. Moreover, the ligands can modify 
the harmful effects of metal ion overload, inhibit selected metallo-enzymes or facilitate 
systemic bioavailability of metal ions and can assist in targeting specific tissues or enzymes. 
In confinuation to the previous studies in our laboratory to identify novel metal-based cancer 
chemotherapeutic agents, we have employed de novo synthetic strategy to design new 
asymmetric chemical entities derived from biologically active ligand motifs {viz., bis-
benzimidazole derived moiety, amino acids, peptides and penicillamine), along with ancillary 
ligands (viz., 1,10-phenanthroline, picolinic acid) with Cu(II) and Zn(ll) metal ions. Cu(ll) 
and Zn(ll) are endogenous biocompatible metal ions known for their essential role in 
biological system and exhibit less toxicity than non-essential metals such as platinum. The 
complexes synthesized have been well-characterized and show distinctive features- i) display 
outstanding DNA binding capabilities, ii) are specific-target oriented, iii) exhibit efficient 
cleavage activity via oxidative or hydrolytic pathway, iv) exhibit reduced toxic effects, v) 
exhibit Topo-I inhibition at low i^M concentrations and vi) display good cytotoxic activity. 
The in vitro DNA binding studies with CT DNA were carried out by employing UV-vis, 
fluorescence titrations, viscosity and circular dichroism measurements. The DNA cleaving 
ability of these complexes was investigated by agarose gel electrophoretic assay using 
supercoiled pBR322 plasmid DNA as a substrate in a medium of 5 mM Tris-HCl/50 mM 
NaCl buffer (pH 7.2) in absence and presence of any external agents. 
The relevance of amino acids lies in their biological importance, not only as they form the 
building block of peptides and proteins but also cellular tissues in fluid in living organism 
which contains a reservoir of free amino acids. Chapter III A involves the synthesis of chiral 
dinuclear zinc(II) drug entities derived from H2bzimed and L-forms of amino acids (viz., 
tryptophan, leucine and valine). The complexes were characterized by spectroscopy (IR, 'H 
and '^ C NMR, UV-vis, ESl-MS), elemental analysis, polarimetry and molar conductance. 
The [a]D values of +122.70, +101.83 and +187.41 of complexes [C27H26N80i,Zn2], 
[C22H27N70iiZn2] and [C2iH25N70iiZn2] respectively, indicated their chiral nature. To 
evaluate the biological preference of asymmetric drug candidates for ultimate target DNA, 
interaction of complexes [C27H26N80iiZn2], [C22H27N70i]Zn2] and [C2iH25N70iiZn2] with 
CT DNA in Tris-HCl buffer was studied by various biophysical techniques, which revealed 
that complexes bind to DNA non-covalently via electrostatic interaction. The higher intrinsic 
binding constant, Kb value of [C27H26NgOnZn2], suggested its greater DNA binding 
propensity. The Kjv value of complexes [C27H26N80uZn2], [C22H27N70iiZn2] and 
[C2iH25N70iiZn2] was found to be 0.48, 0.33 and 0.22, respectively. Further, to evaluate the 
mode of action at the molecular level, interaction studies of [C27H26N80iiZn2] and 
[C22H27N70iiZn2] with 5'-GMP and 5'-TMP were carried out by UV-vis titrations, ' H and 
P NMR which implicates the preferential selectivity of these complexes to N3 of thymine 
rather than N7 of guanine. The DNA cleavage activity of [C27H26N80iiZn2] with pBR322 
plasmid DNA in presence of increasing concentrations of complex showed an efficient 
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cleavage revealing the conversion of supercoiled form (Form 1) to open circular form (Form 
II) in the absence of any redox agents. The complex [C27H26N80iiZn2] in the presence of 
radical scavangers followed a discernible hydrolytic cleavage pathway. In vitro biological 
screening of [C27H26N80iiZn2] for antibacterial activity tested against two Gram-positive [S. 
aureus (ATCC 25923), B. subtilis (MTCC 121)] and two Gram-negative [E .coli (ATCC 
25922), P. aeruginosa (ATCC 27853)] bacterial strains revealed good antibacterial activity. 
Chapter III B describes the synthesis of the structural analogues of Cu(II) complexes of 
H2bzimed (tetranuclear complex, [C64H60N18O26CI2CU4]) and with the L-enantiomers of 
amino acids {viz., tryptophan and valine) {[C27H26N8O11CU2] and [C21H25N7O11CU2]}. The in 
vitro DNA binding studies of [C64H60N18O26CI2CU4] and [C27H26N8O11CU2] were carried out 
to evaluate the differences in the attributes of tetranuclear and dinuclear Cu(ll) complexes. A 
strong 'hyperchromic effect' was observed in the UV-vis spectra of complexes upon 
increasing concentrations of CT DNA with no change in the position of the intraligand band 
revealing groove binding interactions. The Kb values suggested that [C64H60N18O26CI2CU4] 
binds more strongly to CT DNA as compared to [C27H26N8O11CU2] and [C21H25N7O11CU2], 
which could be attributed to the presence of maximum number of -OH groups (of four 
H2bzimed moieties) and as the double helical DNA possess many hydrogen binding sites; 
accessible both in the minor and major grooves, it is likely that the -OH group of 
[C64H60N18O26CI2CU4] forms extensive hydrogen bonding with DNA. The Stem-Volmer 
quenching constant, Ksv for [C64H60N18O26CI2CU4], [C27H26N8O11CU2] and [C2iH25N70nCu2] 
were found to be 1.92, 0.72 and 0.36, respectively and were in agreement with the order of the 
DNA binding propensities. The complex [C64H6oNig026Cl2Cu4] cleaved pBR322 DNA via 
hydrolytic pathway (further validated by T4 ligase assay), accessible to major groove while 
the cleavage by [C27H26N80nCu2] followed an oxidative mechanism, binding to minor 
groove of DNA double helix. Topo-I inhibitors interfere with the action of topoisomerase 
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enzyme, that control the changes in DNA structure by catalyzing the breaking and rejoining of 
the phosphodiester backbone of DNA strands during the normal cell cycle. Topo-I inhibitory 
effect of [C64H60N18O26CI2CU4] and [C27H26N8O11CU2] was investigated by gel electrophoresis 
revealing that both complexes exhibit good Topo-I inhibition activity but at different 
concentrations; 20 and 25 |j.M, respectively. These binding events were further validated by 
molecular docking studies with DNA and Topo-I. [C64H60N18O26CI2CU4], [C27H26N8O11CU2] 
and [C21H25N7O11CU2] were evaluated for in vitro antibacterial activity exhibiting specific 
activity against various genetically characterized bacterial strains. Among the complexes 
screened, the [C27H26N8O11CU2] was found as the most effective complex against Gram-(+) 
bacteria (5. aureus) whereas [C64H60N18O26CI2CU4] and [C21H25N7OHCU2] were found to 
demonstrate substantial activity against Gram-{-) bacteria (E. coli). 
Metal complexes of peptides are gaining importance as they are basic structural units of 
proteins capable of specific recognition of DNA base sequence. However, peptides can 
behave as carrier molecules for the delivery of drugs to the target site. In this regard. Chapter 
IV, incorporates tetrapeptide ligands, Pro-Gly-Pro-Gly/Pro-Leu-Pro-Leu and their Cu(II) 
and Zn(II) complexes [C14H22N4O6CU], [Ci4H22N406Zn], [C22H3SN4O6CU] and 
[C22H38N406Zn] were synthesized and thoroughly characterized by various spectroscopic 
techniques viz., NMR, EPR, ESI-MS, XRD, molar conductance and elemental analysis. The 
chiral nature of [C14H22N4O6CU], [Ci4H22N406Zn], [C22H38N4O6CU] and [C22H38N406Zn] was 
established by [ajo values of-68.2, -59.9, -82.4 and -79.6 for, respectively To confirm the 
stability of tetrapeptide complexes, solution stability studies of Cu(II) complexes over a pH 
range 2-12 at d-d band were carried out which revealed no change in absorption or intensity 
of bands. In vitro DNA binding studies revealed that complexes bind more avidly to the DNA 
in comparison to free ligands, preferentially via groove binding mode. The observed Kb 
values revealed that both Cu(II) complexes [C14H22N4O6CU] and [C22H38N4O6CU] exhibited 
greater binding propensity than Zn(II) complexes [Ci4H22N406Zn] and [C22H3gN406Zn], 
however, steric constraints in the leucine complexes ([C22H38N4O6CU] and [C22H38N406Zn]) 
account for lower DNA binding affinity than glycine analogues ([C14H22N4O6CU], 
[Ci4H22N406Zn]). To compare the binding affinity for nucleotides, UV-vis titrations and 
NMR interaction studies of [C14H22N4O6CU] and [Ci4H22N406Zn] with 5'-GMP and 5'-TMP 
were carried out. The Kb values suggested greater binding affinity of Cu(II) complex to N7 of 
5'-GMP than 5'-TMP, while the Zn(Il) complex binds preferably to 5'-TMP than 5'-GMP, 
through its N3 nitrogen. A gradual enhancement in the fluorescence intensity of the 
complexes with no apparent change in the shape and position of the emission bands was 
observed. However, the steady-state emission quenching experiments using [Fe(CN)6]''~ 
resulted in the decrease in emission intensity. The DNA cleavage activity of [C14H22N4O6CU] 
and [Ci4H22N406Zn] demonstrated that both the complexes displayed efficient cleavage 
activity of pBR322 DNA, but with striking differences in their mechanism; Cu(II) complex 
cleaved DNA through oxidative mechanism while Zn(II) complex followed hydrolytic 
pathway which was further confirmed by T4 DNA ligase assay. Nevertheless, both the 
complexes bind in the minor groove of the DNA double helix. The in vitro cytotoxic activity 
of [C14H22N4O6CU] and [Ci4H22N406Zn] in terms of IC50 values were screened against three 
human carcinoma cell lines of different histological origin by MTT assay; MDA-MB 231 
(breast adenocarcinoma), A375 (malignant melanoma) and HCT116 (colon carcinoma) and 
were compared to cisplatin. The Cu(ll) complex [C14H22N4O6CU] exhibited good cytotoxicity 
against A375 and HCTl 16 cancer cell lines as compared to Zn(II) complex [Ci4H22N406Zn]. 
The chirality of the complex is generally a prerequisite criterion for an appropriate drug 
design, as the two enantiomers of the same metal complex have different binding constants 
and recognition properties. The effect of the configuration of one or more chiral stereocenters 
on DNA binding has been crucial for the development of new drug entities. Those complexes 
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that best fit against the helical structure of DNA, display the highest binding affinity for DNA. 
Chapter V describes the synthesis, characterization and biological preference of enantiomeric 
pairs {(L) and (D)-[Ci9H2iN304SZn]} of Zn(II) complexes derived from penicillamine and 
ancillary ligand, 1,10-phenanthroline. These complexes were characterized by various 
spectroscopic techniques (NMR, IR, ESI-MS), elemental analysis, molar conductance and 
polarimetiy. Complexes (L) and (D)-[Ci9H2iN304SZn] displayed [a]D values of-52 and +31, 
respectively. Interaction studies of enantiomeric complexes with CT DNA, revealed 
electrostatic binding mode of interaction via external contact (surface binding) with the DNA 
duplex. The Kb values and the percent hyperchromism 6.7 x 10'' M ' and 39% in (L)-
[C,9H2iN304SZn] and 2.6 x 10^  M"' and 26% in (D)-[C,9H2iN304SZn] clearly attenuated the 
differences in binding of two enantiomeric forms. This has been attributed to hypothesis 
supported by the literature reports that the L-form of the Zn(II) complex interacts with right 
handed B-DNA forming a two-pole complementary complex compatible to its molecular 
symmetry and therefore, exhibits stronger electrostatic interactions additionally via hydrogen 
bonding. The UV-vis and NMR interaction studies with 5'-GMP and 5'-TMP suggested 
electrostatic mode of binding with the oxygen of the negatively charged surface phosphate 
group of the DNA helix. Kb values suggested greater binding of Zn(ll) complexes with 5'-
TMP rather than 5'-GMP clearly indicating that zinc specifically binds to 5'-TMP through its 
N3 nitrogen. Further, both the enantiomeric complexes of (L) and (D)-|Ci9H2iN304SZn] 
upon binding to CT DNA showed opposite spectral changes in CD spectrum, attributed to the 
different matching between the structure of complexes and the DNA. The DNA cleavage 
activity of (L) and (D)-[Ci9H2iN304SZn] revealed a distinct pattern of cleavage 
discriminating clearly the DNA cleavage activity by L- and D-enantiomers of the complex. 
L-enantiomer cleaves pBR322 DNA with higher efficiency to convert Form I into Form II 
completely. To explore the mechanistic pathway of the cleavage activity, comparative DNA 
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cleavage experiments of (L)- and (D)-[Ci9H2iN304SZn] were carried out in presence of 
radical oxygen species suggesting a hydrolytic pathway for both the complexes which was 
further validated by T4 DNA religation assays. The comparative molecular docking studies of 
(L) and (D)-[Ci9H2iN304SZn] with DNA was also carried out and the resulting binding 
energy of docked metal complexes was found to be -306.4, and -289.1 KJmol ', respectively. 
The more negative the relative binding energy, greater the DNA binding propensity. 
In Chapter VI, novel Cu(II) and Ni(II) complexes derived from L/D-histidine with picolinic 
acid were synthesized and characterized. Ni(II) analogues were synthesized only for NMR 
structure elucidation. In vitro DNA binding studies of enantiomeric pairs of Cu(II) complexes 
were carried out which revealed an electrostatic binding mode. The Kb value of (L) 
[C12H14N4O5CU], 5.6 X 10'' M~' was 5-fold higher in magnitude in comparison to (D)-
[C]2Hi4N405Cu], 9.8 X 10^  M~ which clearly authenticates stronger binding propensity of L-
form of the complex. To ascertain the base specific interaction of the complexes, the 
interaction studies of (L) and (D)-[Ci2Hi4N405Cu] with 5'-GMP were carried out, revealing 
specific binding to N7 of guanine. The DNA cleavage activity of (L)-|Ci2Hi4N405Cu] 
revealed an oxidative cleavage pathway. The molecular docking studies of (L)-
[C12H14N4O5CU] with B-DNA further confirmed that the minor groove was the preferred 
target site. Furthermore, the antibacterial activity of (L) and (D)-[C|2Hi4N40.<;Cu] was carried 
out against two Gram-positive [S. aureus (ATCC 25923), B. subtilis (MTCC 121)] and two 
Gram-negative [E .coli (ATCC 25922), P. aeruginosa (ATCC 27853)] bacterial strains 
compared with reference drug doxycycline, while the antifungal activity against C. albicans 
compared with reference drug nystatin. From these observations, it was concluded that these 
Cu(II) complexes are outstanding antibacterial agents, (L)-form of the complex exhibit 
greater propensity towards DNA, better antibacterial activity as compared to (D)-form, 
therefore can be exploited as a promising anticancer drug candidate. 
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Abstract 
Medicinal inorganic chemistry is a vibrant offspring research area of bioinorganic chemistry-
an interface between inorganic chemistry (coordination chemistry, organometallics and 
reaction mechanism) and medicine discipHnes. There is tremendous development in the field 
of bioinorganic medicinal chemistry both in terms of classes of compounds studied as well as 
breadth of applications in human medicine ranging from potent therapeutics against cancer, 
HIV, and malaria, antibiotics and diagnostic agents as radiopharmaceuticals. After 44 years of 
Bamett Rosenberg's discovery of cis-diamminedichloroplatinum(II), cisplatin- an 
archetypical inorganic antitumor drug clinically in use for treating solid malignancies (viz., 
ovarian, testicular, head and neck cancers); diagnostic and therapeutic applications of metal 
complexes have significantly expanded beyond the use of platinum complexes in anticancer 
chemotherapy owing to multifactorial (acquired and intrinsic) resistance and severe toxicity 
issues of platinum complexes. Therefore, the quest for more efficacious non-platinum 
metallo-drugs with less systemic toxicity and tumor resistance has emerged. 
DNA- an inherently chiral molecule is the most likely molecular receptor for most of the 
cancer chemotherapeutic agents; many metal complexes exert their antitumor effects through 
binding to DNA. In order to understand the mechanism of action of DNA targeting drugs, the 
investigation of interaction of DNA with complexes becomes mandatory. Since, single 
enantiopure drugs have proven to be better drug candidates by exhibiting fewer side effects, 
are safer and more potent than the racemate drugs. Therefore, much attention is paid to design 
and construction of chiral metal complexes as they play a profound role in their interactions 
with DNA as they have the potential to demonstrate both enantioselectivity and 
stereoselectivity with their chiral target-DNA at the molecular level. Among the various 
features governing the binding modes with DNA (covalently or non-covalently by 
intercalation, groove binding or external electrostatic binding), the most significant is the 
"molecular shape" of the interacting metal complex, in addition to ligand modifications in 
geometry, size, hydrophobicity, planarity and hydrogen bonding interaction which leads to 
subtle or to spectacular changes in the binding modes, binding affinity and to a different 
cleavage effect. A large number of transition metal complexes because of their redox 
properties, have been found to promote DNA cleavage which is an outstanding criteria for the 
development of metallo-drugs as chemotherapeutic agents. 
The pharmacological efficacy of metal complexes depends on the nature of the metal ions and 
the ligands. For the inorganic compounds, the metal serves as structural center for organizing 
the organic ligands in the biologically relevant chemical space while the ligand framework 
plays significant role in metal-based pharmaceuticals via alteration in the biological 
properties by modifying reactivity or substitution inertness. Moreover, the ligands can modify 
the harmful effects of metal ion overload, inhibit selected metallo-enzymes or facilitate 
systemic bioavailability of metal ions and can assist in targeting specific tissues or enzymes. 
In continuation to the previous studies in our laboratory to identify novel metal-based cancer 
chemotherapeutic agents, we have employed de novo synthetic strategy to design new 
asymmetric chemical entities derived from biologically active ligand motifs {viz., bis-
benzimidazole derived moiety, amino acids, peptides and penicillamine), along with ancillary 
ligands {viz., 1,10-phenanthroline, picolinic acid) with Cu(II) and Zn(II) metal ions. Cu(II) 
and Zn(II) are endogenous biocompatible metal ions known for their essential role in 
biological system and exhibit less toxicity than non-essential metals such as platinum. The 
complexes synthesized have been well-characterized and show distinctive features- i) display 
outstanding DNA binding capabilities, ii) are specific-target oriented, iii) exhibit efficient 
cleavage activity via oxidative or hydrolytic pathway, iv) exhibit reduced toxic effects, v) 
exhibit Topo-I inhibition at low |iM concentrations and vi) display good cytotoxic acfivity. 
The in vitro DNA binding studies with CT DNA were carried out by employing UV-vis, 
fluorescence titrations, viscosity and circular dichroism measurements. The DNA cleaving 
ability of these complexes was investigated by agarose gel electrophoretic assay using 
supercoiled pBR322 plasmid DNA as a substrate in a medium of 5 mM Tris-HCl/50 mM 
NaCl buffer (pH 7.2) in absence and presence of any external agents. 
The relevance of amino acids lies in their biological importance, not only as they form the 
building block of peptides and proteins but also cellular tissues in fluid in living organism 
which contains a reservoir of free amino acids. Chapter III A involves the synthesis of chiral 
dinuclear zinc(II) drug entities derived from H2bzimed and L-forms of amino acids {viz., 
tryptophan, leucine and valine). The complexes were characterized by spectroscopy (IR, ' H 
and '"C NMR, UV-vis, ESI-MS), elemental analysis, polarimetry and molar conductance. 
The [a]D values of +122.70, +101.83 and +187.41 of complexes [C27H26NgOiiZn2], 
[C22H27N70iiZn2] and [C2iH25N70uZn2] respectively, indicated their chiral nature. To 
evaluate the biological preference of asymmetric drug candidates for ultimate target DNA, 
interaction of complexes [C27H26N80iiZn2], [C22H27N70iiZn2] and [C2iH25N70nZn2] with 
CT DNA in Tris-HCl buffer was studied by various biophysical techniques, which revealed 
that complexes bind to DNA non-covalently via electrostatic interaction, l^ he higher intrinsic 
binding constant, Kb value of [C27H26N8C)nZn2], suggested its greater DNA binding 
propensity. The Ksv value of complexes [C27H26N80i)Zn2], [C22H27N70iiZn2] and 
[C2iH25N70i]Zn2] was found to be 0.48, 0.33 and 0.22, respectively. Further, to evaluate the 
mode of action at the molecular level, interaction studies of [C27H26N80iiZn2] and 
[C22H27N70iiZn2] with 5'-GMP and 5'-TMP were carried out by UV-vis titrations, ' H and 
^'P NMR which implicates the preferential selectivity of these complexes to N3 of thymine 
rather than N7 of guanine. The DNA cleavage activity of [C27H26N80iiZn2] with pBR322 
plasmid DNA in presence of increasing concentrations of complex showed an efficient 
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cleavage revealing the conversion of supercoiled form (Form I) to open circular form (Form 
II) in the absence of any redox agents. The complex [C27H26N80iiZn2] in the presence of 
radical scavangers followed a discernible hydrolytic cleavage pathway. In vitro biological 
screening of [C27H26N80iiZn2] for antibacterial activity tested against two Gram-positive [S. 
aureus (ATCC 25923), B. subtilis (MTCC 121)] and two Gram-negative [E .coli (ATCC 
25922), P. aeruginosa (ATCC 27853)] bacterial strains revealed good antibacterial activity. 
Chapter III B describes the synthesis of the structural analogues of Cu(II) complexes of 
H2bzimed (tetranuclear complex, [C64H60N18O26CI2CU4]) and with the L-enantiomers of 
amino acids {viz., tryptophan and valine) ([C27H26N8O11CU2] and [C21H25N7O11CU2]}. The in 
vitro DNA binding studies of [C64H60N18O26CI2CU4] and [C27H26N8O11CU2] were carried out 
to evaluate the differences in the attributes of tetranuclear and dinuclear Cu(ll) complexes. A 
strong 'hyperchromic effect' was observed in the UV-vis spectra of complexes upon 
increasing concentrations of CT DNA with no change in the position of the intraligand band 
revealing groove binding interactions. The Kb values suggested that [C64H60N18O26CI2CU4] 
binds more strongly to CT DNA as compared to [C27H26N8O11CU2] and [C21H25N7O11CU2], 
which could be attributed to the presence of maximum number of -OH groups (of four 
H2bzimed moieties) and as the double helical DNA possess many hydrogen binding sites; 
accessible both in the minor and major grooves, it is likely that the -OH group of 
[C64H60N18O26CI2CU4] forms extensive hydrogen bonding with DNA. The Stem-Volmer 
quenching constant, Ksv for [C64H60N18O26CI2CU4], [C27H26N8O11CU2] and [C21H25N7O11CU2] 
were found to be 1.92, 0.72 and 0.36, respectively and were in agreement with the order of the 
DNA binding propensities. The complex [C64H60N18O26CI2CU4] cleaved pBR322 DNA via 
hydrolytic pathway (further validated by T4 ligase assay), accessible to major groove while 
the cleavage by [C27H26N8O11CU2] followed an oxidative mechanism, binding to minor 
groove of DNA double helix. Topo-I inhibitors interfere with the action of topoisomerase 
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enzyme, that control the changes in DNA structure by catalyzing the breaking and rejoining of 
the phosphodiester backbone of DNA strands during the normal cell cycle. Topo-I inhibitory 
effect of [C64H6oNis026C]2Cu4] and [C27H26NgOiiCu2] was investigated by gel electrophoresis 
revealing that both complexes exhibit good Topo-I inhibition activity but at different 
concentrations; 20 and 25 |xM, respectively. These binding events were further validated by 
molecular docking studies with DNA and Topa-I. [C64H60N18O26CI2CU4], [C27H26NgOiiCu2] 
and [C21H25N7O11CU2] were evaluated for in vitro antibacterial activity exhibiting specific 
activity against various genetically characterized bacterial strains. Among the complexes 
screened, the [C27H26NgO|iCu2] was found as the most effective complex against Gram-(+) 
bacteria (S. aureus) whereas [C64H60N18O26CI2CU4] and [C21H25N7O11CU2] were found to 
demonstrate substantial activity against Gram-(-) bacteria (E. coli). 
Metal complexes of peptides are gaining importance as they are basic structural units of 
proteins capable of specific recognition of DNA base sequence. However, peptides can 
behave as carrier molecules for the delivery of drugs to the target site. In this regard, Chapter 
IV, incorporates tetrapeptide ligands, Pro-Gly-Pro-Gly/Pro-Leu-Pro-Leu and their Cu(II) 
and Zn(II) complexes [C14H22N4O6CU], [Ci4H22N406Zn], [C22H38N4O6CU] and 
[C22H38N406Zn] were synthesized and thoroughly characterized by various spectroscopic 
techniques viz., NMR, EPR, ESI-MS, XRD, molar conductance and elemental analysis. The 
chiral nature of [C,4H22N406Cu], [Ci4H22N406Zn], [C22H38N4O6CU] and [C22H38N406Zn] was 
established by [a]o values of-68.2, -59.9, -82.4 and -79.6 for, respectively. To confirm the 
stability of tetrapeptide complexes, solution stability studies of Cu(II) complexes over a pH 
range 2-12 at d-d band were carried out which revealed no change in absorption or intensity 
of bands. In vitro DNA binding studies revealed that complexes bind more avidly to the DNA 
in comparison to free ligands, preferentially via groove binding mode. The observed Kb 
values revealed that both Cu(n) complexes [C14H22N4O6CU] and [C22H3)jN406Cu] exhibited 
greater binding propensity than Zn(Il) complexes [Ci4H22N406Zn] and [C22H38N406Zn], 
however, steric constraints in the leucine complexes ([C22H38N4O6CU] and [C22H38N406Zn]) 
account for lower DNA binding affinity than glycine analogues ([C14H22N4O6CU], 
[Ci4H22N406Zn]). To compare the binding affinity for nucleotides, UV-vis titrations and 
NMR interaction studies of [C14H22N4O6CU] and [Ci4H22N406Zn] with 5 ' -<JMP and 5'-TMP 
were carried out. The Kb values suggested greater binding affinity of Cu(II) complex to N7 of 
5'-GMP than 5'-TMP, while the Zn(ll) complex binds preferably to 5'-TMP than 5'-GMP, 
through its N3 nitrogen. A gradual enhancement in the fluorescence intensity of the 
complexes with no apparent change in the shape and position of the emission bands was 
observed. However, the steady-state emission quenching experiments using [Fe(CN)6]'*~ 
resulted in the decrease in emission intensity. The DNA cleavage activity of [C14H22N4O6CU] 
and [Ci4H22N406Zn] demonstrated that both the complexes displayed efficient cleavage 
activity of pBR322 DNA, but with striking differences in their mechanism; Cu(II) complex 
cleaved DNA through oxidative mechanism while Zn(II) complex followed hydrolytic 
pathway which was further confirmed by T4 DNA ligase assay. Nevertheless, both the 
complexes bind in the minor groove of the DNA double helix. The in vitro cytotoxic activity 
of [C14H22N4O6CU] and [Ci4H22N406Zn] in terms of IC50 values were screened against three 
human carcinoma cell lines of different histological origin by MTT assay: MDA-MB 231 
(breast adenocarcinoma), A375 (malignant melanoma) and HCT116 (colon carcinoma) and 
were compared to cisplatin. The Cu(Il) complex [C14H22N4O6CU] exhibited good cytotoxicity 
against A375 and HCTl 16 cancer cell lines as compared to Zn(]I) complex [C)4H22N406Zn]. 
The chirality of the complex is generally a prerequisite criterion for an appropriate drug 
design, as the two enantiomers of the same metal complex have different binding constants 
and recognition properties. The effect of the configuration of one or more chiral stereocenters 
on DNA binding has been crucial for the development of new drug entities. Those complexes 
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that best fit against the helical structure of DNA, display the highest binding affinity for DNA. 
Chapter V describes the synthesis, characterization and biological preference of enantiomeric 
pairs {(L) and (D)-[Ci9H2iN304SZn]} of Zn(ri) complexes derived from penicillamine and 
ancillary ligand, 1,10-phenanthroline. These complexes were characterized by various 
spectroscopic techniques (NMR, IR, ESI-MS), elemental analysis, molar conductance and 
polarimetry. Complexes (L) and (D)-[Ci9H2iN304SZn] displayed [ajo values of-52 and +31, 
respectively. Interaction studies of enantiomeric complexes with CT DNA, revealed 
electrostatic binding mode of interaction via external contact (surface binding) with the DNA 
duplex. The Kb values and the percent hyperchromism 6.7 x 10"* M^ and 39% in (L)-
[Ci9H2iN304SZn] and 2.6 x lO" M"' and 26% in (DHCi9H2iN304SZn] clearly attenuated the 
differences in binding of two enantiomeric forms. This has been attributed to hypothesis 
supported by the literature reports that the L-form of the Zn(ll) complex interacts with right 
handed B-DNA forming a two-pole complementary complex compatible to its molecular 
symmetry and therefore, exhibits stronger electrostatic interactions additionally via hydrogen 
bonding. The UV-vis and NMR interaction studies with 5'-GMP and 5'-TMP suggested 
electrostatic mode of binding with the oxygen of the negatively charged surface phosphate 
group of the DNA helix. Kb values suggested greater binding of Zn(Il) complexes with 5'-
TMP rather than 5'-GMP clearly indicating that zinc specifically binds to 5'-TMP through its 
N3 nitrogen. Further, both the enantiomeric complexes of (L) and (D)-[Ci9H2iN304SZn] 
upon binding to CT DNA showed opposite spectral changes in CD spectrum, attributed to the 
different matching between the structure of complexes and the DNA. The DNA cleavage 
activity of (L) and (D)-[Ci9H2iN304SZn] revealed a distinct pattern of cleavage 
discriminating clearly the DNA cleavage activity by L- and D-enantiomers of the complex. 
L-enantiomer cleaves pBR322 DNA with higher efficiency to convert Form I into Form II 
completely. To explore the mechanistic pathway of the cleavage activity, comparative DNA 
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cleavage experiments of (L)- and (D)-[Ci9H2iN304SZn] were carried out in presence of 
radical oxygen species suggesting a hydrolytic pathway for both the complexes which was 
further validated by T4 DNA religation assays. The comparative molecular docking studies of 
(L) and (D)-[Ci9H2iN304SZn] with DNA was also carried out and the resulting binding 
energy of docked metal complexes was found to be -306.4, and -289.1 KJmol" , respectively. 
The more negative the relative binding energy, greater the DNA binding propensity. 
In Chapter VI, novel Cu(II) and Ni(n) complexes derived from L/D-histidine with picolinic 
acid were synthesized and characterized. Ni(II) analogues were synthesized only for NMR 
structure elucidation. In vitro DNA binding studies of enantiomeric pairs of Cu(II) complexes 
were carried out which revealed an electrostatic binding mode. The Kb value of (L) 
[C12H14N4O5CU], 5.6 x lO'' M~' was 5-fold higher in magnitude in comparison to (D)-
[C12H14N4O5CU], 9.8 X 10^  W^ which clearly authenticates stronger binding propensity of L-
form of the complex. To ascertain the base specific interaction of the complexes, the 
interaction studies of (L) and (D)-[Ci2Hi4N405Cu] with 5'-GMP were carried out, revealing 
specific binding to N7 of guanine. The DNA cleavage activity of (L)-[Ci2Hi4N405Cu] 
revealed an oxidative cleavage pathway. The molecular docking studies of (L)-
[C12H14N4O5CU] with B-DNA further confirmed that the minor groove was the preferred 
target site. Furthermore, the antibacterial activity of (L) and (D)-[Ci2Hi4N405Cu] was carried 
out against two Gram-positive [S. aureus (ATCC 25923), B. subtilis (MTCC 121)] and two 
Gram-negative [E .coli (ATCC 25922), P. aeruginosa (ATCC 27853)] bacterial strains 
compared with reference drug doxycycline, while the antifungal activity against C. albicans 
compared with reference drug nystatin. From these observations, it was concluded that these 
Cu(II) complexes are outstanding antibacterial agents, (L)-fonn of the complex exhibit 
greater propensity towards DNA, better antibacterial activity as compared to (D)-form, 
therefore can be exploited as a promising anticancer drug candidate. 
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CHAPTER I 
Introduction 
Introduction 
The serendipitous discovery of archetypical inorganic anticancer drug, cisplatin {cis-
diamminedichloroplatinum(II), [Pt"Cl2(NH3)2]} by Bamett Rosenberg in mid-1960s, opened 
up new prospects in the area of medicinal inorganic chemistry [1]. The impact of the 
discovery of cisplatin was phenomenal, as it not only cured solid cancers but reduced death 
rates considerably. Since its introduction in the clinical practice in 1978, cisplatin is still 
among the most used cancer chemotherapeutic drug for the treatment of a wide spectrum of 
solid malignancies [2-6], particularly for ovarian and testicular cancer (against which it is 
essentially 100% curative if the cancer is detected early). The impact of discovery of cisplatin 
as chemotherapeutic drug entity is not simply limited to cancer chemotherapy but it has 
brought realization that selected transition metal complexes can exhibit potent and selective 
biological activity; therefore they can be explored in the area of medicinal chemistry. 
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Figure 1. Registered platinum drugs. 
Cisplatin and its second generation improved platinum compounds viz., carboplatin, 
oxaliplatin and nedaplatin obey the devised structure-activity relationships for antitumor 
candidates (Figure 1). These rules are that compounds should possess neutral Pt(II) species 
with two amine ligands or one bidentate chelating diamine and two ligands that can be 
replaced by aquation reactions. In recent clinical trials, some new FDA-approved platinum 
compounds; picoplatin (AMD473) and ProLindac (AP5346) obey original rules (Figure 2) 
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Figure 2. Chemical structures of AMD473 and partial chemical structure of APS346, a 
random copolymer conjugated with a DACH-platinum. 
However, the search for efficacious drugs that are devoid of the limitations of platinum 
compounds such as severe side effects, high systemic toxicities (nephrotoxicity, neurotoxicity, 
ototoxicity and emetogenesis [8-10]) and incidence of drug resistance [11] may possibly 
violate these rules. This has provided motivation for the search of non-platinum transition 
metal-based drugs with a wider spectrum of activity and those employing passive and active 
targeting strategies to overcome aspects of drug resistance, enabling the administration of a 
drug lower dose, a pattern of cytotoxicity different from that of cisplatin and active against a 
panel of cell lines originated from different phenotypes. Thus, there is a considerable attention 
focused on the design of new metal-based anticancer agents that exhibit enhanced selectivity 
and modes of DNA interaction like non-covalent interactions that mimic the native 
biomolecular-interactions [12]. So many other novel transition metal complexes as well as 
small molecule based antitumor agents have been developed with ligand scaffold bearing 
functionalities with improved pharmacological properties and a broader range of antitumor 
activity and some of them are under clinical trial [13-15]. 
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Metal complexes are more appealing for the design of cancer chemotherapeutic agents, as 
they display unique electronic and spectroscopic properties, allowing a diverse coordination 
environment that goes beyond the linear (sp-hybridization), trigonal planar (sp^-
hybridization) and tetrahedral (sp^-hybridization) binding geometries of carbon [16]. Besides 
this, metal complexes play an important role in chaperoning and delivery of drugs away from 
the sites where they exert most toxicity and towards their site of action. 
A characteristic feature of metals is that they easily lose electrons from elemental or metallic 
state to form positively charged ions which tend to be soluble in biological fluids. It is in this 
cationic form that metals play their role in biology. Whereas metal ions are electron deficient, 
most biological molecules such as proteins and DNA are electron rich. Therefore, metal 
complexes are especially well suited for DNA interaction because the electropositive metal 
center (strong Lewis acid) is highly attracted to the negatively charged phosphate backbone of 
DNA. Metal centers also serve as unique three-dimensional structural scaffolds, which can be 
adjusted to fit into the base stacks and grooves of targeted DNA sequences [17,18]. Since 
pharmacological target of the antitumor drugs is cellular DNA, N7 atom of the imidazole ring 
of guanine and N3 atom of adenine residues located in the major groove of the double helix, 
the most accessible and reactive nucleophilic sites for binding to DNA. 
A key aspect for using metal-containing compounds as structural scaffolds is the kinetic 
stability of the coordination sphere in the biological environment which is capable of 
controlling both the thermodynamics (state of equilibrium) and kinetics of ligand substitution 
events that can occur in vivo; for example, the aquation of metal-chloride bonds as the 
chloride concentration diminishes from extracellular to intracellular (cytoplasmic and nuclear) 
compartments. On the basis of its number oi" valence d electrons, a metal ion may prefer 
certain binding geometries over others (LFSE preference). For example, the common 
biologically relevant oxidation states of iron are Fe(II) and Fe(III), which prefer octahedral 
and distorted octahedral geometries. Copper, on the other hand, exists primarily as Cu(I) and 
Cu(II), with Cu(II) favoring square planar, square pyramidal or axially distorted octahedral 
geometries due to Jahn-Teller distortions of its d^  electron configuration [19]. 
The term 'chirality' (originated from the Greek word "cheir" meaning "hand") or handedness 
is used to describe the structural property of an object that is non-super imposable on its 
mirror image. Life is a typical chiral system and chiral phenomena are ubiquitous in nature 
from the macroscopic to the molecular level, ordinarily, proteins and DNA wind in right 
handed helixes; left-handed versions are rare and true mirror image versions do not appear in 
nature. Right and left-handed amino acid molecule exists at different energy levels as a result 
of the asymmetric weak nuclear force; those in organisms are almost always left-handed. 
Because of the chirality of its key molecules, human chemistry is highly sensitive to 
enantiomeric differences. Some chiral examples in nature are given in Figure 3. 
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Figure 3. Depiction of enantiomeric pairs. 
The asymmetric I)-ribose and I>-2-deoxyribose units contain several stereogenic centers, 
whose configuration is important in the overall DNA structure [20]. It is well known that 
DNA does not exist in a single three-dimensional structure, but can adopt different 
conformations which are defined both locally and macroscopicaliy by different sfructural 
parameters. The most common DNA conformations are the B- and the A-forms which are 
both right-handed, but differ in the conformation of the sugar (C2'-endo for B-DNA and 
C3'-endo for A-DNA, and in helical parameters). Another conformation, the Z-DNA, has 
attracted much interest, though it is not very common in nature, since it is a left-handed 
structure and thus represents a good example of how the DNA conformation (and thus the 
helix handedness) can be influenced also by external constraints (Figure 4) [21]. 
(a) BONA (b) A DNA (c) ZONA 
Figure 4. Different conformational forms of DNA. 
The overall handedness of the DNA molecule plays a major role in the recognition of DNA 
by chiral molecules and indeed, DNA can be considered in some cases as a very efficient 
chiral selector. The B-DNA double helical structure is shown in Figure 5. The two strands of 
the double helix are anti-parallel, which means that they run in opposite directions and are 
held together by hydrogen bonding between bases on opposite strands: the most common 
"base-pairing" scheme (Watson-Crick base pairing) involves G-C and A-T purine-
pyrimidine inter-strand pairs. The overall stability of the double-helical arrangement is 
further supported by n-n interactions between the stacked hydrophobic aromatic rings of 
adjacent bases on the polynucleotide chains [22]. The sugar-phosphate backbone is on the 
outside of the helix, and the bases are on the inside. The backbone can be thought of as the 
sides of a ladder, whereas the bases in the middle form the rungs of the ladder. 
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Figure 5. DNA double helix structure. 
Significant efforts have been focused on developing new synthetic molecules that can bind to 
DNA and influence its activity, with the goals of controlling DNA processing, creating new 
therapeutics or diagnostics and to enhance our fundamental understanding of DNA molecular 
recognition [23,24]. It has been demonstrated that DNA-recognition by synthetic agents can 
essentially occur by covalent binding or metal-coordination (cisplatin based drugs are the best 
developed examples) [1,2-6], groove binding recognition [25,26], which involve direct 
interactions of the bound molecule with the edges of base pair in either major (G-C) or minor 
(A-T) grooves of DNA, intercalation of planar molecules in between base pairs [27,28] and 
sugar-phosphate backbone binding [29,30] (Figure 6). <?-
(c) 
>v 
Figure 6. Various modes of interaction with DMA (a) covalent binding (cisplatin) (b) minor 
groove binding (netropsin) and (c) intercalation (actinomycin D). 
Most important advances of last millennium in the pharmacological areas were the proven 
efficacy of chiral or enantiopure drugs as the introduction of chirality not only enforces 
stereoselective specific drug interaction but also promotes the formation of active compounds 
with therapeutic benefit, as most of the biotargets of drugs {viz., DNA, RNA, proteins, etc.) 
are chiral in nature. In pharmacology, chirality is an important factor in drug efficacy. Single 
enantiopure drugs have proven to be better drugs which exhibit fewer side effects, are safer 
and more potent than the racemate drugs [31]. One enantiomer may influence desirable 
physiological, pharmacological, pharmacodynamics, and pharmacokinetic properties while 
other enantiomers often exhibit a very different physiological role, different interactions with 
living organisms, and different activity in chemical and biotechnological processes. 
Furthermore, the debate "racemate-versus-enantiomer" has opened a new market strategy, 
the so called racemic switch. A racemic switch stands for the development in single-
enantiomer form of a drug that was first approved as a racemate. Some potential benefits of 
single enantiomeric drugs are; i) reduced dose and load on metabolism, ii) broader 
applicability of drug, iii) increased specificity and reduced side effects for one enantiomer and 
iv) enhanced activity. For these reasons, the enantiomeric purity of various compounds is 
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important in stereo-specific synthesis, production of pharmaceuticals, pesticides, and some 
food additives, where only one enantiomer may interact satisfactorily. 
An early use of a chiral compound to cure a disease is the case of Vitamin C (ascorbic acid). 
Of the four possible stereoisomeric forms of ascorbic acid only the form identical to natural 
Vitamin C, (+)-ascorbic acid, has the same anti-ascorbutic activity [32], although all of the 
diastereomers show the same strong anti-oxidant properties (Figure 7). Dijffering biological 
effects of ascorbic acid enantiomers and diastereomers have also been shown on the growth of 
human leukemia cells [33]. 
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Figure 7. The (a) enantiomers and (b) diastereomers of ascorbic acid. 
Other examples of enantiomeric drugs are (S)-Ibuprofen and (S)-ketoprofen widely for the 
treatment of inflammatory diseases (rheumatoid arthritis, as both analgesics and antipyretics) 
(Figure 8). However, the racemates are responsible for many adverse reactions affecting a 
range of organs, including the gastrointestinal tract, kidney, bone marrow, respiratory and 
liver systems. The activities of the two enantiomers of Ibuprofen and ketoprofen are 
essentially indistinguishable in vivo, owing to a unidirectional metabolic bioconversion of the 
(R)-enantiomers to (S)-enantiomers [34]. 
OH 
(S)-ibuprofen {S)-Ketoprofen 
Figure 8. Chiral switch drugs ofracemates. 
A number of other examples of new stereochemically pure drugs patented in the last years are 
shown in Figure 9. 
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Figure 9. Chemical structures of some stereochemically pure drugs patented as single 
enantiomers. 
In a pursuit to discriminate the behavior of different enantiomers towards the ultimate 
biological target for most of the chemotherapeutlc drugs i.e. DNA, we have undertaken in our 
laboratory many experiments on chiral metal-based compounds to evaluate their potential to 
act as potent and more efficacious drug entities [35-37]. For example, synthetic design and 
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enantiomeric DNA binding profile of (R)- and (S)- enantiomeric complexes of Cu(II)/Zn(II)-
2-amino-3-(((l-hydroxy propan-2-yl)imino) methyl)-4H-chromen-4-one were carried out 
[38]. In vitro DNA binding studies revealed that these complexes are avid DNA binding 
agents; thereby, they can act as potent chemotherapeutics. However, the (R)- and (S)-
enantiomers exhibit distinctively different binding affinity with DNA that reflects that one of 
the enantiomers, (R)-form, is biologically more active than the other. Notably, (R)-form 
exhibited higher binding affinity than the (S)-form toward CT DNA, clearly attenuating the 
profound influence of chirality of the complexes on the DNA. 
Similarly in an another attempt, specific interaction of chiral complexes of late 3d transition 
metal complexes (Co, Cu and Zn) 1-3 (a and b) derived from (lR,2R)-(2)-l,2-DACH) 
{DACH = diaminocyclohexane} and L- and D-tryptophan with CT DNA and 
mononucleofides was studied (Figure 10) [39]. 
H H 
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Figure 10. Proposed structure of the complexes 1-3 (a andb). 
Two different enantiomers bind to DNA by a similar non-covalent electrostatic mode. 
However, the extent of interaction is different which outlines the effect of chirality (as the 
intrinsic binding constant, Kb values of L-enantiomer suggested that L- form exhibited higher 
DNA binding propensity as compared to D-enantiomeric analogs). As L-form of these metal 
complexes shows greater binding affinity with DNA, antitumor activity has been evaluated 
with L- form of complexes l-3a. In vitro anticancer activity of complexes were screened 
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against 14 different human carcinoma cell lines of different histological origin using SRB 
assay: MIA PaCa-2 (pancreatic), MCF-7, ZR-75-1 (breast), SiHa (uterine cervix), Colo205 
(colon), HOP-62, A549 (lung), DWD (oral), K562 (leukemia), DU145 (prostate), A498 (renal 
cell), A2780 (ovary), T24 (urinary bladder), and PC-3 (prostrate). The results revealed that 
complex 2a demonstrated better selectivity for certain phenotypes of human cancer cell lines 
as compared to la and 3a, showing a GI50 value of 43 in A549, GI50 value of 21 in MIA 
PaCa-2 (Table 1). 
Table 1. Cytotoxicity against different tumor cells in terms ofGI^o (in fig/ml) value. 
Complex 
la 
2a 
3a 
G-ADR 
Hop62 
>80 
>80 
>80 
10 
A549 
38 
43 
>80 
<10 
PCS 
72 
37 
60 
<10 
DU145 
>80 
>80 
>80 
<10 
A498 
>80 
>80 
>80 
<10 
DWD 
>80 
30 
51 
<10 
C0I0205 
>80 
>80 
23 
<10 
Hr29 
>80 
>80 
>S0 
<10 
1^ 4 
>80 
>80 
69 
<10 
ML\PaCa-2 
47 
21 
>80 
<10 
MCF7 
>80 
>80 
47 
<10 
ZR-75-1 
>80 
>80 
>80 
<10 
SiHa 
>80 
29 
>80 
<10 
A278<j 
>80 
>80 
>80 
<10 
GIso = Growth inhibition of 50% (GI50) calculated from [(Ti-Tz)/(C-Tz) x 100 = 50, drug 
concentration resulting in a 50% reduction in the net protein increase. Gho < 10 (jig/ml) is 
considered to demonstrate activity. G-ADR = G-Adriamycin (taken as positive control). 
Chiral molecules therefore, play a critical role in the exploitation of three-dimensional space 
at the target site and regulate stereoselectivity in a highly organized fashion and were assumed 
to be therapeutically active as most of the biotargets of drugs are chiral in nature [40]. 
Therefore, much attention is paid to design and construction of chiral molecules which are i) 
versatile to occupy the active site, ii) possess metal-binding domain and iii) have bioactive 
organic functionality (pharmacophore) which pre-orients the molecule as drug entity by 
reducing the toxicity parameters. 
A novel DNA binding metal complex with good anticancer activity and clinical efficacy must 
fulfill the following key criteria i) good intrinsic properties, including saline solubility and 
enough stability to arrive intact at the cellular target ii) efficient DNA binding properties iii) 
efficient transport in blood and through membranes iv) the ability to differentiate between 
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cancerous and normal cells v) activity against tumors that are, or have become resistant to 
cisplatin and its second generation derivatives. 
Copper is found in all living organisms and is crucial trace element in the redox chemistry, 
growth and development [41-43]. It is important for the function of several enzymes and 
proteins involved in energy metabolism, respiration and DNA synthesis, notably cytochrome 
oxidase, superoxide dismutase, ascorbate oxidase and tyrosinase. Among the essential metal 
ions in the human body, Cu(II) is third in abundance after Fe(III) and Zn(ll) and it has been 
regarded as a 'modem bio-element' by Kaim [44], Ochiai [45] and Williams. Copper exhibits 
considerable biochemical action either as an essential trace metal bound to ceruloplasmin, 
albumin and other proteins, or as a constituent of various exogenously administered 
compounds in humans where it is bound to ligands of various types forming complexes that 
interact with biomolecules, mainly proteins and nucleic acids. The multifaceted role of copper 
in biological systems is demonstrated by several studies. In particular the involvement of 
copper in human diseases has been described from a medicinal-chemical [42] and a 
biochemical point of view focusing on the molecular physiology of Cu transport [46]. 
Current interest in copper complexes is stemming from their potential use as antimicrobial, 
antiviral, anti-inflammatory, antitumor agents, enzyme inhibitors or chemical nucleases. As 
any essential metal that escapes its normal metabolic pathways can be toxic to the organism, 
copper complexes may serve as effective cytotoxic agents [47]. Copper compounds are likely 
to have mechanism of action, bio-distribution and toxicity, which are different from those of 
currently used platinum drugs and might be effective, at least in principle, against human 
cancers that are poor chemosensitive or have become resistant to conventional platinum 
drugs. 
It has been established that copper ion chelation plays a definite role in the biological activity 
of most of the selected organic ligands enhancing the antitumor activity of the metal-free 
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substances. One possible approach for muting toxicity-related problems in a cancer 
chemotherapeutic regime could be the use of appropriate multidentate ligand which offers 
chelation. Chelation removes the undesirable metal ions and can deactivate either the 
carcinogenic metal or the enzyme which is necessary for the rapid growth of both the healthy 
and malignant cells [48]. There are many representative examples of copper complexes 
grouped according to pharmacologically active ligand scaifolds that have been tested for 
antitumor activity in last decade viz., i) thiosemicarbazone complexes [49], ii) conjugate 
Schiff base complexes [50], iii) imidazole, benzimidazole, pyrazole, triazole complexes [51], 
iv) phenanthroline and bipyridine complexes [52] and v) binary complexes with amino acids 
[53]. Most of the investigated Cu(II) complexes exhibit either five-coordinate environments 
comprising distorted square pyramidal and trigonal bipyramidal geometries or six-coordinate 
octahedral geometry. The majority of these complexes are mononuclear species but there are 
few distinctive examples of dimeric compounds exhibiting remarkable antitumor activity. 
A series of copper-based drugs registered under the name of Casiopeinas® (Cas) were 
developed by Ruiz-Azuara et al. [54]. These compounds are mixed chelate Cu(II) complexes 
with a general condensed formula [Cu(N-N)(A-A)N03], where N-N represents neutral 
diimine donors either phenanthroline or bipyridine, A-A is uninegative NO or 0 - 0 donor 
such as amino acids or acetylacetonates. Cas was designed as a chemotherapeutic drug and 
preliminary experiments demonstrated that it exhibited antineoplastic activity both in vitro 
and in vivo and was able to induce apoptosis in murine cancer cell lines (L1210 and CHI). 
Escriba et al. have described the synthesis, structural characterization and biological activity 
of a ternary Cu(II) coordination complex with phenanthroline and an amino acid conjugated 
ortho-iodohippurate (Figure 11) [55]. This complex was capable of cleaving pBR322 plasmid 
DNA confirming the nuclease effect. 
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Figure 11. Structure of Cu(Il) complex with phenanthroline and amino acid conjugated 
ortho-iodohippurate. 
Another series of mixed ligand complexes [Cu(tdp)(N-N)]* complexes, where Htdp is the 
tetradentate ligand 2-[(2-(2-hydroxyethylamino)ethylimino)methyl]phenol and N-N is bipy, 
phen, 3,4,7,8-tetramethyi-l,10-phen (tmp) and dipyrido-[3,2-d:2',3'-f ]-quinoxaline (dpq), 
have been isolated and characterized by Palaniandavar et al. [56]. The representative complex 
[Cu(tdp)(phen)][C104], 1 has been structurally characterized showing a distorted octahedral 
geometry around Cu(n) (Figure 12). 
CIO/ 
H VJ 
Figure 12. Structure of complexes 1 and 2. 
It is noteworthy that the [Cu(tdp)(tmp)][CI04] complex 2, despite its lower DNA binding and 
cleavage activity, exhibited the highest anticancer activity against the human cervical 
epidermoid carcinoma ME 180 cell line. Its potency was approximately 100- and 6-fold 
greater than those of cisplatin and mitomycin C, for 24h and 48h incubation times, 
respectively. Complex 2 mediated the arrest of S and G2/M phases in the cell cycle 
progression which evolved in apoptosis. 
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Recently, P. Jaividhya et al reported mixed ligand redox-active copper(II) complexes of the 
general formula [Cu(L)(H20)2](C104) 1 and [Cu(L)(diimine)](CI04) 2-6 ,where LH is 2-((2-
dimethylamino)ethylimino)methyl)phenol and diimine is 2,2'-bipyridine (bpy) 2 or 1,10-
phenanthroline (phen) 3 or dipyrido-[3,2-<i:2',3'-fl-quinoxaline (dpq) 4 or dipyrido[3,2-
d:2',3'-f]phenazine (dppz) 5 or ll,12-dimethyldioyrido[3,2-a:2'3'-c]phenazine(dmdppz) 6 
(Figure 13) [57]. 
\NI 4 'g.i^-'^: \ |cu J^,5M; Ns", N5 
/1 /I N6 
Figure 13. ORTEP representation of the crystal structures of (a) fCu(L)(bpy)J^ 2, (b) 
[Cu(L)(dpq)]^ 4 and (c) [Cu(L)(dmdppz)]* 6 showing atom numbering scheme and 
displacement ellipsoid (50% probability level). (Hydrogen atoms and perchlorate anions are 
omitted for clarity). 
The mixed ligand dppz complex exhibits DNA binding affinity higher than that of its analogs, 
which is due to the higher planarity and hydrophobicity of the dppz co-Iigand, and 
interestingly, it effects more efficient cleavage of double-stranded DNA without the 
requirement of a reductant. All the complexes, except 1, affected double strand DNA cleavage 
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of plasmid DNA and 5 cleaves piasmid DNA in the absence of a reductant at a concentration 
(40 nM) lower than 4. It is noteworthy that the same complex exhibits the highest anticancer 
activity against human breast cancer cell lines (MCF-7) as well as human cervical epidermoid 
carcinoma cell lines (ME 180) with its potency higher than that of cisplatin as shown in Table 
2. 
Table 2. In vitro cytotoxicity assay for complexes 1-6 against MCF-7 breast cancer cell line 
and human cervical epidermoid carcinoma cell line (ME180). 
Complex ICso, fiM' 
MCF-7 ME 180 
24 h 48 h 24 h 48 h 
lCu(L){H20)2l(CI04) 1 40.4±0.10 28.5 + 0.5 42.0±0.1 30.0±0.2 
|Cu(L)(bpy)l(C104) 2 20.0±0.10 15.0±0.2 38.0±0.2 31.0±0.3 
(Cu(L)(phen)l(C104) 3 2.00 + 0.05 1.20 + 0.10 28.6±0.2 24.6±0.1 
[Cu(i)(dpq)!(CI04) 4 I.58±0.0] 1.55±0.50 19.5±0.] 16.4+0.7 
[Cu{L)(dpp2)](a04) 5 0.46±0.02 0.36 + 0,02 17.0±1.5 13.0±1.3 
lCu(L)(timdppz)l(C!04) 6 0.55±0.01 0.60±0.01 17.7+1.0 14.4±1.3 
Cisplatin 45.7 ±1.0 1.89 ±0.06 46.7 ±1.0 33.5 ±1.0 
"ICso = concentration of drug required to inhibit growth of 50% of the cancer cells (in fiM). 
Taken altogether the results of these studies suggest that DNA may not necessarily be the 
main or unique biological target for this class of metal complexes. With the time it has 
become clear that copper complexes act by different mechanism involving probably DNA 
binding, intercalation and cleavage activity, SOD-mimetic activity as well as generation of 
ROS (reactive oxygen species) by redox cycling leading to oxidative cell damage. Generally, 
these intracellular molecular events trigger cancer cell death through an apoptotic mechanism. 
Zinc is an important trace element owing to its biological relevance to the living system 
[58,59]. The role of zinc in cell growth and division as well as basal homeostasis is of key 
importance. Zinc is required for the stabilization of the nucleic acids deoxyribonucleic acid 
(DNA) and ribonucleic acid (RNA) [60]. In fact, all RNA polymerases (1, II, III) are zinc 
metalio-^nzymes. There are four general biological roles of zinc, which include its structural, 
signaling, catalytic and regulatory functions [66], Zinc complexes with diverse biological 
activity viz., antibacterial [61], anti-diabetic [62], anti-inflammatory [63] antimicrobial [64] 
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and for the treatment of Alzheimer's disease [65] are reported, yet there is scarcity of data 
available on the cytotoxicity of zinc-based compounds against human cancer cell lines 
[66,67]. Nevertheless, certain Zn(II) complexes, which strongly bind and cleave DNA, exhibit 
prominent anticancer activities and regulate apoptosis [68-72]. It is vital for recovery of 
leukemic cells because zinc is required for proper functioning of genetics, immunity, 
formation of red blood cells, organ, muscle and bone function, cell membrane stability, cell 
growth, division and differentiation. 
Another potential biological application of Zn(II) is in the field of artificial nucleases due to 
its virtue of its strong Lewis acidity, high charge density and rapid ligand exchange ability. 
Zn(II) exhibits d electronic configuration and the redox inertness rules out the possibility of 
oxidative cleavage. In addition, it generally has no LFSE and as a consequence, it can easily 
attain variable coordination numbers for water coordination during hydrolytic cleavage. 
Structural changes induced by Zn(II) on DNA suggest that this cation can bind to both the 
nucleobase and the phosphate group [73]. The role and behavior of zinc in bioinorganic 
processes are modulated by its coordination environment, where Zn(II) can be four, five, or 
six-coordinated [74]. Zn(II) based artificial nucleases are more important in the hydrolytic 
cleavage of phosphatediesters [75]. Hydrolysis of phosphodiester linkage leads to cleavage of 
DNA forming fragments that could be religated enzymatically. 
A. Tarushi et al. have reported the synthesis, structural characterization of zinc complexes of 
the antibacterial drug oxolinic acid in the absence, Zn(oxo)2(H20)21, or presence of N-donor 
heterocyclic ligands [2,2'-bipyridine (= bipy) or 1,10-phenanthroline (= phen)] [61]. The 
crystal structures of Zn(oxo)(bipy)Cl, 2 and Zn(oxo)2(phen), 3 were determined with X-ray 
crystallography (Figure 14). The biological activity of the complexes has been evaluated by 
examining their ability to bind CT DNA with UV and fluorescence spectroscopies. 
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Figure 14. The crystal structures of complexes (a) 2 and (b) 3. 
UV spectroscopic studies of interaction of complexes 1-3 with DNA have shown that they 
can bind to CT DNA via external contact (electrostatic binding) and intrinsic binding 
constant, Kb was calculated which revealed Zn(oxo)2(phen) 3 exhibited highest Kb value 
among all the complexes examined (Figure 15). 
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Figure 15. UV spectra of (A) Hoxo (dmf), (B) Zn(oxo)2(H20)2,1 (dmf), (C) Zn(oxo)(bipy)Cl, 2 
(elhanol) and (D) Zn(oxo)2(phen), 3 (dmf), in solution in the presence of CT DNA at 
increasing amounts. [Compound] = 40 //A/, [CT DNA] = 0-40 //M The arrows show the 
changes upon increasing amounts ofCTDNA. 
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Nevertheless, the oxolinato ligands provide to the complexes an aromatic moiety so that the 
binding of the complexes involving intercalation of an aromatic ring between the base pairs of 
CT DNA cannot be ruled out. The possibility of intercalation is enhanced for 3 due to the co-
existence in the molecule of the intercalating agent phenanthroline. Competitive binding 
studies with ethidium bromide performed with UV-vis and fluorescence spectroscopy have 
shown that complexes especially Zn(oxo)2(phen) 3 can displace EB from its DNA complex 
suggesting an intercalative mode of binding with DNA. 
A. Alagha et al. reported the synthesis and X-ray crystal structure of acetatobis(L-arginine) 
zinc(IF) acetate trihydrate, [Zn(OAc)(L-Arg)2]OAc.3H20 [76]. Zinc(n)-arginine complex 
exhibited distorted square-pyramidal geometry around zinc(ll) atom containing two trans-
N,0 chelated L-arginine ligands in the basal plane and the acetato ligand in an axial position. 
The structure reveals second acetate which is salt-bridged to the 5 and (o NH groups of the 
guanidinium side chain of an arginine ligand, and also contains three hydrogen bonded water 
molecules (Figure 16). 
Figure 16. Molecular structure of [Zn(OAc)(L-Arg)2]OAc.3H20. Thermal ellipsoids are 
drawn on the 50% probability level, disorder neglected. 
Benzimidazole and its derivatives are known to exhibit a variety of biological activities, 
including antibacterial, antifungal, antiviral and anticancer activity [77-79]. In lieu of broad 
spectrum of biological activities exhibited by benzimidazole and their derivatives they are 
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highly in demand for use as precursors in metal-based drug regime. Benzimidazole 
substituted derivatives are inhibitors of cyclin-dependent kinase and useful for inhibiting cell 
proliferation, in for the treatment of cancer. Bis-benzimidazoles have potent activity against a 
number of microorganisms including those that lead to AIDS-related infections. These 
compounds bind to DNA in AT-rich sequences [80]. Recently, benzimidazole derived drugs 
have received much attention owing to the fact that benzimidazole residue is a constituent of 
vitamin B12 which supports their potential use as therapeutics [81]. Benzimidazole sometimes 
called 1,2-dideazapurine and its derivatives can serve as model compounds for purine due to 
structural similarity [82]. Hoesct 33258 is widely used as anthelmintic [83] and has shown 
good activity against L1210 and P388 leukemia. 2-substituted benzimidazolps have known to 
act as potential anticancer agents [84,85]. For example, bis-benzimidazole derivatives were 
remarkably active compounds in interfering with DNA topoisomerase-I [86] and were also 
found to be cytotoxic against MCF-7 breast carcinoma cell line [87]. The bis-benzimidazole 
family of DNA binding ligands, therefore, provides a good starting point for rational drug 
design as well as good models to investigate the factors affecting DNA recognition and minor 
groove binding. 
A series of Cu(II) coordination compounds with benzimidazole-derived bidentate chelating 
ligands has been prepared and characterized by Saczewski et al. [88]. In vitro cytotoxicity 
studies of 2-(4,5-dihydro-lH-imidazol-2-yl)-5-nitro-lH-benzimidazole CuCla complex 
with seven different human tumor cell lines, inhibited the growth of cancer cells with IC50 
between 4.76 and 10.84 i^M (Figure 17a). Another related complex [Cu(L)2(N03)](N03) 
(H20)i .(CHjOH), 2 {L= l-[3-(2-pyridyl)pyrazol-l-ylmethyl] naphthalene) (Figure 17b) 
was evaluated against six different cancer cell lines (HL-60 human leukemic cells, PC-3M-
1E8 human prostate tumor cells, BGC~832 cells, MDA cells, Bel-7402 human hepatoma 
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cells, and HeLa human cervix cancer cells) showing considerable inhibitory rate and cytotoxic 
specificity [89]. 
CI CI 
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Figure 17. Cu(II) complexes containing benzimidazole ligand scaffold exhibiting cytotoxic 
activity. 
Devereux et al. studied the synthesis and chemotherapeutic potential of a series of novel 
Cu(II) carboxylate complexes derived from 2-(2-pyridyl)benzimidazole (Figure 18) [57]. In 
particular, a series of Cu(II) carboxylate complexes, some containing one chelating, phen or 
bipy, have been prepared and characterized. All of the complexes were found to be poor 
catalase mimics in the presence of imidazole and totally inactive in its absence. Conversely, 
all the complexes exhibited excellent SOD mimetic activity. The complex and the 
corresponding free ligand were assessed for their chemotherapeutic potential against the 
hepatocellular carcinoma (Hep-G2) and kidney adenocarcinome (A-498) cell lines and the 
complex was found to exhibit a higher antitumor activity as compared to free ligand. 
Ph C u - ^ NT \ 
Figure 18. The structure of Cu(IIJ carboxylate complexes derived fi-om 2~(2-pyridyl) 
benzimidazole. 
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H.-L. Wu et al. reported Zn(II) complexes derived from bis(benzimidazole)-thiapropane 
ligand scaffold and also discussed the possible relations between the structure and DNA-
binding properties (Figure 19) [90]. The experiments revealed that Zn(ll) complexes 1 and 2 
interact with DNA via intercalation mode. The presence of electron donating substituents on 
benzimidazole rings may restrict interaction with the complexes to DNA base pairs. In 
general, low electron density and smaller steric hindrance may facilitate benzimidazole ring 
intercalating to the base pairs of double helical DNA. 
(a) 
Figure 19. Crystal structures of complexes (a) 1 and (b) 2. Hydrogen atoms have been 
omitted for clarity. 
Amino acids, which are naturally occurring chiral compounds, have been extensively used as 
chiral auxiliaries to create/induce a quaternary stereogenic carbon center. The relevance of 
amino acids lies in their biological importance, as they form the basic constituents of living 
organisms. They take part in important metabolic reactions, including the biosynthesis of 
polypeptides and proteins and the synthesis of nucleotides. Cu(Il) and Zn(H) complexes of 
amino acids are known to be important for metal ion transport in blood. High biological 
importance, chirality and amphiphilicity combined with a low molecular weight and relative 
simplicity of molecular structures make amino acids the most suitable candidates for drug 
scaiTold representing typical features of natural bioactive substances [91,92]. Different 
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configurations of amino acids have different roles in living system. L-amino acids are used in 
the synthesis of proteins, while some D-amino acids do not participate in protein synthesis. 
Metal complexes of amino acids are involved in exchange and transport mechanism of trace 
metal ions in human body. Amino acids coordinate to metal ions through amino and 
carboxylato groups, and when the side chain has an additional functional group, it may 
provide an additional binding site. Various side groups of amino acid are found to have a 
potential to recognize the specific base sequence through hydrogen bond formation with the 
nucleic bases in DNA [93,94]. The introduction of chirality due to amino acid ligands could 
enhance the pharmacological behavior of the complexes by adopting a specific conformation 
and may also confer selective binding affinity for the chiral DNA [36]. Amino acids/peptides 
are the basic structural units of proteins that recognize a specific base sequence of DNA. 
Mixed ligand ternary metal complexes of amino acids and nucleic acid constituents play an 
important role in biochemical processes, for example genetics and molecular biology [95] as 
nucleic acids and proteins recognize each other by very specific and selective interactions 
through amino acid side chain and nucleic acid constituents [96]. 
Zhang et al have demonstrated the synthesis and crystal structures of copper, zinc and 
cadmium complexes Cu(C,8Hi6N302)2-2CH30H (1), Zn(Ci8H,6N302)2-2CH3CH2-OH (2) and 
Cd(C|,sHi6N302)2'2CH30H (3) with Schiff base derived from 2-acetylpyridine and L-
tryptophan (Figure 20) [97]. The anticancer activity of these three complexes on MDA-MB-
231 breast cancer cells was investigated. It has been reported that copper, zinc and cadmium 
complexes can induce apoptosis by inhibiting the tumor cellular proteasome. The results 
indicate that all of the three complexes can inhibit the cellular proliferation and have the 
potential to be used as a proteasome inhibitor and anticancer agent. 
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Figure 20. The molecular structure of complexes 1-3 (a-c). 
Peptides can be very effective ligands for a range of metal ions since they contain a variety of 
potential donor centers. Metals may be directly bound to peptides and have been used for 
DNA selective recognition and/or cleavage. It was reported that peptide functionalization of 
polypyridyl ruthenium(n) [98,99]/rhodium(III) [100,101] metallo-intercalators improved the 
selectivity of the parent intercalators, with similar effects observed by conjugating minor 
groove binders with short peptides that mimic natural protein motifs [102]. 
The bleomycins (BLMs), a family of glycopeptide-derived antibiotics produced by several 
Streptomyces species, are used clinically in combination with a number of other agents for the 
treatment of several types of tumors, notably germ cell tumors, squamous cell carcinomas, 
and malignant lymphomas (Figure 21) [103,104]. The combination BLM, etoposide and 
cisplatin treatment regimen cures 90-95% of metastatic testicular cancer patients, clearly 
representing a therapeutic success story [105]. BLMs are thought to exert their biological 
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effects through a sequence selective, metal-dependent oxidative cleavage of double stranded 
DNA in the presence of oxygen. 
OH 9 
Figure 21. Structure of bleomycin (BLM), naturally occurring glycopeptides. 
New synthetic strategies involving innovative chemical modifications and undermining the 
limitations put forth by previous drug candidates have emerged; in this context, a large 
number of peptide-based drugs are being designed, synthesized by pharmaceutical firms and 
marketed for medical purposes [106,107]. For instance, Goserelin (a synthetic gonadotropin-
releasing hormone analog, marketed as Zoladex) is applied to treat breast cancer and prostate 
cancer [108]. Peptide transporters, namely PEPTl and PEPT2, identified in mammals are 
integral plasma proteins that mediate cellular uptake of di- and tri-peptides and peptide-like 
drugs. These transporters are stereoselective toward peptides containing L-enantiomers of 
amino acids. Thus, peptide transporters represent an excellent target for the delivery of 
pharmacologically-active compounds because their substrate binding site can accommodate a 
wide range of molecules of different size, hydrophobicity and charge [109]. 
Recently Reddy et al. reported the synthesis, structural characterization, DNA binding and 
cleavage properties of ternary histidine based dipeptide Cu(II) complexes, [Cu(Il)(boc(tos)-
his-trp-ome)(phen)](C]04)2 (1) and [Cu(Il)(boc(tos)-his-tyr-ome)(phen)](C104)2 (2) 
(Scheme 1) [110]. 
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Scheme 1. General approach for the synthesis of peptides and the Cu(II) complexes 1 and 2. 
Several biophysical experiments which include thermal denaturation studies, UV-vis 
spectroscopy, emission titrations and viscosity measurements revealed that the complexes 
bind to DNA via intercalation mode. The absorption spectra of complex 1 in the absence and 
presence of CT DNA has been displayed in Figure 22a. 
Agarose gel electrophoresis assay, a useful method to investigate various binding modes of 
small molecules to supercoiled DNA, also supports the above intercalative binding mode. 
Intercalation of small molecules to plasmid DNA can loosen or cleave the SC DNA form, 
which decreases its mobility rate and can be separately visualized by the agarose gel 
electrophoresis method, whereas a simple electrostatic interaction of small molecules to DNA 
does not significantly influence the SC form of DNA, thus the mobility of the SC form of 
DNA does not change. These results also confirm that the complexes bind to DNA. The 
cleavage activity on pUC19 plasmid DNA was investigated. Free Cu(OAc)2.H20, peptides, 
phenanthroline and H2O2 did not show any DNA cleavage activity, even after incubation for 
3h at a concentration of 1 mM (Figure 22b Lanes 2-5 and 8). This proves the catalytic role of 
1 and 2 in the presence of H2O2. Further, when SC DNA was incubated with the complexes in 
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the presence of DMSO, without adding H2O2), only slight inhibition of DNA cleavage was 
observed (Lanes 6 and 7). On the other hand, in the presence of H2O2, the DNA cleavage was 
almost eliminated on addition of DMSO, indicating that hydroxy! radicals are generated and 
initiated the cleavage process (Lanes 9 and 10). On the basis of this observation, the 
mechanism of DNA cleavage mediated by complexes 1 and 2 may be via oxidative pathway. 
Since the mixed-ligand complexes, containing bidentate histidine dipeptide and phen, show a 
unique ability to effect DNA double strand scission in both hydrolytic and oxidative cleavage 
reactions, they are considered as better DNA binding and cleavage agents, and hence artificial 
restriction enzymes in nucleic acid biochemistry. 
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Figure 22. (a) Absorption spectra of 1 in the absence (....) and presence (—) of increasing 
amounts of CT DNA. Conditions: [complex] = 10 juM. The arrow shows the ahsorbance 
changes upon increasing the DNA concentration. Inset: linear plot for the calculation ofKi,. 
(b) Agarose gel electrophoresis pattern for the cleavage of supercoiled pUCl 9 DNA by 1 and 
2 at 37 °C in a buffer containing 5 mM Tris-HCl/5 mMaq. NaCl. lane 1, DNA control; lane 
2, DNA+Cu(OAc)2.H20 (1 mM); lane 3, DNA+his-trp (1 mM); lane 4, DNA+his-tyr (1 mM); 
lane 5, DNA+phen (1 mM); lane 6, DNA+1 (]50fjM)+DMSO (1 mM); lane 7, DNA+2 (150 
fiM)+DMSO (1 mM); lane 8, DNA+H2O2 (I mM); lane 9, DNA+1 (10 fiM)+H202 (1 
mM)+DMSO (1 mM); lane 10, DNA+1 (10^M)+H202 (1 mM)+DMSO (1 mM). 
The development of artificial nucleases is an important aspect of biotechnology and drug 
design [111,112] as well as molecular biology [113]. Chemical nucleases could cleave DNA 
by oxidative, photo-induced, and hydrolytic processes [114-116], they present some 
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advantages over conventional enzymatic nucleases in that they are smaller in size and thus 
can reach more sterically hindered regions of a macromolecule. Based on this property, much 
effort has been undertaken by different groups to prepare complexes of transition metals 
capable of binding and cleaving the DNA double helix. First-row transition metals have been 
extensively explored as catalytic agents in mediating phosphate ester backbone cleavage. The 
mode of cleavage (oxidative or hydrolytic) can typically be controlled in vitro, but this is also 
an important consideration if/« vivo use is envisaged (in drug design). By virtue of their high 
charge densities and Lewis acidities, transition metal ions are often effective catalytic agents 
[114]. Among several types of transition metal complexes used as synthetic hydrolases, Cu(II) 
and Zn(ll) complexes are better suited for the hydrolysis of DNA due to the strong Lewis acid 
properties of these metal ions. 
Reddy et al. reported the syntheses and characterization of Schiff base complexes, 
[Cu(saltyr)(phen)] (1) and [Cu(saltyr)(bipy)] (2) (saltyr = salicylidene tyrosine} (Figure 23) 
[117]. 
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Figure 23. Energy-minimized molecular structure of complexes 1 and 2. 
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The complexes were found to exhibit square pyramidal (CUN3O2) geometry. The DNA 
binding and role in the oxidative and hydrolytic cleavage were studied. CT DNA binding 
studies revealed that the complexes show good binding propensity (Kb = 3.47 x 10'' M* and 
3.01 X 10'* M"' for 1 and 2, respectively). The high values of intrinsic binding constants are 
because of the additional stacking interaction of Schiflfbase with DNA in 1 and 2. The higher 
Kb value of 1 compared to 2 could be attributed to the effective stacking interaction in the 
former due to the presence of an extended aromatic phenyl ring which allows an intercalating 
ligand deeply into the DNA base pairs. 
The cleavage activity of complexes 1 and 2 was demonstrated by gel electrophoresis 
experiments. Oxidative cleavage was monitored by treating SC pUC19 DNA with complexes 
1 and 2 in the presence of H2O2 (Figure 24). 
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Figure 24. Oxidative and hydrolytic cleavage ofSCpUC19 DNA at 37 °C in 5mM Tris-HCl/ 
5 mMNaCl buffer by 1 and 2. (a) Lane 1, DNA control; Lane 2, DNA+H2O2 (1 mM); Lane 3, 
DNA+l(J0^M)+H2O2 (1 mM); Lane 4, DNA+1(20 nM)+H202 (1 mM); Lane 5, 
DNA+l(30fiM)+H2O2 (1 mM); Lane 6, DNA+l(40fiM)+H2O2 (1 mM); Lane 7, DNA+1 
(40ftM)+H2O2 (1 mM)+DMSO (25 mM). (b) Lane 1, DNA control; Lane 2, DNA+H2O2 (1 
mM); Lane 3, DNA+2(30ftM)+H2O2 (1 mM); Lane 4, DNA+2(40^iM) H2O2 (1 mM); Lane 5, 
DNA+2(60fiM)+H2O2 (1 mM); Lane 6, DNA+2(60^iM)+H2O2 (1 mM)+DMSO (25 mM).(c) 
Lane 1, DNA control; Lane 2, DNA+1(25MM); Lane 3, DNA+1 (50^M); Lane 4, DNA+1 
(75fiM); Lane 5, DNA+l(100^tM); Lane 6, DNA+l(125fiM); Lane 7, DNA+1 (150^M).(d) 
Lane 1, DNA control; Lane 2, DNA+2(25fiM); Lane 3, DNA+2 (5^ilM); Lane 4, DNA+2 
(75fiM); Lane 5, DNA+2(100nM); Lane 6, DNA+2 (125nM); Lane 7, DNA+2(150^M); Lane 
8, DNA+2(200fiM). 
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Control experiments using only H2O2 did not show any significant DNA cleavage under 
identical experimental conditions (Lane 2). This proves the catalytic role of complexes in 
oxidative cleavage. In order to see the role of hydroxyl radical in the cleavage pathway, an 
experiment was conducted with DMSO, a hydroxyl radical scavenger which completely 
inhibited the cleavage reaction suggesting the involvement of the hydroxyl radical in the 
cleavage pathway (Scheme 2a). A similar pathway was proposed by Sigman and co-workers 
for the oxidative cleavage reaction of the bis(phen) copper complex [118]. 
Attempts were also made to cleave DNA through hydrolysis of phosphodiester bond. Since 
this process does not require any external agents, experiments were performed by treating the 
SC DNA with complexes in the absence of external agents. The complete conversion of SC 
DNA to NC form was achieved at 150 \iM by complex 1 (Figure 24c) while only 79% 
conversion was observed for 2 (Figure 24d) at the same concentration. A tentative mechanism 
was proposed for the hydrolytic pathway. The bonds between Cu(II) and labile carboxylate 
and/or phenolate oxygen of amino acid Schiff base could break under experimental conditions 
followed by simultaneous coordination of Cu(II) to the phosphate oxygen of DNA backbone 
by utilizing the strong Lewis acid property of Cu(II) oxidation state which results in the 
breakage of the phosphodiester bond of DNA (Scheme 2b). 
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Scheme 2. A plausible mechanism for the (a) oxidative cleavage of DNA in the presence of 
H2O2 and (b) hydrolytic cleavage of DNA by complexes 1 and 2. 
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Penicillamine (d-3,3-dimethylcysteine) is an active thiol-containing natural amino acid 
molecule demonstrating diverse pharmacological profile. D-penicillamine, a common organic 
chelating agent has been widely used for the treatment of heavy metal toxicity [119]. 
However, in the case of penicillamine, only the pure D-form is of therapeutic importance as 
the racemate and L-isomer are toxic [120]. As a consequence, D-penicillamine has become 
increasingly important as a therapeutically beneficial molecule, for treating rheumatoid 
arthritis, hepatitis and multiple schlerosis, in addition to its well known role for treating 
Wilson's disease. Interest in D-penicillamine as a ligand arises from several possibilities of 
coordination. D-penicillamine, together with its zwitterionic form, with three functional 
groups (-NH2, -S and -COO ) usually forms bidentate complexes by coordination of N and 
S atoms [121,122], but formation of monodentate (S) [123,124], tridentate (N,0,S,) or 
tetradentate (N,0,0,S) complexes [125,126] cannot be ruled out. The sulfiir, nitrogen or 
oxygen atoms could also act as a bridging ligand [127]. Penicillamine, a chiral scaffold is 
interesting from the point of view: 
(i) amide functionality capable of forming complexes which can serve as model 
systems to metalloenzymes of the living systems; 
(ii) provides various binding sites viz., carboxylic, amino and sulfahydryl groups. 
M. Nath et al. reported synthesis, structural studies and biological activity (anti-inflammatory 
activity, ALD50 and blood pressure lowering activity) of the diorganotin(lV) {R2Sn(lV), R = 
n-Bu and Ph} and triorganotin(lV) {RsSnCIV), R=Ph} derivatives of D-penicillamine, L-
camosine and triglycine (Figure 25) [128]. 
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Figure 25. Structure of (a) diorganotin(IV) complexes of D-penicillamine and (b) n-
Bu2SnCl(D-HPen).H20. 
However, penicillamine derivatives, viz., R2Sn(DL-Pen), R2Sn(DL-PenH)2 (where R=Me 
and Ph), Me3Sn(DL-PenH), Ph3Sn(DL-Pen)SnPh3, Me2Sn-(D-Pen), -(L-Pen), -{D-PenH)2, 
-(L-PenH)2 [129], n-Bu2Sn(DL~Pen) [130] and Me2SnCl(DL-PenH), n-Bu2SnCl(DL-
PenH).H20 [131] were synthesized and their structures in solid state have been established 
by Mossbauer spectral studies [132-135]. These complexes are polymeric in the solid state, 
with a trigonal bipyramidal configuration where the organic radicals and thiol sulfur, bound to 
the metal, lie in the equatorial plane, being axially bridged by amino nitrogen and 
monodentate carboxyl. The antitumor activity and the structure-activity (P-388 leukemic) 
relationship of these diorganotin(IV)-penicillaminates have been reported earlier [133]. In 
order to evaluate a possible contribution of the chirality of the ligands to the antitumor 
activity, investigation of the anti-leukemia action of the L- and D-enantiomers of the 
penicillaminates, Me2Sn(L-Pen) and -(D-Pen), as well as of Me2Sn[SC- (CH3)2CH(NH3^) 
COO ], Me2(L-PenH)2 and -(D~PenH)2, which are water soluble and allow a facile 
administration for the antitumor tests. 
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Present Work 
There is a considerable interest in the development of compounds that bind to specific DNA 
sequences and chirality is one of the crucial factors for the control of stereospecific and 
stereoselective interactions. Owing to this, there is a large demand for enantiomeric 
pharmaceuticals that have proven to be more efficacious, exhibiting less systemic toxicity and 
also possess high specificity. This could be correlated to strong structure-function 
relationship of enantiomers with their biological properties. The two different L- and D-
enantiomers exhibit diverse binding modes with DNA-an inherently chiral target, with one 
form of DNA remaining dominantly active over the other. Current interest in the area of 
metal-based chemotherapeutic chemistry focuses on the use of biologically active essential 
metal complexes, such as copper and zinc (which are less toxic than platinum, a non-essential 
metal ion). The synthetic strategy in the design of chiral metal-based therapeutic agents 
employs chiral ligand scaffolds with bioactive pharmacophore viz., benzimidazole derived 
ligand H2bzimed, amino acids (tryptophan, leucine, valine, histidine), peptides, penicillamine 
and picolinic acid which were explored for the complexation to synthesize asymmetric single 
enantiomeric complexes. The synthesized complexes were thoroughly characterized by 
spectroscopic (IR, 'H and '^ C NMR, EPR, UV-vis, ESI-MS) and analytical methods. 
Chiral dinuclear zinc(II) drug entities derived from H2bzimed and L-forms of amino acids 
{viz., tryptophan, leucine and valine) were synthesized to evaluate their biological preference 
with the molecular target DNA. L-enantiomers of Zn(II) complexes were chosen for this 
work as it has been well reported in literature that L-enantiomer binds to DNA more avidly 
than D- and DL-enantiomers. These chiral bimetallic complexes derived from H2bzimed and 
amino acid framework provide a suitable heteroatom NONO-donor two compartment 
coordination platform for dizinc(II) ions; such compounds can serve as artificial nucleases 
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and efficient therapeutics for treatment of many diseases. Zinc(II) plays a crucial role in 
hydrolytic DNA cleavage, with the synergy between the metal ions contributing to the high 
nucleolytic efficiency. 
The dizinc(Il) complexes [C27H26N80uZn2], [C22H27N70iiZn2] and [C2iH25N70iiZn2] were 
synthesized and thoroughly characterized. The optical rotation values validated their chiral 
nature. The DNA binding profile of complexes [C27H26N80uZn2], [C22H27N70iiZn2] and 
[C2iH25N70|iZn2] were carried out employing various biophysical methods viz., UV-vis 
absorbance and fluorescence spectroscopy, viscosity and circular dichroism measurements. 
To validate the mechanistic approach of binding mode, interaction studies of Zn(II) 
complexes with mononucleotides (5'~GMP and 5'-TMP) were carried out by UV-vis 
titrations, ' H and ^'P NMR methods. The cleavage activity of [C27H2hN80iiZn2] was 
examined by gel electrophoresis with pBR322 plasmid DNA as a substrate. //; vitro biological 
screening of [C27H26N80iiZn2] was carried out for antibacterial activity tested against two 
Gram-positive and two Gram-negative bacterial strains. 
The structural copper analogues of H2bzimed (tetranuclear complex, [C64H60N18O26CI2CU4]) 
and with the L-forms of amino acids (viz., tryptophan and valine) {[C27H.6N8O11CU2] and 
[C21H25N7O11CU2]} were synthesized to explore the most promising copper-benzimidazole 
complexes as chemotherapeutics. It was also thought interesting to evaluate the differences in 
the attributes of tetranuclear and dinuclear Cu(ll) complexes for DNA interaction by 
employing UV-vis titrations, fluorescence, circular dichroic and viscosity studies and 
furthermore to evaluate the inhibitory effect of these complexes on Topo-I. The molecular 
docking studies were performed to further predict the specific binding site available at the 
molecular target. These complexes were evaluated for in vitro antibacterial activity. 
Metal complexes of amino acids and peptides are gaining importance as they are basic 
structural units of proteins capable of specific recognition of DNA base sequence. However, 
35 
peptides can behave as carrier molecules for the delivery of drugs to the target. New Cu(II) 
and Zn(II)-based tetrapeptide complexes were synthesized from Pro-Gly-Pro-Gly/ 
Pro-Leu-Pro-Leu tetrapeptide ligands and thoroughly characterized by various spectroscopic 
techniques. To confirm the stability of peptide complexes in solution, solution stability studies 
of Cu(II) and Zn(II) complexes of Pro-Gly-Pro-Gly {[Ci4H22N406Zn] and [C22H3gN406Zn]} 
over a pH range 2-12 were carried out suggesting their stable nature. Their chiral nature was 
established by the optical rotation values. In vitro DNA binding studies of complexes were 
carried out by employing UV-vis and fluorescence titrations and viscosity and circular 
dichroic studies. To compare the binding affinity for nucleotides, UV-vis titrations of 
complexes with 5'-GMP and 5'-TMP were carried out and were further validated by ' H and 
P NMR interaction studies. The supercoiled pBR322 DNA nuclease activity of 
[C14H22N4O6CU] and [Ci4H22N406Zn] was evaluated. The in vitro cytotoxic activity of Cu(II) 
and Zn(II) complexes of Pro-Giy-Pro-Gly in terms of IC50 values were screened against three 
human carcinoma cell lines of different histological origin by MTT assay: MDA-MB 231 
(breast adenocarcinoma), A375 (malignant melanoma) and HCT116 (colon carcinoma) and 
were compared to cisplatin. 
Understanding the binding modes viz., covalent or non-covalent plays a pronounced influence 
on the efficacy of a drug or chemical entity as a potential drug; among the factors governing 
the binding modes, the most significant and fascinating criteria for drug design is the 
molecular shape-chiral preference or enantioselectivity. Those complexes that fit best against 
the DNA helical structure display the highest binding affinity. Upon binding to DNA, these 
conformations give rise to the preferential binding of one conformation over another, which is 
termed as enantioselectivity. In an attempt to unravel details of conformational differences, 
enantiomeric pairs Zn(II) complexes {(L) and (D)-[Ci9H2iN304SZn]} of L- and D-
penicillamine and 1,10-phenanthroline were designed and thoroughly characterized by 
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various spectroscopic techniques (NMR, IR, ESI-MS), elemental analysis, molar conductance 
and polarimetry. Interaction of complexes with CT DNA was carried out using different 
techniques viz., electronic absorption titrations, fluorescence, viscosity and circular dichroic 
studies. The DNA cleavage activity of (L) and (D)-[Ci9H2iN304SZn] complexes were 
ascertained by gel electrophoresis assay. Further to confirm the cleavage mechanistic 
pathways followed by the complexes T4 DNA religation assays were performed. The 
comparative molecular docking studies of both enantiomers of complexes with DNA was also 
carried out to further predict the exact binding site available at the molecular target. 
Another set of chiral enantiomeric Cu(II) and Ni(II) complexes derived from L/D-histidine 
and picolinic acid were synthesized. The complexes were thoroughly characterized by 
elemental analysis, IR, NMR ( 'H and '^C), ESl-mass spectra and molar conductance 
measurements. The in vitro DNA binding studies of Cu(ll) complexes (L)- and (D)-
[C12H14N4O5CU] were investigated by UV-vis, fluorescence spectroscopy CD and viscosity 
measurements. The interaction studies of Cu(II) complexes with mononucleotides (5'-GMP 
and 5'-TMP) were also performed to assess the base specific interaction of the metal ions. 
The DNA cleavage studies of L-enantiomeric form of Cu(II) complex were carried out using 
gel electrophoresis. Furthermore, the molecular docking studies of L-enanfiomeric Cu(II) 
complex (L)-[Ci2Hi4N405Cu] was carried out. Further the antimicrobial activity of both the 
enantiomeric fonns of Cu(II) complexes (L)- and (D)-[Ci2Hi4N405Cu] was carried out to 
ascertain the differences in the activities of different enantiomeric fornis of the complexes. 
CHAPTER II 
Experimental 
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1. Materials 
CUCI2.2H2O, Cu(N03)2.3H20, Zn(N03)2.6H20, Zn(CH3COO)2, NiCb.eHzO, 1,10-
phenanthroline monohydrate, 1,2-diaminobenzene, L-(+)-tartaric acid, sodium hydroxide, 1-
ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDCI) (Merck), picolinic acid, 
agarose gel, ascorbic acid, sodium azide (NaNs), DMSO, superoxide dismutase (SOD), methyl 
green, DAPI, mercaptopropionic acid (MPA) (Sigma Aldrich Chem. Co.), Glycine, L-leucine, 
L-proline, L/D-histidine, 2-(lH-benzotriazol-l-yl)-l,l,3,3-tetramethyluraniumhexafluoro 
phosphate (HBTU), Tris(hydroxylmethyl) aminomethane (Tris-buffer) (Sigma), N -
hydroxybenzotriazole (HOBT) (SRL), Boc anhydride, SOCI2, Trifluoroacetic acid (TFA), 
Dicyclohexylcarbodiimide (DCC), L/D-penicillamine (Fluka), Doxycycline, Sabouraud's 
dextrose agar (SDA) plates, nystatin (Hi-Media) were utilized as received. Disodium salt of 
calf thymus DNA (CT DNA), guanosine 5-monophosphate disodium salt (5'-GMP) and 
thymine 5'-monophosphate disodium salt (5'-TMP) were purchased from Sigma and stored at 
4 °C. 6X loading dye (Fermentas Life Science), T4 DNA iigase enzyme. Human DNA 
topoisomerase I (CalBiochem) and supercoiled pBR322 DNA (Genei), Foetal bovine serum 
(PAA Laboratories GmbH, Austria, UE) were utilized as received. All reagent grade 
compounds were used without further purification. 
2. Characterization techniques 
Carbon, hydrogen and nitrogen contents were detemiined using Elementar Vario EL III. 
Melting points were determined by electrothermal apparatus. TLC was performed on 
commercial aluminum sheets pre-coated with 0.20 mm layer of silica gel. The visualization of 
spots on TLC plates was effected by exposure to iodine and ninhydrin. 
2,1 Infrared spectroscopy 
Fourier transform infrared spectra were recorded on Interspec 2020 FTIR spectrometer. The 
infrared spectroscopy is a useful technique to characterize a compound. It results from 
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transition between vibrational and rotational energy levels. IR region of the electromagnetic 
spectrum covers a wide range of wavelength from 400^000 cm~V It has been found that in IR 
absorption, some of the vibrational frequencies are associated with specific groups of atoms 
and remain same irrespective of the molecules in which the group is present. These are called 
characteristic frequencies and their constancy results from the constancy of bond force 
constants from molecule to molecule. The important observations that the IR spectrum of a 
complex molecule consists of characteristic group frequencies makes IR spectroscopy, unique 
and powerful tool in structural analysis. 
2.2 Nuclear magnetic resonance spectroscopy 
The nuclei of certain isotopes possess a mechanical spin or angular momentum. The nuclear 
magnetic resonance spectroscopy is concerned with nuclei having nuclear spin quantum 
number I = 1/2, examples of which include 'H, '^C and^'P. 
For a nucleus with I = 1/2, there are two values for the nuclear spin angular momentum 
quantum number mi = ±1/2 which are degenerate in the absence of a magnetic field. However, 
in presence of the magnetic field, this degeneracy is destroyed such that the positive value of mi 
corresponds to the lower energy state and negative value to higher energy state separated by 
AE. In an NMR experiment, one applies strong homogeneous magnetic field causing the nuclei 
to precess. Radiation of energy comparable to AE is then imposed with radio frequency 
transmitter equal to precision or Larmor frequency and the two are said to be in resonance. The 
energy can be transferred from the source to the sample. The NMR signal is obtained when a 
nucleus is excited from low energy to high energy state. ' H and '^ C NMR spectra were obtained 
on a Bruker Avance DRX-400 spectrometer at 400 and 100 MHz, respectively operating at 
room temperature. 
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2.3 Electron paramagnetic resonance spectroscopy 
Electron paramagnetic resonance (EPR) spectra of the Cu(II) complexes were obtained on 
Varian E 112 EPR spectrometer using tetracyanoethylene (TCNE) as field marker. The spectra 
were recorded for solid complexes at room temperature and for the solutions of the complexes 
in appropriate solvents at liquid nitrogen temperature (LNT). 
2.4 Mass spectrometry 
Mass spectrometry is one of the most accurate micro analytical techniques which require only a 
few nanomoles of the sample to obtain characteristic information regarding the molecular mass 
and to detect within a molecule the places at which it prefers to fragment from which the 
presence of recognizable group within the molecule can be deduced. Mass spectrometry is 
complementary to FTIR, NMR, UV-vis and EPR spectral techniques for structural 
identification of compounds. Electrospray mass spectra were recorded on Micromass Quattro II 
triple quadrupol mass spectrometer. 
2.5 Ultra-violet and visible spectroscopy 
The electronic spectral studies of metal complexes provide useful information about the 
stereochemistry, oxidation state of the metal ion and about the nature of metal-ligand bond. 
Electronic spectra were recorded on a UV-1700 PharmaSpec UV-visible spectrophotometer in 
methanol and DMSO as solvent. 
2.6 Molar conductance measurements 
The conductivity measurement is one of the simplest and easily available techniques used to 
study the nature of the complexes. It gives direct information regarding whether a given 
compound is ionic or covalent. 
For this purpose, the measurement of molar conductance (Am), is calculated using the equation; 
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cell constant x conductance 
Am = 
concentration of solute expressed in mol cm~^  
Conventionally, solutions of 10 M strength are used for the conductance measurements. 
Molar conductance was measured at room temperature on a Digisun electronic conductivity 
bridge. 
2.7 Polarimetry 
Optical isomerism manifests itself by the rotation that certain molecules impart to the plane of 
polarized light when in gaseous, liquid or molten state or in solution (Figure 26). This rotation 
is observed and measured by a rather simple instrument, known as polarimeter. The specific 
rotation [a] of a dissolved substance is given by the expression; 
[a] = 
Ixc 
where, a is the observed rotation in degrees 
1 is the path length of the sample in decimeters 
c is the concentration in grams per milliliter 
The dependence on wavelength and temperature is indicated by subscripts and superscripts 
respectively. Thus [ajo means the specific rotation at 25 °C measured at the wavelength of 
the sodium D line. Optical rotation is generally measured using light from a sodium-vapour 
lamp, which gives essentially monochromatic radiation (the yellow sodium D line is a doublet 
at 5890 and 5896 A). A beam of light is polarized by the passage through nicol prism (the 
polarizer), which consists of two calcite prisms cemented together so that only one of the two 
rays formed by double refraction is transmitted. The beam of polarized light passes through the 
solution and then through a second nicol prism. When no optically active material is placed 
between the prisms (0° rotation), the prisms are positioned at right angles so that no light is 
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transmitted. When an optically active material is placed between the prisms, the analyzer must 
be turned in order to maintain the darkness in the field of view. The optical rotation is the angle 
by which the analyzer is turned in order to reach darkness. It is very difficult to determine by 
eye the setting for complete darkness, because positions near the completely dark position are 
very dark. Therefore, many instruments are constructed such that the field of view is divided 
into two equal parts, and the analyzer is adjusted so as to equalize the light intensity in each 
half of the field. Optical rotations of chiral ligands and complexes were determined on a 
Polarimeter Rudolf Autopol III. 
liflil 
Figure 26. Rotation of plane of polarized light by optically active compounds. 
2.8. X-ray difTraction analysis 
To obtain further evidence about the structure of the metal complexes. X-ray powder 
diffraction was performed. The XRPD spectra were recorded on Rikagu mini Flex II 
Instrument. 
3. DNA binding studies 
All the experiments involving interaction of the complexes with CT DNA were conducted in 
Tris buffer containing HCI (0.01 M) adjusted to pH 7.2 with hydrochloric acid. The CT DNA 
was dissolved in Tris-HCl buffer and was dialyzed against the same buffer overnight. Solutions 
of CT DNA gave ratios of UV absorbance at 260 and 280 nm above 1.8, indicating that the 
DNA was sufficiently free of protein [136]. DNA concentration per nucleotide was determined 
by absorption spectroscopy using the molar absorption coefficient 6600 dm mol" cm at 260 
nm [137]. The stock solution was stored at 4 °C. 
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3.1 Absorption spectral studies 
The intrinsic binding constant Kb of the complex to CT DNA was determined by Wolfe-
Shimer equation, from the plot of [DNA]/|Sa-Sfj vs. [DNA], where [DNA] represents the 
concentration of DNA and Sa, Sf, %, the apparent extinction coefficient (Aobs/[M]), the 
extinction coefficient for free metal complex (M), and the extinction coefficient for the 
complex (M) in the fully bound form, respectively. In plots of [DNA]/|£a-Sf| vs. [DNA], Kb is 
given by the ratio of slope to intercept [138]. 
[DNA]/|Sa-8f| = [DNA]/|8b-8fi + l/^ A|Sb-Sf I 
Absorption spectral titration experiments were performed by maintaining a constant 
concentration of the complex and varying the nucleic acid/nucleotide concentration. This was 
achieved by diluting an appropriate amount of the metal complex solutions and DNA/5'-
GMP/5'-TMP stock solutions while maintaining the total volume constant. This results in a 
series of solutions with varying concentrations of DNA/5'-GMP/5'-TMP but a constant 
concentration of the complex. The absorbance (A) was recorded after successive additions of 
DNA/5'-GMP/5'-TMP. While measuring the absorption spectra an equal amount of CT 
DNA/5'-GMP/5'-TMP was added to both the compound solution and reference solution to 
eliminate the absorbance of CT DNA/5'-GMP/5'-TMP itself 
3.2 Fluorescence spectral studies 
The emission spectrum is obtained by setting the excitation monochromator at the maximum 
excitation wavelength and scanning with emission monochromator. Often an excitation 
spectrum is first made in order to confirm the identity of the substance and to select the 
optimum excitation wavelength. Further experiments were carried out to gain support for the 
mode of binding of complexes with CT DNA. Non-fluorescent or weakly fluorescent 
compounds can often be reacted with strong fluorophores enabling them to be determined 
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quantitatively. On this basis moleculai- fluorophore EB was used which emits fluorescence in 
presence of CT DNA due to its strong intercalation. Quenching of the fluorescence of EB 
bound to DNA were measured with increasing amounts of metal complexes as a second 
molecule and Stem-Volmer quenching constant, Ksv was obtained from the following equation 
[139]. 
I„/I = 1+ K,v 
Where, r is the ratio of total concentration of complex to that of DNA, lo and I are the 
fluorescence intensities of EB in the absence and presence of complex. Binding constant, K of 
the metal complexes was also determined using following Scatchard equation by emission 
titration [140]. 
CF = CT(I / IO-P) (1 -P) 
r/CF = K(n-r) 
where, CF is the free metal complex concentration, CT is the total concentration of the probe 
added, 1 and lo are fluorescence intensities in presence and absence of CT DNA, respectively 
and P is the ratio of the observed fluorescence quantum yield of bound probe to that of the free 
probe. The value P was obtained as the intercept by extrapolating from a plot of IQ/I vs. 
1/[DNA], r denotes ratio of CB (CB = CT-CF) to the DNA concentration i.e., the bound probe 
concentration to the CT DNA concentration, K is the binding constant and "n" is the number of 
binding sites. Emission intensity measurements were carried out using Hitachi F-2500 
spectvofluorometer at room temperature. 
3.3. Viscosity measurements 
The hydrodynamic changes are the consequence of the change in length of the molecule, the 
diminished bending between layers and the diminished length-specific mass. Flow time was 
measured with a digital stopwatch. Each sample was measured three times and an average flow 
time was calculated. Data were presented as (Ti/r|o) vs. binding ratio ([Compiex]/[DNA]), where 
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T| is viscosity of DNA in the presence of complex and T|O is the viscosity of DNA alone [141]. 
Viscosity values were calculated from the observed flow time of DNA containing solution (t 
>100s) corrected for the flow time of buffer alone (to), T] = t-t^. Viscosity measurements were 
carried out using Ostwald capillary viscometer maintained at 25 ± 0.01 °C. Several time 
readings were obtained at each titration point. 
3.4 Circular dichroic spectral studies 
Circularly polarized light represents a wave in which the electrical component spirals around 
the direction of propagation of the ray, either clockwise or counterclockwise. Within the 
absorption band, the molar absorptivity for right and left handed circularly polarized light is 
different, i.e. (Ed-Ei) i" 0. This effect changes linearly polarized light into elliptically polarized 
light and is known as circular dichroism. The amplitude of d component will be greater than the 
1 component when 1 component of the substance absorbs left circularly polarized light, more 
strongly than d component which absorb the right circularly polarized light i.e. EI > Sd-
Furthermore, if Sd> Si then the d component will be retarded more than the 1 component (Figure 
27). The ellipticity, that is the angle whose tangent is ratio of minor axis of the ellipse OB to 
the major axis OA, is denoted by 9. The molecular ellipticity [0] can be shown by the 
relationship [142], 
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Figure 27. Elliptically polarized light produced when £rf> £/ andsi> sj. 
46 
Circular dichroism graphs are plots of [0] against wavelength. Circular dichroic spectra were 
obtained on Applied Photophysics Chirascan Circular Dichroism Spectrometer with stop flow. 
3.5 Gel electrophoresis 
Gel electrophoresis is a technique widely used for separation and analysis of charged 
biomolecules like nucleic acids [143]. Any charged biomolecule migrates when placed in an 
electric field. The ratio of migration of a molecule depends on its net charge, size, shape and 
the applied current. This can be represented as follows: 
V = E.q/f 
where, V = velocity of migration of the molecule, E = electric field in volts/cm, q = net charge 
on the molecule, f = frictional coefficient which is function of mass and shape of molecule. The 
movement of a charged molecule in an electric field is often expressed in terms of 
electrophoretic mobility (n), which is defined as the velocity per unit of electric field. 
H = V/E = E. q/f E 
\i = q/f 
For molecules with similar conformation, 'f varies with size but not with shape. Thus 
electrophoretic mobility {\i) of a molecule is directly proportional to the charge density 
(charge/mass ratio). Molecules with different charge/mass ratio migrate under the electric field 
at different rates and hence get separated. This is the basic principle for all the electrophoretic 
techniques. Depending upon the nature of support medium, electrophoresis is of different types 
such as paper, starch, polyacrylamide and agarose gel electrophoresis. We have opted agarose 
gel electrophoresis, because agarose gels are more porous as compared to polyacrylamide gels 
and are, therefore, used to fractionate large macromolecules such as DNA that cannot be 
readily penetrate into and move through other types of supporting materials. Agarose is a linear 
polymer of D-galactose and 3,6-anhydro-L-galactose. When an electric field is applied across 
agarose gel, DNA molecules that are negatively charged at neutral pH, migrate towards 
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oppositely charged electrode at rates determined by their molecular size and conformation. 
DNA molecules of the same size but with different conformation travel at different rates. The 
order of migration velocity in the increasing order of various forms of DNA is: 
supercoiled DNA > linearized DNA > open circular DNA. 
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Figure 28. The three different forms ofplasmid pBR322 DNA and cleavage patterns. 
3.6. Topoisomerase I inhibition assay 
One unit of the enzyme human DNA topoisomerase 1 (Topo-1) was defined as completely 
relaxed 1 ^ ig of negatively supercoiled pBR322 DNA for 30 min at 310 K under the standard 
assay conditions. The reaction mixture (30 fiL) contained 35 mM Tris-HCI (pH 8.0), 72 mM 
KCl, 5 mM MgCl2, 5 mM DTT, 2 mM spermidine, 0.1 mg/mL BSA, 0.25 \ig pBR322 DNA, 2 
Unit Topo-I and complexes. These reaction mixtures were incubated at 310 K for 30 min, and 
the reaction was terminated by addition of 4 ^L of 5X buffer solution consisting of 0.25% 
bromophenol blue, 4.5% SDS and 45% glycerol. The samples were electrophoresed through 
1% agarose in TBE at 30 V for 8h. 
4. Antimicrobial studies 
4.1. Antibacterial activity 
Screening of the drugs for antibacterial activity 
The test organisms chosen for antimicrobial activity were two Gram positive {S. aureus 
(ATCC 25923) and B. subtilis (MTCC 121)} and two Gram negative {E. coll (ATCC 25922) 
and P. aeruginosa (ATCC 27853)} bacteria. A 9 cm nutrient agar plate was swabbed with the 
strains of 5. aureus and E. coli. Wells of 3-4 mm diameter were punched in the agar plates. 20 
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|al suspension of each of the complexes (in DMSO) was inoculated in the respective wells and 
20 fil of DMSO was put as a control in a separate well in order to look for any antibacterial 
activity of DMSO itself The plates were then incubated at 37 °C for 16-18h, after which the 
zones (if present) around the wells were measured, to assess susceptibility to the particular 
complex. 
Bacterial strains used for analyzing the antibacterial potential of the complexes 
For initial screening, standard strains oi S. aureus (ATCC 25923) and E. coli (ATCC 25922) 
were used. Subsequently the complexes were tested for minimum inhibitory concentrations 
(MICs) against genetically characterized isolates harboring antibiotics resistance genes {bla 
genes). E. coli (ATCC 25922) was used as a control. 
Measurement of Minimum Inhibitory Concentrations (MICs) 
Doubling dilutions of the drugs were prepared in sterile nutrient broth, and 100 |il of each drug 
dilution was inoculated serially in each well of a sterile microtitre plate. 100 ^1 of the bacterial 
suspension in sterile nutrient broth (turbidity adjusted to 0.5 McFarland standards) was 
inoculated in each well. Appropriate complex and bacterial controls were put up on the same 
plate. The plates were then incubated at 37 °C for 16-18h. MIC was taken as the concentration 
of the drug in the last well in which no visible bacterial growth was observed. Confirmation of 
the MIC value was done by spot inoculation of the drug-bacterial suspension on a plate of 
blood agar, two wells on either side of the observed MIC value. 
4.2. Antifungal activity 
All cultures were routinely maintained on SDA and incubated at 28 °C. The inoculums of non-
sporing fungi, C. albicans were perfonned by growing the culture in SD broth at 37 °C for 
overnight. Volume of 0.1 ml of diluted fungal culture suspension was spread with the help of 
spreader on SDA plates uniformly. Sterile 8 mm discs were impregnated with the test 
compounds. Wells of 8 mm size were cut and loaded with different concentrations of the test 
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samples. Antibiotic disc, nystatin (30 |ig/disc) were used as positive control. C. albicans plates 
were incubated at 37 °C for 18-48 h. Antifungal activity was determined by measuring the 
diameters of the inhibition zone. 
5. Molecular docking studies 
Molecular docking is carried out using a computer program in order to dock computer-
generated representations of small molecules to a receptor (or to a user-defined part thereof, 
e.g. the active site of an enzyme), followed by evaluation of the molecules with respect to 
complementarity in terms of shape and properties, such as electrostatics. Good 
complementarity of a molecule indicates that the molecule is potentially a good binder. The 
outcome of a docking exercise normally includes some sort of affinity prediction for the 
molecules investigated, yielding a relative rank-ordering of the docked compounds with 
respect to affinity. 
The rigid molecular docking studies were performed by using HEX 6.1 software [144], is an 
interactive molecular graphics program for calculating and displaying feasible docking modes 
of pairs of protein, enzymes and DNA molecule. The coordinates of metal complex was taken 
from its crystal structure as a GIF file and was converted to the PDB format using Mercury 
software (http://www.ccdc.cam.ac.uk/). The crystal structure of the B-DNA dodecamer 
d(CGCGAATTGGCG)2 (PDB ID: IBNA) and human-DNA-Topo-1 complex (PDB ID: 
1SC7) were downloaded from the protein data bank (http://www.rcsb.org./pdb). The human-
DNA-Topo-I complex was prepared using a 5'-bridging phosphorothiolate duplex 
oligonucleotide [145]. The oligonucleotide sequence of the cleavable strand of the duplex 
oligomer was 5'-AAAAAGAGTTsX-GAAAATTTTT-3', where 's ' represents the 5'-bridging 
phosphorothiolate of the cleaved strand and 'X' represents any of the four bases A, G, C or T. 
All calculations were carried out on an Intel penfium4, 2.4 GHz based machine running MS 
Windows XP SP2 as operating system. Visualization of the docked pose has been done by 
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using CHIMERA (www.cgl.ucsf.edu/chimera) and PyMol (http://pymol.sourceforget.net/) 
molecular graphics program. 
6. MTT Cytotoxicity assay 
Human breast adenocarcinoma cell line (MDA-MB 231) and human malignant melanoma cell 
line (A375) were cultured in Dulbecco's Modified Eagle's Medium (DMEM) with 2 mM L-
glutamine, 100 lU/ml penicillin, 100 |xg/ml streptomycin and supplemented with 10% heat 
inactivated foetal bovine serum. Human colon carcinoma cell line (HCT116) was cultured in 
RPMI1640 medium with 2 mM L-glutamine, 100 lU/ml penicillin, 100 (ig/ml streptomycin 
and supplemented with 10% HI-FBS. Cells were cultured in a humidified atmosphere at 37 °C 
in presence of 5% CO2. 
The MTT assay was used as a relative measure of cell viability. Cell viability assays were 
carried out as described [146-148]. Briefly, cells were seeded at the density of 2 x lO'' cells/ml. 
Quadruple cell samples were grown in 96 well micro-titer plates (Iwaki, Tokyo, Japan). After 
24h, samples were exposed to different concentrations of complexes (1.56-100 |aM) in a final 
volume of 100 .^L of culture medium. Cells were incubated for 72h in a humidified atmosphere 
of 5% CO2 at 37 °C. At the end of incubation, each well received 10 ^1 of 3-(4,5-
dimethylthiozol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (5 mg/ml in phosphate-
buffered saline, PBS) and the plates were incubated for 4h at 37 °C. The formazan crystals 
formed were solubilized in 100 p-l dimethyl sulphoxide after aspirating the medium. The extent 
of MTT reduction was measured spectrophoto-metrically at 540 nm using a Titertek Multiscan 
microElisa (Labsystems, Helsinki, Finland) and the cell survival was expressed as percentage 
over the vehicle. Experiments were done in triplicate. Cytotoxicity is expressed as the 
concentration of compound inhibiting cell growth by 50% (IC50). The IC50 values were 
detennined using GraphPad Prism 4 computer program (GraphPad Software, S. Diego, CA, 
USA). 
CHAPTER III A 
De novo design, synthesis and spectroscopic 
characterization of chiral benzimidazole-derived 
amino acid Zn(II) complexes: Development of 
tryptophan-derived specific hydrolytic DNA artificial 
nuclease agent 
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Synthesis 
Synthesis of Ligand 
IC16H14N4O2] 
The ligand, l,2-bis(lH-benzimidazol-2-yl)ethane-l,2-diol, H2bzimed was synthesized from 
L(+)-tartaric acid (3.0 g, 20 mmol) and 1,2-diaminobenzene (4.32 g, 40 mmol) in ethanol-
water mixture according to the procedure reported earlier (Scheme 3) [43]. 
NH, 0 9^^ 4NHC1 H 
NH2 HO 0 
1,2-diaminobenzene L(+)-tartaric acid [CifiHuN^Oo] 
Scheme 3. Synthesis of ligand [C16H14N4O2J. 
Synthesis of Complexes 
[C27H26N80nZn2] 
The complex [C27H26N80iiZn2] was prepared from a general synthetic procedure in which L-
tryptophan (0.408 g, 2 mmol), pretreated with aqueous NaOH (0.08 g, 2 mmol) was added to 
a 10 ml aqueous solution of Zn(N03)2.6H20 (1.188 g, 4 mmol) and stirred for 30 min. A 10 
ml methanolic solution of [C16H14N4O2] (0.588 g, 2 mmol) was added to the resulting solution 
and refluxed at 60 °C for 4h. A white precipitate formed was filtered off The volume of the 
resulting colorless solution was reduced under pressure which on slow evaporation at room 
temperature yielded white product which was isolated by filtration, washed with hexane and 
dried in vacuo (Scheme 4). 
Yield; 62%, m.p. 190-200 °C (d). Anal. Calc. for £27^26^sOuZui (%): C, 42.15; H, 3.41; N, 
14.56, Found: C, 43.03; H, 3.85; N, 14.79. IR (KBr, cm"', v) 3403 v(O-H), 3187 v(N-H), 
1625 Vas(COO), 1494 v(C=N), 1414 v,(COO), 1387 vs(N03), 1284 (imidazole NH), 824 5(0-
H)water, 745 v(Ar). 'H NMR (400 MHz, DMSa^e, 5, ppm): 12.3 (s, 2H, NH)benz,midazoie, 10.8 
52 
(s, IH, indole NH)t,yptophan, 7.17-7.46 (m, 8H, aromatic H)benzimidazoie, 7.26 (d, 2H, aromatic 
H),ryptophan, 7.33 (d, 2H, aromatic H),ryptophan, 6.3 (s, IH, OH)benzimidazoie, 5.47 (d, IH chiral 
CH)benz™idazole, 3 . 3 6 (S, ch i ra l H + NH2)tryp,ophan, 2 . 5 6 (t , 2 H -CH2),ryp,ophan. " C N M R ( 1 0 0 
MHz, DMS0-<l6, 5, ppm): 38.21 (-CH),^ ,p,ophan, 54.6 (chiral -CH)ttyptophan, 79.13 (-C-
^ n /benzimidazolej 
118.26-135.2 (aromatic C); 136.3 (-C=N)benz,midazoie, 179.6 (-€=0). [ajo 
(MeOH): +122.70; Molar conductance, AM (10"^ M, MeOH): 190 n"'cm^mor' (2:1 
electrolyte). UV-vis (10"^ M, MeOH, nm, e, Lmor'cm"'): 244 (12630), 274 (18230), 280 
(22030). ESI-MS (m/z^), 651.3 [C27H26N80iiZn2-2N03+6H^]. 
[C22H27N70llZn2] 
The complex [C22H27N70iiZn2] was synthesized by employing the same procedure as 
described above for [C27H26N80iiZn2] from L-leucine (0.262 g, 2 mmol) and [C16H14N4O2] 
(0.588 g, 2 mmol). 
Yield; 52%, m.p. 185 °C (d). Anal. Calc. for C22H27N70iiZn2 (%): C, 37.95; H, 3.91; N, 
14.08. Found: C, 38.05; H, 3.98; N, 14.78. IR (KBr, cm"', v) 3386 v(O-H), 3193 v(N-H), 
1626 Vas(COO), 1491 v(C=N), 1418 Vs(COO), 1383 vs(N03), 1291 (imidazole NH), 838 5(0-
H)wa,er, 747 v(Ar). ' H NMR (400 MHz, DMSO-de, 5, ppm): 12.43 (s, 2H, NH)be„zimidazoie, 
7.12-7.49 (m, 8H, aromatic H)benzimidazoie, 6.3 (s, IH, OH)benzimidazoie, 5.38 (d, IH, chiral 
CH)benzimidazole, 3 . 3 5 (t , Chiral C H + NH2)leucine, 2 .51 (t , 2 H , CH2)leucine, 2 . 2 3 ( m , I H , CH)leucine, 
0.85 (d, 6H, CH3)ieucine. '^ C NMR (100 MHz, DMSO-ds, 5, ppm): 23.2 (-CH3)ieucine, 25.6 (-
CH),eacme, 4 0 . 1 (-CH2)leucine, 5 6 . 8 ( c h i r a l -CH),eucme, 7 8 . 8 (-C-OH)ben^imidazole, 1 1 4 . 7 - 1 3 8 . 3 
(aromatic C); 137.2 (-C=N)benzim,dazoie, 180.2 (-C=0). [ajo (MeOH): +101.83, Molar 
conductance, AM (10"^ M, MeOH): 185 Q"'cm^mor' (2:1 electrolyte). UV-vis (10"* M, 
MeOH, nm, e, Lmor'cm'^): 243 (14600), 274 (15820), 281 (26620). ESI-MS {m/z"), 697.7 
[C22H27N70iiZn2+H^]. 
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[CziHzsNvOnZnz] 
The complex [C2iH25N70iiZn2] was synthesized by employing the same procedure as 
described above for [C27H26N80iiZn2] from L-valine (0.234 g, 2 mmoi) and [C16H14N4O2] 
(0.588 g, 2 mmol). 
Yield; 44%, m.p. 180 °C (d), Anal. Calc. for C2iH25N70i,Zn2 (%): C, 36.97; H, 3.69; N, 
14.37. Found: C, 37.75; H, 3.86; N, 14.71. IR (KBr, cm"', v) 3396 v(0-H), 3183 v(N-H), 
1626vas(COO), 1510v(C=N), 1410vs(COO), 1383 vs(N03), 1281 (imidazole NH), 850 8(0-
H)water, 743 v(Ar). 'H NMR (400 MHz, DMS0-<l6, 5, ppm): 12.9 (s, 2H, NH)benz,midazoie, 7.12-
7.54 (m, 8H, aromatic H)benzimidazoie, 6.3 (s, IH, OH)benzimidazoie, 5.38 (d, IH, chiral 
CH)benz.midazole, 3 . 6 3 (d, chiral C H + NH2)vali„e, 2 . 2 1 ( m , I H , CH)vali„e, 0 .81 (d , 3 H , CH3)valine. 
'^C NMR (100 MHz, DMSO-dg, 5, ppm): 23.1 (-CHsXaiine, 38.8 (-CH)vaiine, 68.4 (chiral -
CH)val,ne, 7 8 . 7 (-C-OH)benzimida2ole, 1 1 4 . 3 - 1 2 8 . 3 (aromatic C) ; 139 .7 (-€=N)benzimidazoIe, 178 .6 
(-C=0). [a]D (MeOH): +187.41, Molar conductance, AM (10"^ M, MeOH): 218 Q"'cm^mor' 
(2:1 electrolyte). UV-vis (10"^ M, MeOH, nm, E, Lmor'cm"'): 243 (13200), 274 (15600), 
281 (16620). ESI-MS {m/z^), 679 [C2iH25N70uZn2-3H^]. 
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Zn(N03)2.6H20 
+ 
[C,6H,4N402] 
+ 
L- amino acid +NaOH 
MeOH, H2O 
60 °C reflux 
3-4h 
V-r R 
H OH 
R= —CH2 
N 
H 
(N03)2 
J [C27H26N80„Zn2] 
.CH3 
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CH, 
Scheme 4. Synthesis of complexes [C27H26NsOuZn2], [C22H27N70iiZn2] and 
[C2,H25N70uZn2]. 
Results and discussion 
The complexes were obtained in good yield and were thoroughly characterized by elemental 
analysis, IR, NMR, ESI-MS and UV-vis spectroscopic methods. The complexes due to the 
presence of chiral auxiliary, L-amino acids {viz., trptophan, leucine and valine) exhibited 
optical rotation, [ajo values of+122.70, +101.83 and +187.41 respectively, which indicated 
that all the complexes were optically active. All the complexes were stable towards air and 
moisture and were soluble in methanol and DMSO. Molar conductance values of these 
— I "^  —1 
complexes in MeOH suggested their 2:1 electrolyte nature (185-218 Q. cm'mol ). In all the 
complexes, the Zn(Il) metal ions were four coordinated preferably in a tetrahedral 
coordination geometry. The energy minimized 3-dimensional molecular structures of 
complexes [C27H26N80iiZn2], [C22H27N70iiZn2] and [C2iH25N70iiZn2] are represented in 
Figure 29. 
.^ \f .6 6^y^ 
w -
(a) (b) (c) 
Figure 29. The energy minimized cylindrical bonded 3-dimensional molecular structures of 
complexes (a) [C2?H26N80iiZn2j, (b) [C22H27N70iiZn2] and (c) [C2iH25N70iiZn2]. Color 
scheme: Nitrogen (blue), oxygen (red) Zn(II) (dark grey) and carbon (grey). Hydrogen atoms 
and non-coordinated nitrate ions have been omitted for clarity. 
Infrared spectroscopy 
The free ligand [C16H14N4O2] displayed v(O-H) bands at -3487 cm"', a medium intensity 
band at 1538 cm"' assigned to v(C=N) of the imidazole moiety and a characteristic v{N-H) 
stretching band at 3180 cm"', v(C-N) and v(C-O) frequency at 1317 and 1267 cm"', 
respectively. In the complexes, the v(O-H) stretching band shifted to a lower wavelength 
around 3400 cm"' indicating the coordination of one oxygen atom of one alcoholic group to 
the metal center while other remains uncoordinated [77,149]. The band due to v(N-H) 
remained unaltered in all the complexes indicating non-participation of -NH group in 
complex formation. There was a negative shift at 1494 cm"' (in [C27H26N80iiZn2]), 1491 
cm"' (in [C22H27N70iiZn2]) and 1510 cm"' (in [C2iH25N70nZn2]) of v(C=N) vibration which 
indicated the involvement of nitrogen atoms in the formation of dinuclear Zn(II) complexes. 
The IR spectra of these complexes displayed bands in the region 1280-1281 cm"' due to the 
presence of imidazole ring NH [150]. Coordinated water was confirmed by the presence of 
band at -824-850 cm"', the rocking mode of water [151]. Additionally, the presence of the 
vibrational bands in the region of 1621-1629 cm"' and 1410-1414 cm"' were characteristic of 
antisymmefric and symmetric COO stretching vibrations, respectively. The Av value which 
represents the separation of the Vas(COO) and Vs(COO), reflects the coordination modes of the 
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carboxyl group [152]. In general, the Av value <200 cm"' suggests bidentate character while 
>200 cm" implies unidentate carboxylate moiety [153]. In the complexes, the Av values >200 
cm"' were observed which was indicative of the unidentate carboxylate ligation. Further, the 
bands around 1660 cm" and 1430 cm" observed in free amino acids corresponding to 
Vas(COO) and Vs(COO), respectively shifted to a lower frequency which indicated that the 
terminal coordination mode of carboxylate group of the amino acid to metal ion was via 
deprotonation [154]. The IR spectra of complexes exhibited a broad band at -3387 cm"' 
corresponding to the coordinated amino group of the amino acid moiety which has been 
shifted by -87 cm'' from free amino acid moiety suggested the coordination of-NH2 group 
amino acid to the metal ions. 
Nuclear magnetic resonance spectroscopy 
The ' H N M R spectra of diamagnetic Zn(II) complexes were recorded in DMSO-de solution 
and exhibited signals for aliphatic and aromatic protons with chemical shift values in 
accordance with their proposed structure. In complex [C27H26NgOiiZn2], a characteristic 
signal at 5 10.8 ppm assigned to the indole -NH proton of the tryptophan moiety was 
observed. The characteristic aromatic signatures were observed at 5 6.8 ppm. The chiral -CH 
of the tryptophan moiety was confinned by the signal at 5 3.36 ppm [155]. In complex 
[C22H27N70iiZn2], the presence of resonance signals at 5 2.51, 2.23 and 0.85 ppm confirmed 
the presence of leucine moiety [156]. In complex [C2iH25N70iiZn2], the valine moiety was 
confirmed by the appearance of signals at 8 2.09 and 0.81 ppm [157]. The ligand 
[C16H14N4O2] revealed -OH proton at 5 5.5 ppm [77]. This signal disappeared in the 
complexes suggesting that the -OH group was coordinated to the metal center. However, 
appearance of a new signal at 8 6.3 ppm revealed that one -OH group is uncoordinated and is 
involved in H-bonding with the anion and solvent [77]. 
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The '^ C NMR spectra of complexes |C27H26N80iiZn2], [C22H27N70iiZn2] and 
[C2iH25N70iiZn2] exhibited characteristic signals at 5 -180, -137 and -79 ppm 
corresponding to carbonyl carbon of the amino acid moiety, -C=N and -C-OH of Hibzimed 
moiety, respectively. The aromatic carbons were observed at 5 -114-138 ppm. The 
complexes [C27H26NsOnZn2], [C22H27N70nZn2] and [C2iH25N70nZn2] exhibited the signal 
corresponding to the chiral amino acid carbon at 5 54.6, 56.8 and 68.4 ppm, respectively. 
Complex [C27H26N80iiZn2] exhibited a signal at 6 38.21 ppm which could be attributed to the 
tryptophan -CH carbon. Other signals at 5 23.21 and 5 25.6 ppm in the spectra of complex 
[C22H27N70uZn2] were ascribed to -CH3 and -C'H of leucine moiety. Similarly, the signals of 
-CH3 and -CH of valine moiety in complex [C2iH25N70iiZn2] appeared at 8 23.1 and 38.8 
ppm, respectively. 
Mass spectrometry 
The formation of metal-amino acid dizinc(II) complexes and the speciation of various ionic 
forms in methanol solution were studied with ESI-MS. Three major peaks at m/z 651, 421 
and 357 were observed for complex [C27H26N80iiZn2] corresponding to the fragments 
[C27H26N8O1 iZn2 - 2NO3 + 6H^], after the removal of both the nitrate ions, [C27H26N8O1 iZn2 -
2NO3 - H2O - Trp], after the removal of water molecule and the tr>'ptophan moiety, 
[C27H26NgOiiZn2 - 2NO3 - H2O - Trp - Zn], on further removal of one zinc metal ion. 
Complex [C22H27N70iiZn2] exhibited molecular ion peak at m/z 697 corresponding to 
[C22H27N70iiZn2 + 2H^], peaks at m/z 421 and 360 corresponding to the fragments 
[C22H27N70iiZn2 - 2NO3 - H2O - Leu] and [C22H27N7O1 iZn2 - 2NO3 - H2O - Leu - Zn], 
respectively. Similarly, complex [C2iH25N70iiZn2] exhibited molecular ion peak at m/z 679 
corresponding to [C2iH25N70nZn2 - 31^ "^ ], other fragmentation peaks at m/z 537 and 360 
which were assigned to [C2iH25N70„Zn2-2N03-H20] and [C2iH25N70,iZn2-2N03-H2O 
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- Val - Zn], respectively. All complexes exhibited a peak at mJz 295 corresponding to the 
Habzimed after the removal of second zinc metal atom [C16H14N4O2 + 2H^]. 
Electronic spectra 
The electronic absorption spectra can often provide quick and reliable infomiation about the 
ligand arrangement in transition metal complexes. It also serves as a useful tool to distinguish 
among the square planar, octahedral or tetrahedral geometries of the complexes. The UV-vis 
spectra of complexes were carried out in the region of 190-1100 nm in MeOH at room 
temperature. The complexes [C27H26NgOiiZn2], [C22H27N70iiZn2] and [C2iH25N70iiZn2] 
exhibited three absorption bands in the UV region- ligand centered n->7t* and n^TC* 
transitions at -273 nm and -281 nm [149] and intraligand bands at 244 nm [37]. The 
similarity of the position of these bands in the UV-vis spectra of these complexes indicated 
similar chromophore with different N,0 coordinated ligand. 
DNA binding studies 
DNA is the primary cellular target for numerous antitumor drugs. Hence, DNA-binding 
studies are important for the rational design and construction of new and more efficient drugs 
targeted to DNA. A variety of small molecules interact reversibly with double stranded DNA, 
primarily through three modes: (i) electrostatic interactions with the negatively charged 
nucleic sugar-phosphate structure, which are along the external DNA double helix; (ii) 
binding interactions with two grooves of DNA double helix and (iii) intercalation between the 
stacked base pairs of native DNA. The DNA binding studies were carried out by employing 
various biophysical methods viz., electronic absorption titrations, emission spectroscopic 
titrations, viscosity measurements and circular dichroism. 
Electronic absorption titration 
The binding mode of the metal complexes to DNA helix is often examined by the electronic 
absorption spectroscopy, followed by the changes in the absorbance and shift in wavelength. 
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The complexes [C27H26N80iiZn2], [C22H27N70iiZn2] and [C2iH25N70iiZn2] displayed intense 
absorption bands at 273 nm assigned to intraligand transition. Upon addition of increasing 
amounts of CT DNA, these complexes exhibited an increase in the absorption spectral 
intensity of the band with a blue shift of 1-2 nm (Figure 30). 
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Figure 30. Absorption spectra of complexes (a) fC27H26NsOiiZn2j (b) [C22H27N70iiZn2] and 
(c) [C2iH25N70uZn2] in Tris-HCl buffer (pH = 7.2) in the absence and presence of 
increasing amounts ofCTDNA. Inset: Plots of [DNAJ/fSa-Sj) vs. [DNA] for the titration of 
CT DNA with complexes. Arrow indicates the increase in absorbance upon increasing DNA 
concentration, m, experimental data points; full lines, linear fitting of the data. [Complex] 
6.66x 10'^M, [DNA] 0-4.0x10'M. 
These hyperchromic changes are characteristic of the complexes bound to DNA through non-
covalent interactions or the complex could uncoil the helix and made more bases embedding 
in DNA exposed [158]. Hyperchromism and hypochromism are the spectral changes typical 
of a metal complex's association with the DNA helix. Hyperchromic effect reflects the 
corresponding changes of the DNA in its conformation and structure after the complexes are 
bound to DNA. Hypochromism results from the contraction of the DNA helix while 
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hyperchromism results from DNA helix structural damage [159]. The intrinsic binding 
constant (Kb) values of the complexes to CT DNA have been calculated to quantify the extent 
of DNA binding and are represented in Table 3. 
Table 3. The intrinsic binding constant (Kb) values of complexes with CT DNA (mean 
standard deviation of± 0.12). 
Complex Kb(]Vr') Monitored at % Blue shift 
(nm) hyperchromism (nm) 
[C27H26NgOi,Zn2] 2.78x10" 273 50 1 
[C22H27N70,iZn2] 1.89x10" 273 48 1 
[C2iH25N70iiZn2] 1.41x10" 274 21 2 
Kb values followed the order [C27H26N80iiZn2] > [C22H27N70iiZn2] > [C2iH25N70|iZn2], 
indicating that the L-tryptophan complex binds to the CT DNA with greater propensity than 
other two complexes. The higher binding propensity is due to the presence of extended planar 
aromatic ring of the tryptophan moiety, facilitating non-covalent interactions between the Jt-
system of the ligand and DNA base pairs [160]. Previous literature studies reveal that the 
complexes which lack planar aromatic moiety displays weaker DNA binding propensity 
[161]. Further, the higher the ring polarizability, more stable is the complex [92]. This clearly 
validated the order of the DNA binding propensity. Studies on some ternary complexes of 
amino acids indicated that size, shape and polarity of side chains of different amino acids may 
influence their binding mode to DNA [162]. The H2bzimed, [C16H14N4O2] as well as the 
tryptophan moiety in [C27H26N80iiZn2] possess an aromatic moiety, therefore, the probability 
of binding of these complexes to CT DNA via partial intercalation cannot be ruled out, 
nonetheless hyperchromism supports electrostatic interactions [36]. 
Interaction with mononucleotides (5'-GMP and 5'-TMP) 
To determine the coordination of zinc metal ion to the specific site of CT DNA, interaction 
with low molecular building blocks of DNA molecule viz., 5'-GMP and 5'-TMP, the studies 
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of complexes [C27H26N80iiZn2], [C22H27N70uZn2] and [C2iH25N70iiZn2] were carried out 
by UV-vis absorption titrations (Figures 31 and 32). Nucleotide-metal interactions have been 
reported to occur at nitrogen atom of the purine and pyrimidine rings as well as oxygen atom 
of the phosphate group present on the nucleotide. 
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Figure 31. Absorption spectral traces of complexes (a) fC27H26NHOiiZn2j (b) 
[C22H27N70iiZn2] and (c) [C2iH25N70iiZn2] in Tris-HCl upon the addition of 5'-GMP. 
[Complex] 6.66 xlO'^M, [5'~GMP] 0-2.OxlO~^M. 
On addition of 5'-GMP, there was an increase in the absorption intensity (hyperchromism) of 
the band centered at 273 nm in complexes [C27H26N80iiZn2], [C22H27N70iiZn2] and 
[C2iH25N70iiZn2] with no shift in position of the band, while upon the addition of 5'-TMP a 
blue shift of 1-2 nm was observed indicating the binding of these complexes to these 
mononucleotides (5'-GMP and 5'-TMP) through electrostatic interaction. 
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Figure 32. Absorption spectral traces of complexes (a) [C27H26N80iiZn2] (b) 
[C22H27N70iiZn2] and (c) [C2iH25N70uZn2] in Tris-HCl upon the addition of 5'-TMP. 
[Complex] 6.66x Kf^M, [5'-TMP] 0-2.0x10'^M. 
The Kb values revealed greater binding with 5'-TMP than 5'-GMP which clearly indicated 
that zinc specifically binds to 5'-TMP through its N3 nitrogen as compared to 5'-GMP (Table 
4) [163]. Also the Kb revealed that complex [C27H26N8O1 iZn2] binds to CT DNA with greater 
propensity than [C22H27N70iiZn2] and [C2iH25N70iiZn2]. This observation is consistent with 
previous literature reports that Zn(II) complexes in contrast to Cu(II) break the hydrogen 
bonds of A-T base pairs of the DNA helix, binding selectively to thymine, altering the local 
structure of the A-T regions of the DNA. The complex show preference for thymine due to 
two effects- i) when thymine binds, hydrogen bonds are formed between NH2 groups of the 
ligand and ii) a significant stronger molecular orbital interaction was identified in thymine in 
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comparison to guanine. The presence of two electron withdrawing oxo groups at C2 and C3 
position of thymine ring lower the energy of the lone pair orbital at N3 of thymine base [35]. 
Table 4. The intrinsic binding constant (Kb) values of complexes [C27H26NsOuZn2] and 
[C22H27N70iiZn2] with nucleotides (mean standard deviation of± 0.14). 
Complex Kb(lVr') Monitored at % Blue shift 
(nm) liyperchromism (nm) 
5'-GMP 5'-TMP 
[C27H26N80„Zn2] 2.09x10^ 
[C22H27N70iiZn2] 1.06x10^ 
[C2iH25N70iiZn2] 0.89x10^ 
To further validate our hypothesis, the binding of complexes [C27H26N80iiZn2] and 
[C22H27N70iiZn2] to 5'-GMP/5'-TMP, ' H and ^'P NMR spectroscopy was carried out. The 
' H NMR of free 5'-GMP in DMSO-de exhibited H8 signal at 5 8.07 ppm and the ribose peak 
signals at 5 3.85-5.80 ppm, respectively. On addition of complex [C27H26N80iiZn2] and 
[C22H27N70iiZn2], there was no significant shift in H8 signal of free 5'-GMP attributing to 
non-participation of guanine on binding with these complexes through coordination mode 
(Figure 33). Similarly, the ^'P NMR signal appeared at 5 3.73 ppm in free 5'-GMP did not 
show any shift on the addition of these complexes (Figure 34). On interaction of complexes 
[C27H26N80iiZn2] and [C22H27N70iiZn2] with 5'-TMP, the N3-H signal of free 5'-TMP (8 
7.64 ppm) showed a significant shift (5 7.93 ppm in [C27H26N80iiZn2] and 5 8.13 ppm in 
[C22H27N70iiZn2]). The C6-H atom of free 5'-TMP showed a signal at 5 6.2 ppm was shifted 
to 5 6.18 ppm and 6.19 ppm with increased intensity upon addition of the complexes 
[C27H26N80iiZn2] and [C22H27N70iiZn2], respectively. Further the T-CH3 peaks at 5 1.95 
ppm shifted to a slightly higher frequency to that of free 5'-TMP. The ^'P NMR signal at 5 
3.67 ppm in free 5'-TMP was shifted upfield to 5 2.15 ppm and 2.08 ppm upon the addition 
of complexes [C27H26N80iiZn2] and [C22H27N70uZn2], respectively (Figures 35 and 36). 
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These findings validate that the Zn(II) complexes preferentially bind to N3 of 5'-TMP via 
coordination rather than 5'-GMP. 
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Figure 33. 'HNMR spectra of 5'-GMP (5 mmol) (a) alone, (b) with [CiiHieNgOuZn:] (2.5 
mmol) and (c) with [C22H27N70uZn2] (2.5 mmol) at 25 V. 
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Figure 34. ^'P NMR A(Mi? spectra of5'-GMP (5 mmol) (a) alone, (b) with [C27H26NHOnZn2] 
(2.5 mmol) and (c) with fC22H27N70iiZn2j (2.5 mmol) at 25 V. 
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Figure 35. 'HNMR spectra ofS'-TMP (5 mmol) (a) alone, (b) with [C27H26N80,!Zn2] (2.5 
mmol) and(c) with [CjiHjiNjOnZm] (2.5 mmol) at 25 V. 
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31 Figure 36. "P NMR spectra of 5'-TMP (5 mmol) (a) alone, (b) with [C^jHioNnOnZnj] (2.5 
mmol) and (c) with [C22H27N70iiZn2] (2.5 mmol) at 25 °C. 
Fluorescence spectral studies 
No luminescence was observed for complexes [C27H26N80iiZn2], [C22H27N70iiZn2] and 
[C2iH25N70uZn2] either in MeOH or in the presence of CT DNA. Hence, steady state 
competitive binding studies of these complexes were monitored in order to investigate if the 
complexes could displace ethidium bromide (EB) from its EB-DNA complex. EB, 3,8-
diamino-5-€thyl-6-phenylphenanthridinium bromide, is a planar aromatic heterocyclic 
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indicator of intercalation. In the presence of DNA, it emits intense fluorescence due to 
intercalation of planar phenanthridinium ring between adjacent base pairs on the DNA double 
helix [158]. The fluorescence intensities of EB-DNA at 560 nm (270 nm excitation) with an 
increasing amount of complex concentration were recorded (Figure 37). 
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Figure 37. Emission spectra of the complexes (a) [C27H26N80iiZn2] (b) [C22H27N70uZn2] 
and (c) [C2iH25N70iiZn2] in Tris-HCl buffer (pH = 7.2) with increasing concentration of 
complexes in presence of fixed concentration of EB-DNA. Arrow indicates the change in 
intensity upon increasing concentration of complexes. Inset: fluorescence quenching curve of 
DNA bound EB with complexes m, experimental data points; full lines, linear fitting of the 
data. [Complex] 6.66-4x KT^M, [EB-DNA] 6.66x 10'^M. 
EB was non-emissive in Tris-HCl buffer medium due to fluorescence quenching of free EB 
by solvent molecules [164]. Addition of second DNA binding molecule results in a decrease 
in emission intensity of EB-DNA system. Two mechanisms either replacement of EB by the 
second molecule or electron transfer, have been proposed to account tor this reduction in 
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emission intensity [165]. The complexes [C27H26N80iiZn2], [C22H27N70iiZn2] and 
[C2iH25N70iiZn2] exhibited a decrease in the emission intensity of EB-DNA system. As 
these complexes bind to DNA by electrostatic interactions via surface binding hence observed 
quenching is due to the photoelectron transfer mechanism [166]. 
The quenching efficiency for each complex was evaluated by the Stem-Volmer quenching 
constant, Ksv, obtained as the slope of 1Q/1 vs. r (= [complex]/[DNA]) for complexes 
[C27H26N80,,Zn2], [C22H27N70iiZn2] and [C2iH25N70iiZn2] and were found to be 0.48, 0.33 
and 0.22, respectively. The maximum value obtained for L-tryptophan complex, 
[C27H26N8O1 iZn2] is in agreement with its highest Kb value, i.e. it binds to CT DNA with 
greater propensity, hence maximum quenching. High Ksv value of the complex revealed that 
they could bind to CT DNA avidly [36]. 
Viscosity measurements 
In the absence of any crystallographic data, viscosity measurements are regarded as the most 
critical and least ambiguous method to determine the binding mode of the DNA in the 
solution [167]. While intercalation results in substantial increase in the viscosity of DNA due 
to stiffening and lengthening of the helix, the other types of interactions produce only 
substantial changes in the structure of the DNA and DNA remains essentially in unperturbed 
form [168]. Lengthening of DNA helix occurs on intercalation as base pairs are separated to 
accommodate the binding ligand leading to increase in DNA viscosity. Partial or non-
classical intercalation of ligand may bend or kink the DNA helix, thereby decreasing its 
effective length and subsequently viscosity. For complexes [C27H26N80iiZn2], 
[C22H27N7O1 |Zn2] and [C2iH25N70iiZn2] the plot of relative specific viscosity TI/TIO vs. 
[complex]/[DNA] showed irregular changes in the viscosity of the DNA (Figure 38). A low 
complex concentration induced very large decrease in the viscosity which reversed on further 
addition of the complex. The initial decrease in the viscosity was due to the substrate induced 
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DNA kinking, since changes in the viscosity of a rigid rod like DNA solutions are directly 
proportional to changes in its hydrodynamic length. While at higher binding ratios much more 
kinks produced rod like DNA structure with contour lengths comparable to DNA molecules. 
The consequent increase in the length of DNA may also be due to the formation of 
supercoiled helical structure [169]. These observations are in accordance with the absorption 
and fluorescence spectral titrations and account for an external DNA binding mode-
electrostatic and/or groove binding for the complex [170]. 
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Figure 38. Effect of increasing amounts of complexes (a) [C27H26NsOuZn2], (b) 
[C22H27N70iiZn2j and (c) [C2iH25N70,iZn2] on the viscosity ofCTDNA in Tris~HCl buffer 
(pH = 7.2). Relative viscosity tj/rio vs. [complex]/[DNA]. [Complex] 0.2-1 x lO^M, [DNA] 
lOr^M. 
Circular dichroic studies 
Circular dichroic spectral technique is usefiil in monitoring the conformational variations of 
DNA during complex-DNA interactions [171]. The observed CD spectrum of CT DNA 
consists of a positive band at 275 nm (UV, Xmax, 260 nm) due to base stacking and a negative 
band at 245 nm caused by helicity, which are characteristic of DNA in the right-handed B -
form [172]. Simple groove binding and electrostatic interaction of the complexes with DNA 
shows less or no perturbation on the base stacking while intercalator enhances the intensities 
of both the bands. Upon the addition of [C27H26NgOiiZn2], [C22H27N70nZn2] and 
[C2iH25N70nZn2] to CT DNA, the CD spectrum of DNA undergoes changes in both positive 
and negative bands (Figure 39). The intensities of both the bands decreases (negative band 
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tending to zero levels). The decrease in ellipticity is due to destabilization of DNA form 
attributed to the opening of DNA structure by formation of intra-strand DNA cross-linkings 
[173]. The decrease in the positive band suggested that the complex could unwind the DNA 
helix and lead to loss of helicity [174]. 
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Figure 39. CD spectra of CT DNA alone (red), in presence of complex [C27H26NsO]jZn2] 
(brown), [C22H27N70j,Zn2j (green) and[C2iH25N70uZn2] (blue). [Complex] 10^ M, [DNA] 
l(r*M. 
DNA cleavage assay 
The DNA cleavage ability of the complex [C27H26N80nZn2] was assessed by agarose gel 
electrophoresis with supercoiled pBR322 plasmid DNA as a substrate. A concentration 
dependent DNA cleavage by complex [C27H26NgOi |Zn2] was performed in which pBR322 
DNA (300ng) was incubated at 310 K for 45 min. The activity of complex [C27H26NgOi]Zn2] 
was assessed by the conversion of DNA from Form I to Form 11 and/or Form 111. When 
pBR322 DNA undergoes electrophoresis, there is a fast migration of the supercoiled form 
(Form 1). If one strand is cleaved, the supercoiled form will relax to produce slower moving 
nicked circular (Form II). If both strands are cleaved, a linear form (Form III) will be 
generated which migrates in between [175,176]. With the increase in concentration of 
complex [C27H26N80iiZn2], DNA was converted from Form I to Form II without the 
formation of Foim III, suggesting single strand DNA cleavage (Figure 40). Complex 
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[C27H26N8O1 iZna] shows discemable cleavage with increase in concentration and intensified 
nicked (Form II) was observed. 
^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ B — * • Form 
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Figure 40. The cleavage pattern of the agarose gel electrophoresis for pBR322 plasmid DNA 
(300 ng) by [CjiHif^sOuZrij] after incubation for 45 min. Lane 1: DNA control; Lane 2: 15 
HM of [C27H26N80nZn2] + DNA; Lane 3: 30 fiM of [C27H26N80iiZn2] + DNA; Lane 4: 45 
^iM of [C27H26NsOuZn2] + DNA; Lane 5: 60 ^M of [C27H26NiiOnZn2] + DNA; Lane 6: 75 
fiMof [C27H26N80,,Zn2] + DNA. 
Since the nuclease efficiency of complexes is usually dependent on activators [177]. 
Therefore, DNA cleavage activity of [C27H26NgOuZn2] in the presence of ascorbic acid, 
glutathione, H2O2 and 3-mercaptopropionic acid (MPA) was evaluated (Figure 41). The 
cleavage activity was significantly enhanced by these activators and followed the order 
H2O2 > MPA = Asc » GSH. 
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Figure 41. Agarose gel electrophoresis pattern for the cleavage ofpBR322 supercoiled DNA 
(300 ng) by [C27H26NHOuZn2] in presence of different activating agents at 310 K after 
incubation in buffer (5mM Tris-HCl/50 mM NaCl, pH = 7.2) for 45 min. Lane 1: DNA 
control; Lane 2: 50^Mof fC27H26N80uZn2j + Ascorbic acid (0.4 M) + DNA; Lane 3: 50^M 
of[C27H2(NHOi,Zn2] + GSH(0.4 M) + DNA; Lane 4: 50,uMof[C27H26N8O,,Zn2j + H2O2 (0.4 
M) + DNA; Lane 5: 50^Mof[C27H26N8OiiZn2j + MPA (0.4 M) + DNA. 
DNA recognition elements (groove binding), DAPI (minor groove binding) and methyl green 
(major groove binding) were used to probe the potential interacting site of complex 
[C27H26N80iiZn2] with supercoiled pBR322 DNA [178]. As shown in Figure 42, upon the 
addition of DAPI (Lane 2), there was apparent inhibition of the cleavage activity of 
[C27H26NgOiiZn2] suggesting that the complex [C27H76NgO] iZn2] binds in minor groove 
which is in conformity with many literature reports revealing that benzimidazole ligands play 
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important roles in several DNA minor groove binding agents such as Hoechst 33258 and 
Hoechst 33342 [179,180]. 
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Figure 42. Agarose gel electrophoresis pattern for the cleavage of pBR322 plasmid DNA 
(300 ng) by [C27H26NHOuZn2] (0.25 mmol) in the presence of DNA groove binding agents at 
310 K after incubation for 45 min. Lane 1, DNA+[C27H26NsOiiZn2] + Methyl green; Lane 2, 
DNA + [C27H26N80iiZn2] + DAPI (8 mM); Lane 3; DNA control (2.5 mL of 
[C27H26NiiOiiZn2] mg/ml solution). 
To postulate a mechanism responsible for DNA cleavage mediated by [C27H26N80iiZn2], the 
cleaving ability in presence of various radical scavengers was carried out such as DMSO, 
tert-butyl alcohol as OH radical scavenger [181], NaNs as singlet oxygen ('O2) scavenger 
[182] and SOD as superoxide anion radical scavenger [183]. Upon the addition of NaNa and 
SOD (Lanes 2 and 3), the cleavage ability was enhanced suggesting the non-involvement of 
the singlet oxygen radical and superoxide anion radical in the mechanistic pathway of DNA 
cleavage. While in the presence of the hydroxyl radicals, DMSO and TBA (Lanes 4 and 5) the 
DNA cleavage was inhibited which suggests the involvement of diffusible OH radicals as one 
of the ROS responsible for DNA breakage (Figure 43) [184]. 
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Figure 43. Agarose gel electrophoresis pattern for the cleavage ofpBR322 supercoiled DNA 
(300 ng) by [C27H2(NnOuZn2] in presence of reactive oxygen species at 310 K after 
incubation for 45 min. Lane 1: DNA control; Lane 2: 50fiM of [C27H26NsOiiZn2j + sodium 
azide (0.4 M) + DNA; Lane 3: 50fiMof[C27H26N8Oi,Zn2] + SOD (15 units) + DNA; Lane 4: 
50fjMof[C27H26N8OiiZn2] + DMSO (0.4 M) + DNA; Lane 5: 50nM of [C27H26NHOuZn2] + 
tert-butyl alcohol (0.4 M) + DNA. 
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These OH free radicals participate in the oxidation of the deoxyribose moiety followed by the 
hydrolytic cleavage of sugar phosphate backbone [185]. Therefore, cleavage of the DNA 
occurs by hydrolytic pathway which was consistent with the previous studies demonstrating 
that Zn(I]) complexes generally cleave DNA by hydrolytic pathway [186]. 
Hydrolytic degradation of DNA by nuclease is an important biochemical reaction in living 
cells. Divalent metal zinc ions are present as catalytic centers in many natural nucleases. The 
coordinated water molecule of [C27H26N8O1 iZn2] facilitates the nucleophilic attack of oxygen 
of water to phosphorus of DNA helix to form a pentacovalent phosphorane intermediate, 
ultimately leading to P-0 bond cleavage. Furthermore, phosphate-water and could help to 
stabilize the intermediate (Scheme 5). 
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Scheme 5: Proposed simple mechanism for the hydrolysis of DNA by the Zn(II) complex 
[C27H26N80llZn2j. 
T4 DNA ligase assay 
To ascertain the discernible hydrolytic DNA cleavage pathway in presence of 
[C27H26NgOi]Zn2], DNA religation experiment was further performed in which supercoiied 
pBR322 DNA was treated with T4 DNA ligase enzyme and subjected to gel electrophoresis 
[187] (Figure 44). In our case, the nicked form (Form II) was religated to a large extent in the 
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presence of T4 DNA ligase enzyme in comparison to control DNA alone in supercoiled form 
providing supportive evidence in favor of hydrolytic mechanism. 
Formn 
Form I 
Figure 44. DNA religation by T4 DNA ligase enzyme of pBR322 plasmid DNA cleaved by 
[C27H26N80iiZn2]. Lane 1: DNA control; Lane 2: DNA cleaved by [C27H26N80nZn2]; Lane 
3: ligation of linearized DNA by T4 DNA ligase. 
Antibacterial activity 
In vitro biocidal screening of complex [C27H26N80iiZn2] was carried out for antibacterial 
activity tested against two Gram-positive [S. aureus (ATCC 25923), B. subtilis (MTCC 121)] 
and two Gram-negative [E .coli (ATCC 25922), P. aeruginosa (ATCC 27853)] bacterial 
strains. The activity was evaluated by measuring the zone of inhibition (mm) against the test 
organism representing the mean value of three readings (Figure 45). 
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Figure 45. The antibacterial activity of complex [C'27H26N80iiZn2j against different bacterial 
strains at different concentrations (250, 500 and 1000 /ig/ml). The maximum zone is 
represented by reference drug (doxycycline). 
Criteria for activity is based on zone of inhibition (mm); if more than 20 mm shows 
significant activity, for 17-20 mm inhibition activity is good, 12-17 mm it is low, and below 
74 
12 mm is insignificant. The screening results indicated that [C27H26N80iiZn2] exhibited 
significant activity against S. aureus at low concentration, whereas, at higher concentrations 
[C27H26N80iiZn2] exhibited good activity against all tested bacteria. The activity could be 
attributed to the lipophilicity of the complex [C27H26N80iiZn2]; due to the presence of phenyl 
groups which increases the solubility of molecule in lipids and they can cross the biological 
membranes with higher efficiency [188]. 
CHAPTER III B 
Synthesis, characterization, biological studies (DNA 
binding, cleavage, antibacterial and topoisomerase I) 
and molecular docking of copper(II) benzimidazole 
complexes 
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Synthesis 
Synthesis of Complexes 
[C64H6«N,8026Cl2CU4] 
The complex [C64H6oNig026Cl2Cu4] was synthesized by the sHght modification of the method 
described previously in literature [189] in which a mixture of Cu(C104)2.6H20 (0.741 g, 2 
mmol), Cu(N03)2.3H20 (0.483 g, 2 mmol) and [C16H14N4O2] (1.170 g, 4 mmol) was 
dissolved in each 10 ml of EtOH and H2O, which on slow evaporation yielded green 
crystalline solid, washed in hexane and dried in vacuo. 
Yield, 42%, m.p. 236 °C (d), Anal. Calc. for C64H6oN,8026Cl2Cu4 (%) C, 42.18; H, 3.32; N, 
13.83. Found C, 42.97; H, 3.98; N, 13.97. IR (KBr, cm"', v) 3198 b v(N-H), 1532 v(C=N), 
1280 (imidazole NH), 1093 vs v(C104 ), 743 s v(Ar). UV-vis (MeOH, 10"^  M, X^ ax, nm), 243, 
273, 281, 349 (sh), 682 (d^ ) . [ajo (MeOH), +166.00. Molar conductance, A ,^, r^-'cm^mof' 
(10"^ M, MeOH, 25 °C) 219 (2:1 electrolyte). ESI-MS (m/z^) 875 [C64H60N18O26CI2CU4-
4H2O/2]. 
[C27H26N80„CU2] 
The complex [C27H26N8O11CU2] was prepared from a general synthetic procedure in which L-
tryptophan (0.408 g, 2 mmol) pretreated with aqueous NaOH (0.08 g, 2 mmol) was added to a 
10 ml aqueous solution of Cu(N03)2.3H20 (0.966 g, 4 mmol) and stirred for 30 min. A 10 ml 
methanolic solution of [Ci6H!4N402] (0.588 g, 2 mmol) was added to the resulting solution 
and refluxed at 60 °C for 4h. A blue precipitate formed was filtered off. The volume of the 
resulting solution was reduced which on slow evaporation at room temperature yielded blue 
product which was isolated by filtration, washed with hexane and dried in vacuo (Scheme 6). 
Yield, 60%, m.p. 230-233 °C (d). Anal. Calc. for C27H26N80nCu2 (%) C, 42.36; H, 3.42; N, 
14.64. Found C, 42.22; H, 3.98; N, 14.89. IR (KBr, cm'', v) 3390 b v(H20), 3196 b v(N-H), 
1623 s Vas(COO), 1530 v(C=N), 1457 s 5(CH2), 1386 vs v(N03"), 1353 Vs(COO), 1279 
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(imidazole NH), 832 5(0-H)water, 744 s v(Ar). UV-vis (MeOH, 10^ M, X a^x, nm), 244, 274, 
280, 348 (sli), 523 (d-<l). [a]D (MeOH), +139.92. Molar conductance. A™, a"'cm^mor' (10"^ 
M, MeOH, 25 °C) 182 (2:1 electrolyte). ESI-MS (m/z^) 650 [C27H26N8OnCu2-2NO3+0.5 
H2O]. 
[C2,H25N70„CU2] 
The complex [C21H25N7O11CU2] was synthesized from L-valine (0.234 g, 2 mmol) and 
[C16H14N4O2] (0.588 g, 2 mmol) according to the method outlined above for 
[C27H26N8O11CU2]. 
Yield, 60%, m.p. 235 °C (d). Anal. Calc. for C21H25N7O11CU2 (%); C, 37.17; H, 3.71; N,14.45. 
Found C, 37.86; H, 3.98; N, 14.92. IR (KBr, cm"', v) 3482 b v(H20), 3228 b v(NH), 1622 s 
v(C=0), 1526 v(C=N), 1457 s 5(CH2), 1383 vs v(N03l, 1351 Vs(COO), 1282 (imidazole 
NH), 830 5(0-H)^ater, 747 s v(Ar). UV-vis (MeOH, 10"^  M, K^^, nm), 247, 273, 280, 343 
(sh), 528 (d-d), [ajo (MeOH), +51.88. Molar conductance, A^, Q-'cm^mof' (10"^ M, MeOH, 
25 °C) 198 (2:1 electrolyte). ESI-MS (w/z^), 565 [C21H25N7O11CU2-2NO3+O.5 H2O]. 
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Scheme 6. Synthesis of complexes [C64H6oNi802(^l2Cu4], [C27H26NHO]ICU2] and 
[C21H25N7OUCU2]. 
Results and discussion 
Benzimidazole-derived Cu(II) complexes [C64H60N18O26CI2CU4], [C27H26N8O11CU2] and 
[C21H25N7O11CU2], where [C64H60N18O26CI2CU4] is a tetranuclear cluster while 
[C27H26N8OUCU2] and [C21H25N7O11CU2] are dinuclear ternary amino acid complexes {viz., 
L-tryptophan and L-valine, respectively) were synthesized and thoroughly characterized by 
elemental analysis and various spectroscopic techniques (IR, EPR and UV-vis). All of these 
complexes are air stable for extended periods, 2:1 electrolyte and remarkably soluble in 
methanol, DMF and DMSO. The complex [C64H60N18O26CI2CU4] displayed d-d bands in the 
range of 682 nm exhibiting five and six coordination environment while complexes 
[C27H26N80nCu2] and [C2!H25N70iiCu2] exhibited bands at 523 and 528 nm, respectively 
suggestive of Cu(II) in a four-coordinate environment. All the complexes 
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[C64H60N18O26CI2CU4], [C27H26N8O11CU2] and [C21H25N7O11CU2] exhibited optical rotation, 
[aJD values of+166.00, +139.92 and +51.88, respectively, indicative of the chiral nature of 
these complexes. 
Infrared spectroscopy 
The IR spectra of complexes [C64H60N18O26CI2CU4], [C27H26N8O11CU2] and 
[C21H25N7O11CU2] were recorded in the region of 4000-400 cm"'. The free ligand, 
[C16H14N4O2] displayed v(O-H) bands at 3497 cm"', a medium intensity band at 1538 cm"' 
assigned to v(C=N) of the imidazole moiety and a characteristic v(N-H) stretching band at 
3180 cm"' in addition to other v(C-N) and v(C-O) frequency at 1317 and 1267 cm"', 
respectively [77,149]. The IR specfra of all the complexes exhibited a broad band at -3390-
3482 cm" corresponding to the coordinated amino group of the 1,2-diaminobenzene and the 
amino acid moiety (in [C27H26N80]iCu2] and [C21H25N7O11CU2]), suggesting the coordination 
of NH2 group to copper. There was a negative shift at 1532, 1530 and 1526 cm"' in 
[C64H50N18O26CI2CU4], [C27H26N8O11CU2] and [C21H25N7O11CU2], respectively in the band 
characteristic of v(C=N) which indicated the involvement of nitrogen atoms in the formation 
of complexes. The presence of bands in the region 1279-1282 cm"' could be attributed to the 
imidazole ring NH [150]. Furthermore, in the amino acid complexes [C27H26N8O11CU2] and 
[C2iH25N70nCu2], the bands around 1660 and 1430 cm"' observed in free amino acid 
assigned to antisymmetric and symmetric 0-C=0 stretching vibrations, shifted to lower 
frequencies which suggested the terminal coordination mode of the amino acids to the copper 
ion via deprotonation. The presence of bands in the region of 1622-1626 and -1351 cm" in 
[C27H26N80]iCu2] and [C2iH25N70!iCu2] corresponds to the antisymmefric and symmetric 0 -
C=0 stretching vibrations confirms the presence of the amino acid moiety. In complexes 
[C27H26N8O11CU2] and [C21H25N7O11CU2], Av value of >243 cm"' reflected monodendate 
carboxylate moiety [153]. Coordinated water in [C27H26N8O11CU2] and [C21H25N7O11CU2] was 
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confirmed by the presence of rocking mode of water at -830 cm"* [36]. The uncoordinated 
NOa'in [C27H26N8O11CU2] and [C21H25N7OUCU2] was detected at -1383 cm ', suggesting its 
presence as counter ion. 
Electron paramagnetic resonance spectroscopy 
The X-band EPR spectra of complexes [C64H60N18O26CI2CU4] and [C27H26N8O11CU2] were 
recorded both at room temperature and at LNT at a frequency of 9.1 GHz under the magnetic 
field strength 3000±1000G, with tetracyanoethylene (TCNE) as field marker (g=0.0027) 
(Figure 46), 
Room Temp 
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Figure 46. X-band EPR spectra of complexes (a) [C64H6()Nis026ChCu4] and (b) 
[C27H26NiiOiiCu2] at room temperature and LNT. 
In the spectra of complex [C64H60N18O26CI2CU4] at room temperature, a very broad axial 
symmetrical signal with g|| at 2.31, gJ- at 2.093 and gav at 2.16 computed from the formula gav 
= l/3(g|[ + 2g-L) was observed. The EPR spectra of binuclear Cu(II) complex 
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[C27H26N8OUCU2] showed a single broad band centered at g|| at 2.14, gxat 2.08 and gav at 
2.10. The calculated values g|| and gx for the complexes exhibited the order as g|| > gx > 
2.0023 which was indicative of the presence of an unpaired electron in the d / - / orbital [190]. 
At LNT, both complexes showed hyperfine splitting due to coupling of one unpaired electron 
with '*'Cu nuclei [191]. The geometric parameter G, which is a measure of the exchange 
interaction between copper centers in the polycrystalline compound, is calculated using 
Hathway expression (G = g||-2.0023/gx-2.0023) [192]. According to Hathway, if the value of 
G > 4, the exchange interaction is negligible in solid complexes but G < 4 indicates 
considerable interaction in solid complexes. In [C64H6oNig026Cl2Cu4] and [C27H26NgOiiCu2] 
the 'G' values were found to be 3.50 and 1.77, respectively, indicating considerable exchange 
interaction between the Cu(II) centers in the solid phase. 
Electronic spectra 
The absorption spectra of [C64H60N18O26CI2CU4], [C27H26N8O11CU2] and [C21H25N7O11CU2] 
exhibited three ligand centered electronic absorption bands in the UV region at 244 nm, high 
energy bands at 274 nm and 280 nm which could be attributed to intraligand 7t—>jr* transitions 
[149]. One charge transfer shoulder band near 350 nm was assignable to the 7r-*7t* electronic 
transitions of the coordinated H2bzimed ligand. Complex [C64H60N18O26CI2CU4] exhibited one 
low energy band at 682 nm confirming the dissociation of complex [C64H60N18O26CI2CU4] in 
solution [189]. Complexes [C27H26N8O11CU2] and [C21H25N7O11CU2] exhibited low energy 
bands at 523 and 528 nm, respectively, suggesting that Cu(II) ions exhibited four-coordinate 
square planar geometry exhibiting d-d transitions (dxy, dyz-^dx%^) [193]. Since, only one d-d 
transition was observed it indicated that both the Cu(II) atoms were in the same environment. 
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DNA binding studies 
Electronic absorption titration 
The absorption spectra of complexes [C64H6oNig026Cl2Cu4], [C27H26N8O11CU2] and 
[C21H25N7O11CU2] were recorded for a fixed concentration of free metal complex [6.66 x 10"^  
M] with increasing concentrations of CT DNA [0-4.0 x 10"^  M] (Figure 47). 
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Figure 47. Absorption spectral traces of complexes (a) [C64H60N1HO26CI2CU4], (b) 
[C27H26NsOnCu2] and (c) [C21H25N7O11CU2], in O.IM Tris-HCl/lOMNaCl buffer at pH 7.2 
in the absence and presence of increasing amounts of CT DNA. Inset: plots of [DNA]/ea-Sf 
(m^cm) vs. [DNA] for the titration of CT DNA with complexes m, experimental data points; 
full lines, linear fitting of the data [Complex] 6.66x lO'^M, [DNA] 0-4.0 xJO'^M. 
A strong "hyperchromic effect" was observed on increasing concentrations of CT DNA, 
although no appreciable change in the position of the intraligand band in complexes 
[C64H60N18O26CI2CU4], [C27H26N8O11CU2] and [C21H25N7O11CU2] was observed. 
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Hyperchromism could be attributed to the presence of synergic non-covalent interactions: 
external contact (electrostatic binding), hydrogen bonding and groove surface binding (major 
or minor) along outside of DNA helix. As there is no change in position of absorption bands 
(bathochromic or hypsochromic shift), it could be inferred that complexes exhibit groove 
binding interactions. Groove binding of complexes to DNA usually results in hyperchromism 
in absorption intensity, suggestive of the unwinding of the DNA double helix as well as its 
unstacking and the concomitant exposure of the bases. The intrinsic binding constant, Kb 
values for complexes [C64H6oNig026Cl2Cu4], [C27H26N8O11CU2] and [C21H25N7OUCU2] were 
calculated and are represented in Table 5. 
Table 5. The intrinsic binding constant (Kb) values of complexes with CT DNA (mean 
standard deviation of± 0.15). 
Complex Kb(]Vr') Monitored at % Blue shift 
(nm) hyperchromism (nm) 
[C64H60N18O26CI2CU4] 1.38x10^ rh 62 2 
[C27H26N8O11CU2] 2.4x10" 273 45 1 
[C21H25N7O11CU2] 1.11 X 10" 272 3j 1 
From the observed Kb values, it was evident that [C64H60N18O26CI2CU4] binds more strongly 
to CT DNA as compared to [C27H26N8O11CU2] and [C21H25N7O11CU2] which exhibited 
relatively less binding strength. This could be attributed to the different binding modes of 
Cu(II) complexes due to their structure, charge and type of ligands [194]. The complex 
[C64H60N18O26CI2CU4] is a tetranuclear molecular entity possessing four copper centers in 
cubane arrangement, two copper centers in five coordinate and other two in six coordinate 
arrangements. On the other hand, the complexes [C27H26N80nCu2] and [C2iH25N70nCu2] are 
dinuclear ternary Cu(ll) complexes showing four coordinate arrangement, the geometrical 
topology being restricted by amino acid scaffold, as the complexes possess identical charge. 
Evidently, complex [C64H60N18O26CI2CU4] is structurally different from [C27H26N8O11CU2] 
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and [C21H25N7O11CU2] owing to its tetranuclearity and maximum number of-OH groups due 
to four H2bzimed moieties in comparison to [C27H26N8O11CU2] and [C21H25N7O11CU2], and 
the DNA double helix possess many hydrogen binding sites which are accessible both in the 
minor and major grooves, it is likely that the -OH group of complex [C64H6oNig026Cl2Cu4] 
could form extensive hydrogen bonding with DNA [195]. The complexes with -NH/-OH 
groups (benzimidazole) can form hydrogen bonds with A-T base pairs (N-3 of adenine or O-
2 of thymine) of the DNA [196]. Though the intercalation of the H2bzimed moiety between a 
set of adjacent base pairs of DNA is sterically impossible, but some type of partial 
intercalation can be envisioned in such complexes. 
Emission spectral studies 
Since, no luminescence was observed for [C64H60N18O26CI2CU4], [C27H26N8O11CU2] and 
[C21H25N7O11CU2] at room temperature in MeOH or in the presence of CT DNA, competitive 
binding studies using EB were carried out. When complexes [C64H60N18O26CI2CU4], 
[C27H26N8O11CU2] and [C21H25N7O11CU2] were added to CT DNA pretreated with EB, the 
DNA induced emission intensity at 560 nm (270 nm excitation) was decreased (Figure 48). 
As these complexes bind to DNA via non-covalent groove binding interactions, the observed 
quenching is due to the photoelectron transfer mechanism [166]. Relative binding of these 
complexes to CT DNA is measured from the extent of reduction in emission intensity. The 
Stern-Volmer quenching constant, Ksv values calculated for [C64H6oNig026Cl2Cu4], 
[C27H26N8O11CU2] and [C21H25N7O11CU2] were found to be 1.92, 0.72 and 0.36, respectively. 
A large decrease in emission intensity suggests stronger binding propensity to CT DNA [36]. 
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Figure 48. Emission spectra of the complexes (a) [C6^H6oNis026Cl2Cu4], (b) 
[C27H26NSO11CU2] and (c) [C21H25N7O11CU2]. Tris-HCl buffer (pH = 7.2) with increasing 
concentration of complexes in presence of faed concentration of EB-DNA. Arrow indicates 
the change in intensity upon increasing concentration of complexes. Inset: fluorescence 
quenching curve of DNA bound EB with complexes m, experimental data points; full lines, 
linear fitting of the data. [Complex] 6.66-4 x 10^ M, [EB-DNA] 6.66 x lO'^M. 
Viscosity measurements 
The relative specific viscosity of the DNA reduces steadily upon addition of complexes 
[C64H60N18O26CI2CU4], [C27H26N8O11CU2] and [C21H25N7O11CU2] indicating the complexes 
bind to DNA via non-covalent interactions (Figure 49) [197]. The decreased relative viscosity 
of DNA may be explained by a binding mode which produced bends or kinks in the DNA and 
thus reduced its effective length and concomitantly its viscosity. 
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Figure 49. Effect of viscosity of complex [C64H60N1SO26CI2CU4] (black), [C27H26N80,]Cu2] 
(blue) and[C2iH2sM70iiCu2] (red) on the viscosity ofCTDNA. Relative viscosity t}/rjo vs. 
[complex]/[DNAJ. [Complex] 0.2-1.0 x lO^M, [DNA] lO^M. 
Circular dichroic studies 
The CD spectra of complexes [C64H6oN)8026Cl2Cu4], [C27H26N8O11CU2] and 
[C21H25N7OUCU2] on addition of CT DNA showed conformational changes upon the addition 
of the complexes without any changes in the wavelength (Figure 50). 
Figure SO. CD spectra ofCTDNA alone (red), in presence of complex [C64H6(iN 18O26CI2CU4] 
(brown), [C27H26N80nCu2] (green) and [C21H25N7O11CU2] (blue). [Complex] 10^^ M, [DNA] 
10" M. 
Both the bands show a slight change in the intensities. Groove binding and electrostatic 
interaction of the complexes with DNA reveals slight changes in the intensity of both negative 
as well as positive band of DNA. Therefore, CD spectral changes suggest groove binding 
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interaction that stabilizes the right-handed B-form of DNA [198]. On the basis of all of the 
spectroscopic studies, we concluded that the complexes [C64H60N18O26CI2CU4], 
[C27H26N8O11CU2] and [C21H25N7O11CU2] bind to CT DNA preferentially in a non-covalent 
groove binding mode. 
DNA cleavage assay 
The DNA cleaving capability of complexes [C64H60N18O26CI2CU4] and [C27H26N8O11CU2] 
were assessed by gel electrophoresis. Figure 51 shows agarose gel electrophoresis patterns of 
pBR322 DNA after incubation with complexes [C64H60N18O26CI2CU4] and [C27H26N8O11CU2] 
for 45 min in Tris-HCl buffer (pH 7.2) at 37 °C. Compared with DNA control (Lane 1), the 
patterns of lanes 2-6, demonstrate that the DNA cleavage occurs only when incubated with 
complexes [C64H60N18O26CI2CU4] and [C27H26N8O11CU2]. The conversion of supercoiled form 
(Form I) to nicked form (Form II) becomes more efficient with increasing concentration of 
complexes [C64H60N18O26CI2CU4] and [C27H26N8O11CU2] and a third form (linear form) 
migrated in between Form I and Form II suggesting double strand DNA cleavage. 
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Figure 51. The cleavage patterns of the agarose Gel electrophoresis diagram showing 
cleavage ofpBR322 supercoiled DNA (300 ng) at 310 K after 45 min of incubation by (a) 
Lane 1: DNA control; Lane 2: 5 nM of [C64H6oNt,026Cl2Cu^] + DNA; Lane 3: 10 ^iM of 
[C64H60N1HO26CI2CU4] + DNA; Lane 4: 15 ^ M of [C64H6(,N„026Cl2CuJ + DNA; Lane 5: 20 
fiM of [C64H60N1HO26CI2CUJ + DNA; Lane 6: 25 ^M of [C64H60N18O26CI2CU4] + DNA, (b) 
Lane 1: DNA control; Lane 2: 10 nM of [C27H26N,OnCu2] + DNA; Lane 3: 20 ^tM of 
[C2?H26NtiOiiCu2j + DNA; Lane 4: 30 fiM of [C27H26NsO},Cu2] + DNA; Lane 5: 40 ^iM of 
[C27H2MOUCU2] + DNA; Lane 6: 50 ^ Mof[C27H26N,OnCu2j+ DNA. 
87 
When inhibitors of oxygen-based radicals, ascorbic acid, glutathione (GSH), H2O2 and 3 -
mercaptopropionic acid (MPA) were added to the complexes [C64H60N18O26CI2CU4] and 
[C27H26N8O11CU2] to establish the reactive species responsible for DNA cleavage, the 
cleavage ability of [C64H60N18O26CI2CU4] was significantly enhanced by these activators 
following the order H2O2 ~ MPA > GSH » Asc (Figure 52). The conversion to Form III 
(linear DNA) was observed in the presence of MPA and GSH. Similarly, complex 
[C27H26NgOiiCu2] exhibited DNA cleavage in the presence of these activators showing 
complete inhibition in the case of H2O2 and MPA, following the order H2O2 ~ MPA > GSH > 
Asc. 
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Figure 52. Agarose Gel electrophoresis pattern for the cleavage ofpBR322 supercoiled DNA 
(300ng) by complex (a) [C6-1H60N1SO26CI2CUJ and (b) [C27H26NSO11CU2] in presence of 
different activating agents at 310 K after incubation for 45 min. Lane 1: DNA Control; Lane 
2: 25 ^iM of complex + H2O2 (0.4 M) + DNA; Lane 3: 25 /uM of complex+MPA (0.4 M) + 
DNA; Lane 4: 25 ^M of complex + GSH (0.4 M) + DNA; Lane 5: 25 jiM of complex + ASc 
(0.4 M) + DNA; Lane 6: 25 ^iM of complex + DMSO (0.4 M) + DNA; Lane 7: 25 nM of 
complex + EtOLL (0.4 M) + DNA; Lane 8: 25 j^M of complex^ sodium azide (0.4 M) + DNA; 
Lane 9: 25 juM of complex + SOD (15 units) + DNA; Lane 10: 25 juM of complex + DNA + 
DAPl (8 juM); Lane 11: 25 /uM of complex + DNA + methyl green (2.5 juL of a O.Olmg/ml 
solution). 
To determine the potential interacting site of [C64H6oNig026Cl2Cu4] and [C27H26N8O11CU2] 
with pBR322 DNA, control experiments was performed using DNA recognition elements 
DAPI (minor groove binding) and methyl green (major groove binding) prior to the addition 
of complexes [C64H60N18O26CI2CU4] and [C27H26N8O11CU2]. The cleavage reaction mediated 
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by complex [C64H60N18O26CI2CU4] was inhibited in presence of methyl green (Lane 10, Figure 
52a) while, [C27H26NgOnCu2] inhibited DNA cleavage in presence of DAPI (Lane 11 Figure 
52b), suggesting that major groove was the preferred interacting site of 
[C64H6oNig026Cl2Cu4], whcrcas [C27H26N8O11CU2] prefers minor groove which has been 
further validated by molecular docking studies. 
Reactive oxygen species generated during the interaction between metal complexes and 
dioxygen or redox reagents are major cause of DNA damage. To postulate a mechanism 
responsible for DNA cleavage mediated by complexes [C64H6oNig026Cl2Cu4] and 
[C27H26N8O11CU2], electrophoretic study with some standard radical scavengers was also 
carried out, viz., ethanol, DMSO (hydroxyl radical scavengers), sodium azide (singlet oxygen 
scavenger) and SOD (superoxide radical scavenger) under identical conditions (Figure 52). 
Copper complexes are able to cleave DNA through both oxidative and hydrolytic processes. 
The addition of DMSO (Lane 6), EtOH (Lane 7) to [C64H60N18O26CI2CU4] diminishes the 
cleavage activity which is indicative of the involvement of hydroxyl radical in the cleavage 
process. In the case of SOD (Lane 9) the Form II of plasmid DNA was converted to linear 
Form III indicating two subsequent and proximate single strand breaks of DNA non-
randomly. This result demonstrates that there is no involvement of superoxide radical in DNA 
scission. Since [C64H60N18O26CI2CU4] is able to cleave DNA in the absence of any reducing 
agent, it may be assumed that DNA might be cleaved by a discernible hydrolytic path. The 
commonly accepted mechanism of hydrolysis of deoxynucleotide phosphates involves 
nucleophilic attack of hydroxyl oxygen on the phosphorus to give a five-coordinate 
phosphate intermediate [75]. The complex [C64H60N18O26CI2CU4] lacks coordinated water 
molecule but has Cu-N groups, and it has been reported previously that a phosphate ester 
bond can be also hydrolytically cleaved by Cu(II) complexes with N-containing ligands 
[199], and this eventuality cannot therefore, be ruled out. Direct evidence in support of 
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hydrolytic cleavage mechanism of exhibited by [C64H60N18O26CI2CU4] was obtained by the 
religation assays in which supercoiled pBR322 DNA was treated with T4 DNA Hgase enzyme 
and subjected to gel electrophoresis. 
In the case of [C27H26N8O11CU2], the addition of DMSO (Lane 6) and EtOH (Lane 7) did not 
show any inhibition of the nuclease activity. Addition of singlet oxygen quencher NaNs (Lane 
8) did not show any appreciable inhibitory effect on the chemical nuclease activity by the 
complex, so there is no involvement of singlet oxygen of DNA cleavage process. No obvious 
inhibitions are observed for the Cu(II) complex in the presence of SOD (Lane 9), the results 
rule out the possibility of DNA cleavage by superoxide. These results are indicative of the 
involvement of hydroxyl radical and/or "metal-oxo" intermediate. Furthermore, there was 
no DNA-cleavage (complete inhibition) observed (Lane 3, Figure 52). The DNA cleavage 
reaction of the [C27H26N80i]Cu2] in the presence of MPA probably proceeds through the 
oxidative hydroxyl radical pathway in a similar way as proposed by Sigman and co-workers 
as shown below [118]. 
Cu(ll) complex + DNA -* Cu(II)-DNA 
Cu(ll>-DNA + MPA ^ Cu(I)-DNA 
Cu(I)-DNA + ^02 ^ 'OH + SC DNA-> Cleaved DNA. 
T4 DNA ligase assay 
The hydrolytic mechanism of pBR322 DNA cleavage by [C64H60N18O26CI2CU4] was further 
supported by DNA religation experiments in which supercoiled pBR322 DNA was treated 
with T4 DNA ligase enzyme and subjected to gel electrophoresis. The complex 
[C64H60N18O26CI2CU4] yielded linearized DNA which was religated by using T4 DNA ligase 
enzyme (Figure 53). In DNA hydrolytic cleavage, 3'-0H and S'-OPOs (5'-0H and 3 ' -
phosphate) fragments must exclusively afford and that these fragments can be enzymatically 
ligated [200]. In some cases, the hydrolytic products either did not end at the required 5'-
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phosphate and 3'-0H (ribose) termini or the complex sometimes bound to the termini of 
cleaved DNA which would result in the religation being incomplete or even failing 
completely [201]. The complex [C64H60N18O26CI2CU4] yielded linearized DNA which was 
religated by using T4 DNA ligase enzyme. In our case, DNA religation was complete and 
after ligation there was complete repair which was quantitatively ascertained by comparison 
of complex treated DNA and with the control DNA alone in SC form. 
^ Form-II 
*^¥orm - III 
• • F o r m - I 
1 2 3 
Figure 53. Agarose Gel electrophoresis pattern for the ligation pBR322 plasmid DNA 
linearized by [C64H6(tNis026Cl2Cu4]; Lane 1: DNA control; Lane 2: pBR322 plasmid DNA 
cleaved by [C64H60N1SO26CI2CU4]; Lane 3: ligation of linearized pBR322 plasmid DNA by T4 
DNA ligase. 
Topoisomerase-I inhibition assay 
Topo-I is one of the DNA-targeting enzymes that control the topology of the DNA by a 
single-strand cut, allowing the DNA helix to swivel and release torsional strain which results 
in relaxation of supercoiled DNA, which is required during the transcription or replication. 
Blocking the binding of transcription factors to DNA by DNA-binding drugs and in turn 
modulating gene expression have become an attractive strategy in cancer therapy [202]. 
Topoisomerases (-agents designed to interfere with the action of topoisomerase enzymes) 
have become popular targets for cancer chemotherapy treatments. It is thought that 
topoisomerase inhibitors block the ligation step of the cell cycle, generating single and double 
stranded breaks that harm the integrity of the genome. Introduction of these breaks 
subsequently leads to apoptosis and cell death. A plasmid DNA cleavage assay of the 
complexes [C64H60N18O26CI2CU4] and [C27H26N8O11CU2] were used to investigate the 
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influence of the complexes on the activity of human Topo-I by agarose gel electrophoresis. 
This assay provides direct means of determining if the drug affects the unwinding of a 
supercoiled (SC) duplex DNA substrate, because the enzyme converts SC DNA to relaxed (R) 
DNA and open circular (OC) DNA. When catalytic activity of Topo-I was assayed, 
[C64H6oNig026Cl2Cu4] and [C27H26N8O11CU2] inhibited this process in a concentration-
dependent manner [203]. As shown in Figure 54, supercoiled DNA was fiilly converted into 
open circular form (Lane 2, Topo-I) in the absence of complex. However, upon increasing 
concentrations of [C64H60N18O26CI2CU4] and [C27H26N8O11CU2] (10-25 ^M), the levels of 
open circular form were diminished (Lanes 3-10). 
1 2 3 4 5 6 7 8 9 10 
Figure 54. The cleavage patterns of the agarose Gel electrophoresis diagram showing effect 
of different concentrations of [C64H60N1SO26CI2CU4J and [C27H26NsOaCu2j on the activity of 
DNA Topo-I); Lane 1: DNA control; lane 2: Topo-I + DNA; Lane 3: 10 nM of 
fCfi,H6(iNi8026Cl2CuJ + DNA + Topo-I; Lane 4: 15 ^iMoffC64H6()N!fi026Cl2CuJ + DNA + 
Topo-L Lane 5: 20 //M of fCn,H6oN,s026Cl2CuJ + DNA + Topa-I; Lane 6: 25 nM of 
fC64H6oNi8026Cl2CuJ + DNA + Topo-L Lane 7: 10 nM of [C27H26NHOI,CU2] + DNA + 
Topo-L Lane 8: 15 //M of [C27H26N80nCu2] + DNA + Topo-L Lane 9: 20 fiM of 
[C27H26NHOJ,CU2] + DNA + Topo-I; Lane 10: 25 jitMof[C27H26NsOjjCu2j + DNA+Topo-L 
The DNA relaxation effects caused by Top-I were totally inhibited by [C64H6oNig026Cl2Cu4] 
and [C27H26N8O11CU2] at 20 ^M (IC50 -20 ^M) and 25 ^M (IC50 -25 ^M), respectively, 
comparing with some classical Topo-I inhibitors (Table 6) [204-208]. These findings imply 
that both complexes may block the DNA strand passage event of the enzyme, and serve as 
catalytic inhibitor of Topo-I, due to (i) relatively strong DNA binding ability of 
[C64H60N18O26CI2CU4] and [C27H26N8O11CU2] with DNA at higher concentration which expels 
the Topo-I from approaching plasmid DNA and in turn leads to a lower level of DNA 
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relaxation or (ii) direct interference with the enzyme (i.e., stabiHzation of topoisomerase-
DNA cleavable complexes) and inactivating its proper functioning or (iii) ligand that occupies 
the topoisomerase binding site may suppress the association of topoisomerase with DNA, thus 
influencing the topoisomerase activity. 
Table 6: ICso (/uM) values of complexes [C64H60N 1SO26CI2CU4] and [C27H26N8O11CU2J on 
topoisomerase I activities, some of the classical Topo-I inhibitors. 
Complexes 
Etoposide 
Camptothecin 
Doxorubicin 
Novobiocin 
Topostatin 
Hoechst 33258 
A-[Ru(bpy)2(uip)]'" 
A-[Ru(bpy)2(uip)]'" 
[Ru(bpy)2(appo)]^^ 
[C64H60N,8O26Cl2CU4] 
[C27H26N80nCU2l 
ICs«(nM) 
>1000 
17 
>100 
>100 
17 
30 
-40 
-40 
-25 
25 J 
Ref 
[204] 
[205] 
[205] 
[205] 
[205] 
[206] 
[207] 
[207] 
[208] 
This 
work 
Molecular docking 
Molecular docking studies with DNA 
The design of molecules that can recognize specific sequences and structures of nucleic acids 
plays an important role both for understanding nucleic acid molecular recognition as well as 
for the development of new chemotherapeutic drugs. Molecular docking technique is an 
attractive scaffold to understand the Drug-DNA interactions for the rational drug design and 
discovery, as well as in the mechanistic study by placing a small molecule into the binding 
site of the target specific region of the DNA mainly in a non-covalent fashion [209], which 
can substantiate the spectroscopic results. 
In our experiment, molecular docking studies of complexes [C64H60N18O26CI2CU4], 
[C27H26N8O11CU2] and [C21H25N7O11CU2] with DNA duplex of sequence 
93 
d(CGCGAATTCGCG)2 dodecamer (PDB ID: IBNA) were performed in order to predict the 
chosen binding site along with preferred orientation of the molecules inside the DNA groove. 
The energetically most favorable conformation of the docked pose from Figure 55 revealed 
that [C64H60N18O26CI2CU4] approaches towards the gap between DNA major groove mainly 
through H2bzimed ring while [C27H26N8O11CU2] and [C21H25N7O11CU2] fits snugly into the 
curved contour of the targeted DNA in the minor groove and is situated within narrower A-T 
(-10.8 A) regions compared to G-C (-13.2 A) ones, due to preferential binding of 
[C64H60N18O26CI2CU4], [C27H26NgOiiCu2] and [C21H25N7O11CU2] bearing H2bzimed moiety to 
A-T regions compared to the G-C region and leads to van der Waals interaction and 
hydrophobic contacts with DNA functional groups which define the stability of groove [210]. 
It is well known that the interactions of chemical species with the minor groove of B-DNA 
differ from those occurring in the major groove, both in terms of electrostatic potential and 
steric effects, because of the narrow shape of the former. Small molecules interact with the 
minor groove, while large molecules tend to recognize the major groove binding site [211]. 
Changes in accessible surface area of interacting residues show a preferential binding of 
[C64H60N18O26CI2CU4], [C27H26N8O11CU2] and [C21H25N7O11CU2] between A-T base pairs, 
and bends the DNA slightly in such a way that a part of the molecule comes between the two 
base pairs of the DNA helix which makes favorable stacking interactions between the ring 
systems of the DNA bases and the H2bzimed ring of complexes. Hydrogen bonding from the 
C-2 carbonyl oxygen of T or the N-3 nitrogen of A to the minor groove binders is important 
[212]. In addition, there are H-bonds (2.8-3.0 A) between the -OH groups of H2bzimed and 
C-2 carbonyl oxygen of T8 at a distance of 3.71 A. The resulting binding energy of docked 
metal complexes [C64H6oN]8026Cl2Cu4], [C27H26N80i]Cu2] and [C21H25N7O11CU2] were 
found to be -321.3, -294.6 and -262.4 KJmol', respectively, correlating well with the 
experimental DNA binding values. The more negative the relative binding, the more potent 
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the binding as between DNA and target molecules. Thus, we can conclude that there is a 
mutual complement between spectroscopic techniques and molecular docked model, which 
can be substantiate our spectroscopic results and at the same time provides further evidence of 
groove binding. 
Figure 55. Molecular docked model of complexes (a) [C64H6oNi8026ChCu4], (b) 
[C27H26N8OHCU2J and (c) [C21H25N7O11CU2J with DNA dodecamer duplex of sequence 
d(CGCGAATTCGCG}2 (PDB ID: IBNA) and the brown solid line showing hydrogen bond 
interaction between them. 
Docking studies with DNA-Topo-I 
In order to further rationalize the observed Topo-I inhibitory assay, molecular docking studies 
of [C64H6oN|g026Cl2Cu4] and [C27H26N80,,Cu2] with human-DNA-Topo-I (PDB ID: 1SC7) 
were performed to understand the putative binding site. The X-ray crystallographic structure 
of the human-DNA-Topo-I complex was retrieved from Protein Data Bank in which Topo-I 
is bound to the oligonucleotide sequence S'-AAAAAGACTTsX-GAAAATTTTT-S', where 
's' is 5'-bridging phosphorothiolate of the cleaved strand and 'X' represents any of the four 
bases A, G. C or T. The phosphoester bond of G12 in 1SC7 was rebuilt and SH of Gl 1 on the 
scissile strand was changed to OH [213], The analysis of best docked conformation (Figure 
56) revealed that both [C64H6oNig026Cl2Cu4] and [C27H26NgO, ,Cu2] approaches towards the 
DNA cleavage site in the Topo-I -DNA complex and forming a stable complex through JI-TT 
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stacking interactions between the Gil (+1) and pyrimidine ring of TIO (-1) in the minor 
groove on the scissile strand and CI 12 and A113, on the non-scissile strand, parallel to the 
plane of base pairs without having hydrogen bonds with the enzyme, subsequently leading to 
inhibitory effect on Topo-1 [214]. The intercalation of complexes between the DNA base 
pairs at the cleavage site results in increased physical distance between the cleaved DNA 
termini and consequently inhibition of the religation step catalyzed by Topo-I. The resulting 
relative binding energy of Topo-1 docked [C64H60N18O26CI2CU4] and [C27H26N8O11CU2] were 
found to be -361.6 and -347.1 KJmof' respectively, which revealed that 
[C64H6oNig026Cl2Cu4] binds the cleavable complex more efficiently suggesting that it can be 
a potential scaffold to be used for therapeutic purpose. Furthermore, DNA intercalating forces 
was much more important than hydrogen bonding of the ligand to the surrounding amino 
acids residues of the protein, or to the base pairs [215]. Hence, we could conclude that the 
complex occupies the topoisomerase binding site and may suppress the association of 
topoisomerase with DNA, thus influencing the topoisomerase inhibition activity or form 
stable complex with DNA and have a high potential to act as DNA-targeting anticancer 
drugs, 
(a) VLWl maKli^m^^^\ (b) 
Figure 56. Molecular docked model showing intercalation of complexes (a) 
[C64H60N18O26CI2CU4J and (b) [C27H26^80iiCu2j in the cleavage site of human DNA 
topoisomerase I (PDB ID: 1SC7). 
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Antibacterial activity 
The diameter of the zone is measured to the nearest millimeter. Test substances which 
produce the zone of inhibition with diameters 9 mm or more are regarded as positive, i.e. 
having antimicrobial activity; while those cases where the diameter is below 9 mm, the 
bacteria are resistant to the sample tested and the sample is said to have no antimicrobial 
activity. In our experimental sets, all the complexes were found to exhibit significant 
antimicrobial activity. The minimum inhibitory concentration expressed in micrograms, of the 
complexes showing positive antimicrobial property is given in Table 7 (Figure 57). 
30 
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-*f - [CwHaiNigOasCljCiu: 
- ^ [C?7H26N80„C'n2] 
-m~ [C21H25N7O11C112] 
Genetically Characterized Bacterial Isolates {1-8) 
Strain 9 = f, coli ATCC 25922 
Figure 57. In vitro antibacterial activities of complexes [C64H60N18O26CI2CU4], 
[C27H26N8O11CU2] and [C21H25N7O11CU2] indicated by MIC ffJg/ml) against genetically 
characterized bacterial isolates. 
Activity against resistant bacterial isolates harboring blacrxm blOampCt blasHv and blarEM-
The tetranuclear Cu(ll) complex [C64H6oNig026Cl2Cu4] demonstrated marked activities 
against isolates I (/J/OCTX-M), 3 {bla^mpc + i/acix-M), and 4 (6/acTx-M + blasm); best being 
against isolate 4 harboring blacixu + blasm The amino acid derived complex 
[C27H26N80nCu2] showed potential antimicrobial activity against genotypically characterized 
isolates [1 {blacjx-M), 4 {blacTx-u + blasm) and 5 {blacrx-u + /'/o'ampc + blasm)] when 
97 
compared against the standard E. coli (ATCC 25922) while the complex [C21H25N7O11CU2] 
showed potential activity against isolate 5 {blacvx-u + bhampc+blasm)-
Table 7: Minimal inhibitory concentrations of the complexes [C(yiH6oNi802^l2Cu4], 
[C27H26N80]jCu2] and [C21H25N7OUCU2] for the Gram-(+) bacteria assayed. 
Complex MIC value (fig/mL) 
1 
Strains 
5 6 8 E. coli 
[C64H60N18O26CI2CU4] 3.12 6.25 1.57 0.78 - - - - 3.12 
[C27H26N8OUCU2] 6.25 12.5 12.5 6.25 6.25 12.5 12.5 25 6.25 
[C21H25N7O11CU2] 12.5 6.25 6.25 6.25 3.12 12.5 12.5 12.5 3.12 
The results for the zones of inhibition of the respective complexes against Staphylococcus 
aureus (ATCC 25923) and Escherichia coli (ATCC 25922) are shown in Figure 58. Among 
the complexes screened, the [C27H26N8O11CU2] was found as the most effective complex 
against Gram-{+) bacteria (S. aureus) whereas [C64H6oNig026Cl2Cu4] and [C2iH25N70iiCu2] 
were found to demonstrate substantial activity against Gram-{-) bacteria {E. coli). 
25 
1 ^  
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- 8 . auieusATCC29n23 
- E coli ATCC25922 
_ 1 1 1 
[CrKisNsOnC'nj) [CaHisNTOnCii:] [CMH<j)Ni80aiCl2C'n4l 
Complex 
Figure 58. Graph showing zone inhibition diameter vs. complexes [C64H6oNis02^l2Cu4], 
[C27H26N80i,Cu2]and[C2iH25N70nCu2j. 
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Conclusion 
Multinuclear Zn(II) and Cu(II) complexes of benzimidazole scaffold (H2bzimed); tetranuclear 
Cu(II) benzimidazole and dinuclear Cu(II)/Zn(II) benzimidazole with ancillary ligands (L-trp, 
L-leu and L-val) were synthesized, characterized by structural, analytical and spectral 
methods and their biological potential as therapeutic agents for their possible use as 
antibacterial agents was studied. The in vitro DNA binding profile of [C27H26N80iiZn2], 
[C22H27N70nZn2], [C2iH25N70uZn2] [C64H60N18O26CI2CU4], [C27H26N80„Cu2] and 
[C21H25N7O11CU2] investigated by absorption spectroscopy, fluorescence spectroscopy, 
viscosity and CD measurements revealed that the binding mode to CT DNA was essentially 
non-covalent via electrostatic interactions. The gel electrophoresis assay demonstrated that 
[C27H26N80iiZn2], [C64H60N18O26CI2CU4] and [C27H26N8O11CU2] promote the cleavage ability 
of the pBR322 plasmid DNA but with different cleavage mechanisms: dinuclear Zn(II) 
complex [C27H26N80iiZn2] and tetranuclear Cu(II) complex [C64H60N18O26CI2CU4] cleaves 
DNA via hydrolytic pathway (further validated by T4 DNA ligase assay), while the DNA 
cleavage by dinuclear Cu(II) complex [C27H26N8O11CU2] followed oxidative pathway. 
Further, both the Cu(II) complexes displayed good Topo-I inhibition activity at different 
concentrations. The complex [C64H6oNig026Cl2Cu4], binds to the major groove of the DNA 
helix while complex [C27H26N8O11CU2], prefers the minor groove; further validated by 
molecular docking studies. The complexes [C27H26N80iiZn2], [C64H60N18O26CI2CU4], 
[C27H26N8O11CU2] and [C21H25N7O11CU2] were evaluated for in vitro antibacterial activity 
exhibiting specific activity against various genetically characterized bacterial strains. 
CHAPTER IV 
Synthesis and characterization of Cu(II) and Zn(II) 
complexes of proline-glycine and proline-leucine 
tetrapeptides: in vitro DNA binding, cleavage and 
cytotoxic activity 
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Synthesis 
Synthesis of peptide ligands 
Protection of terminal amino group of amino acid (Boc-protection of L-Gly/L-Leu) 
The amino group ofL-amino acids was protected by the introduction of a Boc group: 
To a stirred solutuion of NaOH (2.5 M) in H20-dioxane (1:1) mixture, L-glycine (0.75 g, 10 
mmol)/L-leucine (1.31 g, 10 mmol) was added. To this, Boc anhydride (2.62 g, 10 mmol) 
was added drop wise and stirred for 6h at room temperature to give a white precipitate. 
Dioxane was removed under reduced pressure, acidified with KHSO4 upto pH 3 on ice bath. 
The organic layer was dried over anhydrous Na2S04 and evaporated under reduced pressure 
to give the crude product which was finally purified by column chromatography. 
Protection of terminal carboxyl of amino acid (Ester protection ofL-Pro) 
The carboxyl group ofL-amino acids was protected by esterification with MeOH/SOCh: 
To a stirred solution of L-proline (1.15 g, 10 mmol) in methanol (30 mL), SOCI2 (2.86 mL, 
40 mmol) was added drop wise at 0 "C under inert atmosphere and refluxed at 70 °C for 3^h . 
The progress of the reaction was monitored by TLC. On completion of the reaction the 
solvent was removed under reduced pressure to give yellow colored oil of L-proline methyl 
ester hydrochloride. 
Dipeptide ligands 
IC13H22N2O5] 
The dipeptide ligand [C13H22N2O5] (Pro-Gly) was synthesized by solution phase 
methodology and is represented in Scheme 7 [216]. 
Boc-Gly-OH (1.75 g, 10 mmol) was dissolved in dichloromethane (DCM, 20 mL). To this 
solution, EDCI (4.77 g, 25 mmol) was added at 0 °C at inert atmosphere. Pro-OMe (1.29 g, 
10 mmol) was added followed by HOBT (2.74 g, 20 mmol) to the above reaction mixture 
under stirring. After 24h, the reaction mixture was filtered. The filtrate was washed with 5% 
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sodium bicarbonate and saturated sodium chloride solutions. The organic layer was dried over 
anhydrous Na2S04, filtered and concentrated under reduced pressure. The crude product was 
purified by column chromatography. 
Yield: 62%, Anal. Calc. for C,3H22N205 (%) C, 54.53; H, 7.74; N, 9.78. Found: C, 54.78; H, 
7.92; N, 10.12. Selected IR data (KBr, cm"', v); 2885 v(0-H)carbonyi, 1710 v(C0)pep amide I, 
1654 Vas(COO), 1364 Vs(COO). ' H N M R (300 MHz, CDCI3, 5, ppm): 5.4 (IH, NH)BOC, 4.5 (t, 
IH, chiral CH)proiine, 3.9 (s, 2H, -CH2)giycine, 3.7 (s, 3H, O-CH3 ester H), 3.6 (t, 2H, -
CH)proiine, 2.2-2.4 (m, 4H, -CH2)proiine, 1-4 (s, 9H, Boc protons). "C NMR (300 MHz, CDCI3, 
5, ppm): 172 (C=Opep carbonyl), 167 (C=0 ester carbonyl), 155 (C=0, Boc carbonyl C), 58.8 
(chiral C)proiine, 52.3 (ester C), 45.8 (2C, CH2)g,ycine, 42.9 (IC, -CH2)proiine, 28.9 (3C, Boc-C), 
24 (2C, C)proiine- UV-vis (10"* M, MeOH, nm): 225.2, 283.2. [ajo (MeOH), -56.9. ESI-MS 
(m/z^l 287 [C,3H22N205+H"]. 
[C17H30N2O5] 
The ligand [C17H30N2O5] (Pro-Leu) was synthesised by the procedure outlined above for 
[C13H22N2O5] from Boc-Leu-OH (2.31 g, 10 mmol) and Pro-OMe (1.29 g, 10 mmol). 
Yield: 58%, Anal. Calc. for C17H30N2O5 (%) C, 59.63; H, 8.83; N, 8.18. Found: C, 59.86; H, 
8.91; N, 8.79. Selected IR data (KBr, cm"', v); 2876 v(0-H)carbonyi 1705 v(C0)pep amide I, 
1650 Vas(COO), 1366 Vs(COO). ' H NMR (300 MHz, CDCI3, 5, ppm): 5.1 (IH, NH)BOC, 4.5 (t, 
IH, chiral CH)proime, 3.7 (m, chiral CH2)ieucine, 3.5 (t, 2H, -CH2)proiine, 3.6 (s, 3H, O-CH3 ester 
H), 2.1 (m, 4H, -CH2)proi,ne, 1.7 (dd, 2H, -CH2),eucine, 1-4 (s, 9H, Boc protons), 0.98 (6H, 
CH3)ieucine. '^ C NMR (300 MHz, CDCI3, 5, ppm): 172.4 (C=Opep carbonyl), 171.7 (C=0 ester 
carbonyl), 155.6 (C=0, Boc carbonyl C), 58.6 (chiral C)proiine, 52.09 (IC, C)ieucine, 50.21 (ester 
C), 46.6 ( I C , CH2)proIine, 41.8 ( I C , CH2),euc,ne, 28.8 (3C, BoC-C), 24 (2C, Oproline, 2 1 - 2 3 (2C, 
CH3 and IC, CH)ieucine- UV-vis (lO"* M, MeOH, nm): 226.6, 282.0. [a]n (MeOH), -63.8. 
ESI-MS (m//), 343 [CyHjoNzOs+H*]. 
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Deprotection of Ester-protected amino acids 
The methyl ester group was removed by alkaline hydrolysis with LiOH: 
Dried THF:H20 (1:1) was added to Boc-gly-pro-OMe (2.86 g, 10 mmol)/Boc-leu-pro-OMe 
(3.42 g, 10 mmol). To this, lithium hydroxide monohydrate (0.36 g, 15 mmol) was added at 
0 °C and stirred for 4-5h. The product was isolated by adding water, acidifying upto pH 3 
with KHSO4 and extracted with EtOAc (3 x 35mL). The colorless oil was dried under reduced 
pressure and dried over NaS04. 
Deprotection of Boc-protected amino acids 
The Boc group was removed by treatment with trijluoroacetic acid: 
To a stirred solution of Boc-gly-pro-OMe (2.86 g, 10 mmol)/Boc-leu-pro-OMe (3.42 g, 10 
mmol) in anhydrous DCM, TFA was added slowly at 0 °C (DCM : TFA = 5:1) under inert 
atmosphere and stirred for 2-3h. The unreacted TFA was removed under reduced pressure 
and resulting solution was diluted with DCM, neutralized with DIPEA or ammonia solution. 
Tetrapeptide ligands 
The tetrapeptide ligands [C20H32N4O7] (Pro-Gly-Pro-Gly) and [C28H48N4O7] (Pro-Leu-Pro-
Leu) were synthesized by solution phase methodology. 
[C20H32N4O7] 
Dry dichloromethane (DCM, 20 mL) was added to dipeptide Boc-pro-gly-OH (2.72 g, 10 
mmol) under inert atmosphere. To this solution, EDCI (4.77 g, 25 mmol) was added at 0 °C 
and the reaction mixture was stirred for 20 min. Dipeptide Pro-gly-OMe (1.86 g, 10 mmol) 
was added followed by HOBT (2.74 g, 20 mmol) to the above reaction mixture under stirring 
and the reaction was continued for 12h. On completion of the reaction, it was monitored by 
TLC using EtOAc. For detection a solution of ninhydrin was used. The reaction mixture was 
filtered to remove white precipitate. The residue was washed with DCM (30 mL) and added 
to this filtrate. The filtrate was washed with 5% sodium bicarbonate and saturated sodium 
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chloride solutions. The organic layer was dried over anhydrous Na2S04, filtered and 
evaporated under reduced pressure. The crude product was purified by column 
chromatography (15% acetone and hexane mixture). 
Yield: 54%, Anal. Calc. for C20H32N4O7 (%) C, 54.53; H, 7.32; N, 12.72. Found: C, 54.89; H, 
7.99; N, 13.01. ' H N M R (300 MHz, CDCI3, 8, ppra): 7.24 (s, IH, NHpep), 5.6 (IH, NHBOC), 
4.5 (J=4.2 Hz, t, IH, chiral CH)proii„e, 3.9 (s, 2H, -CH2)giycine, 3-6 (J=6.4 Hz, t, 4H, -CH)proii„e, 
3.6 (s, 3H, O-CH3 ester H), 2.2-2.4 (J=3.21 Hz, m, 8H, pro -CH2), 1.4 (s, 9H, Boc protons). 
'^C NMR (300 MHz, CDCI3, 5, ppm): 172 (C=Opep carbonyl), 171 (C=Opep carbonyl), 155 
(C=0, Boc carbonyl C), 67.04 (IC, Boc-C), 58.7 (chiral C)proii„e, 46.13 (2C, CH2)giyc,ne, 41 
(2C, -CH2)proii„e, 28 (3C, Boc-C), 20-24 (4C, C)proii„e. UV-vis (MeOH, nm, e, Lmof'cm"'): 
232 (4200), 283 (3200), 321 (1100). [ab (MeOH), -82.3. ESl-MS (m/z*), 441, 
[C2oH32N407+H ]^. 
IC28H48N4O7] 
The ligand [C2gH48N407] (Pro-Leu-Pro-Leu) was synthesised by the procedure outlined 
above for [C20H32N4O7] from dipeptides Boc-pro-leu-OH (3.28 g, 10 mmol) and Pro-leu-
OMe(2.42g, 10 mmol). 
Yield: 57%, Anal. Calc. for C2gH48N407 (%) C, 60.85; H, 8.75; N, 10.14. Found: C, 60.92; H, 
8.96; N, 10.63. ' H NMR (300 MHz, CDCI3, 5, ppm): 7.32 (s, IH, NHpep), 5.2 (IH, NHBOC), 
4.6 (J= 3.62 Hz, t, IH, chiral CH)proi,ne, 4.0 (J=3.2 Hz, m, chiral CH2)ieucine, 3.6 (, s, 3H, 0 -
CH3 ester H), 3.5 (J=2.3 Hz, t, 4H, pro -CH2), 2.2 (J=3.22 Hz, m, 8H, -CH2)proiine, L7 (J=4.3 
Hz, dd, 6H, -CH2)ieucine, 1-3 (s, 9H, Boc protons), 0.91 (s, 12H, CH3)ieucine. '^ C NMR (300 
MHz, CDCI3, 5, ppm): 172 (C=Opep carbonyl), 171 (C=Opep carbonyl), 154 (C=0, Boc 
carbonyl C), 67.18 (IC, Boc-C), 59.0 (chiral C)proi,ne, 46.70 (2C, CH3)ieucme, 41.20 (20, -
CH2)leucme, 28.31 (3C, BoC-C), 25.02 ( IC , CH2)|eucme, 20 -24 (4C, C)proline. UV-v iS (McOH, 
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-I - K 
nm, s, Lmofcm"'): 226 (23200), 282 (17500), 322 (2300). [ajo (MeOH), -73.5. ESI-MS 
(m//), 553 [C28H4gN407+ir]. 
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Z*-" \ H20:Dioxane 
•^  OH 6h,r.t, 
R=H, L-Gly 
= -CH2-CH-C(CH3)2, L-Leu 
,CH—C 
0 R / \ OH 
Boc-protected amino acid 
A 
COOH SOCl, 
N 
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Scheme 7: Schematic representation of synthesis of tetrapeptide ligands [C2oH32N^07j and 
[C28H,sN407j. 
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Synthesis of tetrapeptide complexes 
[C14H22N4O6CU] 
To a stirred methanolic solution of deprotected [C20H32N4O7] (0.652 g, 2 mmol), 
Cu(N03)2.3H20 (0.483 g, 2 mmol) was added under dry conditions and the resultant solution 
was stirred for 2h. The complex precipitated as a blue product which was filtered, washed 
with petroleum ether and dried in vacuo (Scheme 8). 
Yield, 72%. Anal. Calc. for C14H22N4O6CU (%) C, 41.43; H, 5.46; N, 13.80. Found: C, 41.89; 
H, 5.98; N, 14.00. Molar Conductance, AM ( D M S O ) : 19.0 Q"'cm^mor' (non electrolyte), [ajo 
(MeOH), -68.2. UV-vis (MeOH, nm, e, Lmof'cm"'): 227 (7800), 288 (4300), 660(128) (d-
d). ESI-MS (m/zy. 445 [Ci4H22N406Cu+K^]. 
[Ci4H22N406Zn] 
The complex [Ci4H22N406Zn] was synthesised by the procedure oulined above for 
[C,4H22N406Cu] from [C20H32N4O7] (0.652 g, 2 mmol) and Zn(N03)2.6H20 (0.594 g, 2 
mmol). 
Yield, 68%. Anal. Calc. for C,4H22N406Zn (%) C, 41.24; H, 5.44; N, 13.74. Found: C, 41.68; 
H, 5.73; N, 13.99. ' H N M R (400 MHz, D2O, 8, ppm): 4.33 (J=9.19 Hz, t, 2H, chiral CH)proiine, 
3.85 (s, 4H, -CH2)giycine, 3.6 (J- 4.12 Hz, t, 4H, -CH)proiine, 2.02-2.33 (J=8.65 Hz, 8H, -
CH2)proiine. '^ C NMR (100 MHz, D2O, 5 ppm): 174.8 (C=Opep carbonyl), 171 (C=Opep 
carbonyl), 59.31 (chiral C)proiine, 46.48 (2C, CH2)giycine, 41.8 (2C, -CH2)proii„e, 20-24 (4C, 
C)proiine- Molar Conductance, AM (DMSO): 13.0 Q"'cm^mor' (non electrolyte), [ajo (MeOH), 
-59.9. UV-vis (MeOH, nm, s, Lmol 'cm"'): 223 (10200), 281 (7900). ESI-MS {m/zy. 455 
[C,4H22N4O6Zn+r+0.5H2O]. 
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[C22H38N4O6CU] 
The complex [C22H38N4O6CU] was synthesised by the procedure oulined above for 
[C,4H22N406Cu] from [C28H48N4O7] (0.876 g, 2 mmol) and Cu(N03)2.3H20 (0.483 g, 2 
mmol). 
Yield, 66%. Anal. Calc. for C22H38N4O6CU (%) C, 51.0; H, 7.39; N, 10.81. Found: C, 50.89; 
H, 7.46; N, 11.01. Molar Conductance, AM ( D M S O ) : 18.0 Q'^cm^mol'^ (non electrolyte). 
[a]D (MeOH), -82.4. UV-vls (MeOH, nm, e, Lmor'cm"'): 225 (8700), 283 (11900), 662 
(210) (d-d). ESI-MS (w/z^): 516 [C22H38N406Cu-2}f ]. 
[C22H38N406Zn] 
The complex [C22H38N406Zn] was synthesised by the procedure oulined above for 
[C,4H22N406Zn] from [C28H4«N407] (0.876 g, 2 mmol) and Zn(N03)2.6H20 (0.594 g, 2 
mmol). 
Yield, 75%. Anal. Calc. for C22H38N406Zn (%) C, 50.82; H, 7.37; N, 10.78. Found: C, 51.0; 
H, 7.95; N, 10.86. ' H N M R (400 MHz, D2O, 5, ppm): 4.58 (J=8.40 Hz, t, 2H, chiral CH)p,oime, 
3.9 (J= 12, m, chiral CH2)ieucine, 3.51-3.60 (J=3.92 Hz, t, 4H, -CH2)proiine, 2.13-2.26 (J=9.19 
Hz, 8H, -CH2)p,oI,„e, 2.03 (J-3.2 Hz, d, 6H, -CH2),euane, 1.01 (S, 12H, CH3)leuc,„e. "C NMR 
(300 MHz, D2O, 5, ppm): 173.67 (C=Opep carbonyl), 171.79 (C=Opep carbonyl), 60.02 (chiral 
C)proline, 46.43 (2C, CH3),euci„e, 41.89 (2C, -CH2)proline, 25.7 (IC, -CH2),eucine, 20-24 (4C, 
C)proiine- Molar Conductance, A^ (DMSO): 22 Q'cm^mol' (non electrolyte), [ajo (MeOH), -
79.6. UV-vis (MeOH, nm, 8, Lmof'cm''): 222 (7500), 283 (4400). ESl-MS (w/z^): 497 
[C22H38N406Zn-H20-3H"]. 
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R = H, M = CU [C,4H22N406Cu] 
= H, M = Zn [C,4H22N406Zn] 
= -CH2-CH-(CH3)2, M = CU [C22H3gN406Cu] 
= -CH2-CH-(CH3)2, M = Zn [C22H38N406Zn] 
Scheme 8: Synthesis of tetrapeptide complexes [C14H22N4O6CU], [CuHiiNAOeTn], 
[C22H3SN4O6CU] and [C22H38N40,Zn]. 
Results and discussion 
The complexes [C,4H22N406Cu], [C,4H22N406Zn], [C22H38N406Cu] and [C22H38N406Zn] 
were synthesized from [C20H32N4O7] and [C28H4gN407], characterized by NMR spectroscopy 
(in case of [Ci4H22N406Zn] and [C22H38N406Zn]), mass spectrometry, IR, EPR spectroscopy 
(in case of [C14H22N4O6CU] and [C22H3gN406Cu]), elemental analysis and molar conductance 
values. The molar conductance values of [C14H22N4O6CU], [Ci4H22N406Zn], [C22H38N4O6CU] 
and [C22H38N406Zn] were found to be 60, 53, 62 and 56 n^'cm^mof', respectively suggesting 
their non-electrolytic nature. Further the optical rotation values [ajo of [C14H22N4O6CU], 
[Ci4H22N406Zn], [C22H38N4O6CU] and [C22H38N406Zn] were calculated to be -68.2, -59.9, 
-82.4 and -79.6, respectively confirming their chiral nature. 3-dimensional energy minimized 
molecular structures of Cu(II) complexes [C14H22N4O6CU] and [C22H38N4O6CU] have been 
depicted in Figure 59. 
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(a) (b) 
Figure 59. Energy minimized cylindrical bonded 3-dimensional molecular structures of 
complexes (a) [C14I22N4O6CU] and (b) [C22H38N4O6CUJ. Color scheme: Nitrogen (blue), 
oxygen (red) Cu(IJ) (dark grey) and carbon (grey). Hydrogen atoms have been omitted for 
clarity. 
Infrared spectroscopy 
The IR spectra of non-coordinated peptides usually exhibit strong absorption bands due to 
v(N-H) in the range of 3288-3017 cm"', however they were absent in the ligands 
[C20H32N4O7] and [C28H48N4O7] as the terminal amino group was Boc-protected [128]. In the 
complexes, the IR region at 3204-3030 cm~' corresponding to the antisymmetric and 
symmetric -NH2 stretching modes, and the amide II and III (due to 6(N-H) + v(C-N)) were 
observed at 1521-1526 cm~' respectively, but -NH2 stretching modes exhibited a substantial 
lowering indicating the coordination of amino group to the metal ion. New amide bands were 
observed at 1548, 1542, 1532 and 1526 cm"' in [C,4H22N406Cu], [Ci4H22N406Zn], 
[C22H38N4O6CU] and [C22H38N406Zn], respectively which are characteristic signatures for the 
deprotonated secondary peptide complexes [217]. The diflFerence between Vas(COO)-Vs(COO) 
(Av) vibrations were in the range of 235-294 cm"' in all the complexes which was indicative 
of monodendate carboxylate coordination [218]. In the far-IR region medium intensity bands 
at -458 and -553 cm"' corresponding to (Cu/Zn-N) and (Cu/Zn-0), respectively were 
observed. The characteristic IR absorption frequencies and their assignments for the ligands 
Pro-Gly-Pro-Gly, [C20H32N4O7] and Pro-Leu-Pro-Leu, [C28H48N4O7] and complexes 
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[C14H22N4O6CU], [Ci4H22N406Zn], [C22H38N4O6CU] and [C22H38N406Zn] are given in Table 
8. 
Table 8: Characteristic IR frequencies (in cm') of tetrapeptide ligands [C2oH32N^07] and 
[CJXH^HN^O?] and their complexes [C14H22N4O6CU], [Ci^H22N^06ZnJ, [C22H38N4O6CU] and 
[C22H3HN,06Zn]. 
m bands (cm') 
MCOO) 
v,(COO) 
Amide I 
v(C-0)„ 
v(NH)p^ 
VasiNHj) 
Vs(NH2) 
Amide II 
«(NH) + v(C-N) 
Amide III 
v{CN)p,p + 5(NH) 
v(OH)„a„ 
v(0-H)c„box,i 
[C20H32N4O,] 
1648 
1368 
1704 
3328 
-
-
1526 
1241 
_ 
2880 
[C,4H22N40,CnJ 
1660 
1406 
1660 
-
3233 
3189 
1548 
1258 
3447 
-
[C,4HaN406Zn] 
1649 
1400 
1649 
-
3204 
3030 
1542 
1247 
3410 
-
[CaBUN^O,] 
1638 
1363 
1704 
3302 
-
-
1521 
1246 
_ 
2875 
[CaHasN^OjCu] 
1683 
1397 
1683 
-
3140 
3041 
1532 
1252 
3482 
-
[C22H3,N40«Znl 
1645 
1410 
1645 
-
3198 
3195 
1526 
1248 
3496 
-
Nuclear magnetic resonance spectroscopy 
The ' H N M R spectra of the ligands, Pro-Gly-Pro-Gly, [C20H32N4O7] and Pro-Leu-Pro-Leu, 
[C28H48N4O7] (Figure 60) were recorded in CDCI3 while for complexes [Ci4H22N406Zn] and 
[C22H38N406Zn], the spectra were recorded in D2O. The ligands displayed characteristic 
signals of free tetrapeptides revealing singlets of O-CH3 ester protons and t-Boc protons at 8 
3.6 and 5 1.4 ppm, respectively, which disappeared upon deprotection of these groups and 
new signals at 5 12.0-13.0 ppm corresponding to -COOH group were observed. The signals 
shifted downfield upon the complexation with the tetrapeptides. The absence of -COOH 
signal at 5 12.0-13.0 ppm in the complexes indicated the coordination of carboxylic group to 
Zn(II) through deprotonation [219]. The -NHpep and -NHBOC signals in the free tetrapeptide 
ligands were observed at 5 5.0-8.0 ppm [128] which disappeared in the complexes due to the 
deprotonation of the -CO(NH) peptide proton suggesting the involvement of peptide N in 
coordination to the metal center [220]. The NH2 signal in the complexes merged with the 
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solvent peak at 8 4.8 ppm due to the rapid proton exchange with the solvent D2O [221]. The 
signals appearing at 5 2.2-2.4 (quintet), 5 3.5-3.6 (triplet), 5 4.5-4.6 (triplet) ppm attributed to 
proline moiety were observed in the ligands and both the complexes, while a singlet at 5 3.9 
ppm was attributed to the -CH of glycine. Similarly, the signals at 5 1.7 (doublet) and 5 0.91 
ppm were attributed to leucine moiety in the ligands and complexes. 
(a) 
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Figure 60. 'HNMR spectra of tetrapeptides (a) [C20H32N4O7] and (b) [C2HH4HN407]. 
The '^ C NMR spectra of the both the tetrapeptide complexes [Ci4H22N406Zn] and 
[C22H38N406Zn] exhibited signals of-NCO and -COO group at 5 -174.8 and -171.0 ppm, 
respectively (Figure 61). The signal observed at 5 59.31 ppm was attributed to the chiral 
proline carbon, while other proline carbons were observed at 5 41.8 and 20-24 ppm. The 
signals in the spectra of [Ci4H22N406Zn] at 5 46.48 ppm corresponded to the glycine carbon. 
While the presence of leucine moiety in [C22H38N406Zn] was confirmed by the presence of 
the signals at 5 46.43 and 25.7 ppm. 
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F/^ M/-g 6/. "C A^ Mi? spectra of tetrapeptide ligands (a) [C20H32N4O7J, (b) [C2HH4HN407] and 
their Zn(ll) complexes (c) [CuH22N406Zn] and (d) fC22H2HN406ZnJ. 
Mass spectrometry 
The ESI mass spectra were recorded in the positive ion mode for the Hgands and complexes 
[C,4H22N406Cu], [C,4H22N406Zn], [C22H38N4O6CU] and [C22H38N406Zn] in methanol 
I l l 
solution. The ESI mass spectra of the ligands displayed prominent peaks at m/z 441 and 553 
corresponding to [C20H32N4O7 + H"^ ] and [C28H4«N407 + H^j, respectively while the ESI mass 
spectra of complexes displayed prominent molecular ion fragment peaks. The complex 
[C14H22N4O6CU] exhibited a prominent peak at m/z 445 corresponding to the fragment 
[C14H22N4O6CU + K^], while complexes [Ci4H22N406Zn] and [C22H38N4O6CU] exhibited 
molecular ion peaks at m/z 455 [Ci4H22N406Zn + K" + O.5H2O] and 516 [C22H38N4O6CU -
2H^], respectively. The complex [C22H38N406Zn] did not show molecular ion peak but a 
fragmentation peak upon removal of the water molecule at m/z 497 corresponding to 
[C22H38N406Zn-H20-3H"]. 
Electron paramagnetic resonance spectroscopy 
The EPR spectra of complexes [C14H22N4O6CU] and [C22H38N4O6CU] recorded at LNT under 
the magnetic field strength of 3000±1000 G with tetracyanoethylene (TCNE) as a field 
marker (g = 0.0027) (Figure 62). The EPR spectra of [C14H22N4O6CU] and [C22H38N4O6CU] 
revealed g values, g||=2.37, gx=2.14 and gavg=2.21 and g||=2.38, g-i-=2.12 and gavg=2.20, 
respectively computed from the formula gav=l/3 (g||+2g-L) suggestive of Cu(II) ion in 
octahedral geometry [222]. The trend gpgx >2.0023 observed for the complexes indicated 
that the unpaired electron was localized in the dx%^ orbital of the Cu(ll) ion and was 
characteristic for the axial symmetry [223]. 
(a) (b) 
, / 
figure 62. EPR spectra of tetrapeptide complexes (a) [CHH22N4O6CU] and (b) 
[C22H38N4O6CUJ at LNT. 
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Absorption spectra 
The absorption spectra of the iigands, recorded in H2O at room temperature revealed n—>Ji* 
transitions around 220 nm while the complexes [C14H22N4O6CU], [Ci4H22N406Zn], 
[C22H38N4O6CU] and [C22H38N406Zn] exhibited (N-^M) LMCT transition bands at -222-231 
nm [224,225]. The complexes also revealed other transitions corresponding to (C00~—>M) 
charge transfer bands at -270-290 nm [225]. The complexes [C14H22N4O6CU] and 
[C22H38N4O6CU] exhibited strong d-d bands at 660 and 662 nm, respectively characteristic of 
the octahedral geometry around the Cu(II) ion [226]. 
X-ray difTraction analysis 
Akhough single crystals of the complexes were not obtained, the crystalline nature of the 
complexes was authenticated by XRPD measurements. The diffractograms obtained for the 
metal complexes [C14H22N4O6CU], [Ci4H22N406Zn], [C22H38N4O6CU] and [C22H38N406Zn] 
are given in Figure 63. The XRPD patterns ascertained the crystalline nature of all the 
complexes. 
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Figure 63. The XRPD pattern of complexes (a) [C14H22N4O6CU], (b) [Ci4H22N40^nJ, (c) 
[C22HS8N4O6CU] and (d) [C22Hs8N406Zn] showing peaks at different scattered angles. 
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Solution stability studies 
To confirm the stability of the tetrapeptide complexes [C14H22N4O6CU] and [C22H38N4O6CU], 
UV-vis absorption studies at d-d band were performed under identical conditions to those 
used for DNA binding studies in buffered solution at various pH values. UV-vis spectra of 
complex [C14H22N4O6CU] and [C22H38N4O6CU] exhibited no change in the position of the d-d 
band over a wide pH range 2-12 with only a minor change in intensity (Figure 64). The 
complexes displayed similar spectra over a period of 24h confirming the stability of the metal 
ion in the tetrapeptide metal complexes and also no precipitation was observed. The non-
precipitation after a 24h time period and over a broad range of pH suggested the stable nature 
of these complexes in solution. 
Wavdeiifffli (iim) Wiivekugth (um) 
Figure 64. UV-vis absorption spectra at d-d band of complexes (a) [C14H22N4O6CU] and (a') 
[Ci4H22N406Zn] as a function of pH. UV-vis absorption spectra of complexes (b) 
[C14H22N4O6CU] and (b') [Ci4H22N40fiZn], after 24h as a function ofpH. Conditions: Tris-
HCl buffer, 25 "C, The curves from top to bottom correspond to pH 12, 10, 8, 6, 4, 2, 
respectively. 
DNA binding studies 
Metal-based peptide scaffolds could provide an excellent delivery system into the specific 
tumor target sites and could be less toxic to normal tissues. Peptide-based drug design is a 
challenging option to address issues of toxicity and efficacy and chemical strategies that 
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involve therapeutic peptides as scaffolds for drug design and these are currently gaining much 
attention for use in cancer chemotherapy as their primary metabolites are free amino acids. 
The interaction of tetrapeptide complexes with CT DNA was carried out using different 
methodologies viz., absorption spectral titrations, emission spectroscopy, viscosity 
measurements and circular dichroism. 
Electronic absorption titration 
The absorption spectral properties of the interactions of [C14H22N4O6CU], [Ci4H22N406Zn], 
[C22H3gN406Cu] and [C22H38N406Zn] with CT DNA were investigated using the absorption 
titration spectral studies. Figure 65 exhibited variation in the intense charge transfer bands of 
the complexes [C14H22N4O6CU], [Ci4H22N406Zn], [C22H3gN406Cu] and [C22H3gN406Zn] at 
-270-290 nm with increasing amounts of CT DNA as compared to that of the ligands 
[C20H32N4O7] and [C2gH48N407]. All the charge transfer bands of the complexes exhibited 
hyperchromism, without any change in the position of the absorption bands of the complexes 
in the presence of DNA. Observed spectral behavior clearly ruled out intercalative binding of 
the complexes to DNA, since intercalation leads to hypochromism in the spectral band. The 
results suggested the possibility of groove binding for the complexes to CT DNA [227]. The 
DNA double helix is stabilized by binding of small ligands like peptides in either major or 
minor groove via a number of hydrogen bonds and van der Waals interactions with the 
functional groups on base edges [228] and the binding affinity for a particular target site is a 
function of both the metal and peptide moieties. The formation of a DNA-peptide metal 
complex could induce changes in the spectral characteristics of both or either of DNA or 
peptide complex [228]. It has been noted previously that hydrophobic shells around 
hydrophilic ligands appear to enhance metal binding to proteins [229]. The amino group of 
the peptide forms hydrogen bonds with DNA, contributing to the hyperchromism observed in 
the absorption spectra. 
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Figure 65. Absorption spectra of tetrapeptide ligands (a) [C20H32N4O7] and (h) [C28H48N4O7J 
and their complexes (c) [C14H22N4O6CU], (d) [Ci4H22N40(,Zn], (e) [C22H3HN4O6CU] and (f) 
fC22H3HN40eZnJ and in Tris~HCl buffer (pH = 7.2) in the absence and presence of increasing 
amounts ofCTDNA. Inset: Plots of [DNAJ/(s^-£f) vs. [DNA] for the titration ofCTDNA with 
complexes. Arrow indicates the increase in absorbance upon increasing DNA concentration. 
m, experimental data points; full lines, linear fitting of the data. [Complex] KT M, [DNA] 0-
4.66 X 10'^ M. 
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In order to compare the binding strength of the ligands, [C20H32N4O7] and [C28H4gN407] and 
their complexes, [C14H22N4O6CU], [Ci4H22N406Zn], [C22H38N4O6CU] and [C22H38N406Zn] 
with CT DNA, the intrinsic binding constant (Kb) values were obtained. The Kb values of the 
ligands, [C20H32N4O7] and [C28H48N4O7] and their complexes [C14H22N4O6CU], 
[Ci4H22N406Zn], [C22H38N4O6CU] and [C22H38N406Zn] are given in Table 9. 
Table 9. The intrinsic binding constant (Kh) values of tetrapeptide ligands and their 
complexes with CTDNA (mean standard deviation of± 0.12). 
Complex Kb (M") Monitored at (nm) % Hyperchromism 
_ 
22 
32 
28 
30 
26 
Furthermore, Cu(II) complexes depicted more binding affinity for CT DNA than the Zn(II) 
complexes. An explanation for higher Kb value of copper complexes is that copper complexes 
are 'borderline' metals which show high affinity for both nucleobases and phosphate binding 
specifically to N7 of guanine nucleobase of DNA helix [230]. The high Kb value for glycine 
complexes ([C14H22N4O6CU] and [Ci4H22N406Zn]) as compared to leucine complexes 
([C22H38N4O6CU] and [C22H38N406Zn]) was due to the fact that leucine complexes have steric 
constraints due to its bulky side chain containing methyl groups resulting in the relatively 
close stacking between the complex and the DNA base pairs, and consequently accounting for 
its lower binding propensity with DNA. 
Interaction with mononucleotides (5'-GMP and 5'-TMP) 
The principles that govern the site-selective recognition of nucleic acid fragments such as 5'-
GMP/5'-TMP by the metal complexes include inherent specificity of binding of the Cu(II) 
and Zn(II) ions towards N7 of guanine as well as N3 of thymine base, respectively [187]. In 
order to elucidate this preferential selectivity, the interaction of [C14H22N4O6CU] and 
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[Ci4H22N406Zn] with 5'-GMP and 5'-TMP were investigated using electronic absorption 
spectroscopy. Addition of 5'-GMP/5'-TMP to the [C14H22N4O6CU] and [Ci4H22N406Zn] 
resulted in a sharp increase in absorbance, i.e. 'hyperchromism' with no substantial change in 
the position of the intraligand band (Figures 66 and 67) authenticating the binding of these 
complexes to different nucleotides through electrostatic surface binding interactions. 
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Figure 66. Absorption spectral traces of tetrapeptide complexes (a) [C14H22N4O6CU] and (b) 
IH5 [Ci4H22N406Zn] in Tris-HCl buffer upon the addition of 5'-GMP. [Complex] 6.66 x 10 M, 
[S'-GMP] 0-2.0X l(r^ M. 
(b) t 
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Figure 67. Absorption spectral traces of tetrapeptide complexes (a) [C14H22N4O6CU] and (b) 
[Ci4H22N406Zn] in Tris-HCl buffer upon addition of5'-TMP. [Complex] 6.66x 10'^ M, [5-
TMP] 0-2.0xlO~^M. 
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The purine and pyrimidine bases of CT DNA become exposed because of the unwinding of 
the DNA helix promoting an effective binding to these base pairs with the transition metal 
complexes [231]. To evaluate the binding preferences, Kb values were calculated for 
[C14H22N4O6CU] and [Ci4H22N406Zn] are shown in Table 10. 
Table 10: The intrinsic binding constant (Kh) values of [C14H22N4O6CU] and [Ci4H22N406Zn] 
with nucleotides (mean standard deviation of± 0.06). 
Complex 
[C,4H22N406CU] 
[Ci4H22N406Zn] 
Kb(]vr') 
5'-GMP 
1.98x10'* 
1.13x10" 
5'-TMP 
1.41x10" 
4.80x10" 
Monitored at 
(nm) 
263 
263 
263 
263 
% 
hyperchromism 
39 
27 
42 
36 
The Kb values calculated suggested greater binding affinity of Cu(II) complex 
[C14H22N4O6CU] to 5'-GMP than 5'-TMP, while the Zn(Il) complex [C,4H22N406Zn] binds 
preferably to 5'-TMP than 5'-GMP, indicating that Cu(II) binds to N7 of 5'-GMP while 
Zn(II) specifically to 5'-TMP through its N3 nitrogen. 
The more conclusive evidence for the interaction of [C14H22N4O6CU] and [Ci4H22N406Zn] 
with 5'-GMP/5'-TMP was further obtained by 'H and '^P NMR spectroscopy. The 'H NMR 
of free 5'-GMP in D2O solvent recorded the proton resonance of guanine H8 at 5 8.1 ppm and 
ribose Hi-Hj' at 5 3.8-5.8 ppm, respectively. On addition of the [C14H22N4O6CU], the guanine 
H8 signal shifted to 5 7.73 ppm suggesting the binding of the Cu(II) complex to 5'-GMP 
while upon the addition of [C]4H22N406Zn] there was no significant shift in H8 signal of free 
5'-GMP attributed to non-participation of guanine on binding with these complexes through 
coordination mode (Figure 68). Similarly, in the -"P NMR spectra of 5'-GMP upon addition 
of [C14H22N4O6CU], the signal at 5 3.73 ppm in free 5'-GMP completely disappeared, while 
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upon the addition of [Ci4H22N406Zn], this signal shifted to 5 2.53 ppm suggesting that 
[Ci4H22N406Cu] interacted with 5'-GMP (Figure 69). 
(O 
Figure 68: 'HNMR spectra of5'-GMP (5 mmol) (a) alone, (b) with [Cj^H22N^06CuJ and (c) 
with [CuH22N406Zn] (2.5 mmol) at 25 °C. 
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31 Figure 69. "P NMR spectra of 5'-GMP (5 mmol), (a) alone, (h) with [C14H22N4O6CUJ and 
(c) with [Ci4H22N406ZnJ (2.5 mmol) at 25 °C. 
To validate the binding preference of the zinc(II) complex with 5'-TMP, the interaction 
pattern of [C,4H22N406Zn] with 5'-TMP was also studied by ' H NMR (Figure 70). The ' H 
NMR spectrum of free 5'-TMP before the addition of complex revealed signals at 5 7.64, 6.20 
and 1.98 ppm attributed for N3-H proton, C6-H and CH3 of thymine group (T-CH3), 
respectively. After the addition of [Ci4H22N406Zn], there was a slight chemical shift of N3 
from 8 7.64 ppm to 7.72 ppm suggestive of some interaction of complex with 5'-TMP. The 
^'P NMR signal of free of 5'-TMP which appeared at 5 3.67 ppm was shifted to 5 1.93 ppm in 
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presence of [Ci4H22N406Zn] (Figure 71). This accounts for the presence of higher binding 
exhibited by the Zn(ir) complex for 5'-TMP as compared to 5'-GMP [232]. 
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Figure 70. 'HNMR spectrum of 5'-TMP (5 minol) (a) alone and (b) with [Ci4H22N406Zn] 
(2.5 mmol) at 25 °C. 
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Figure 71. ^'P NMR spectrum of 5'-TMP (5 mmol) (a) alone and (b) with [Ci4H22N40^n] 
(2.5 mmol) at 25 °C. 
These pronounced changes in ^'P chemical shift values arise due to the changes in O-P-O 
bond angles after its coordination with [C14H22N4O6CU] and [Ci4H22N406Zn] revealing a 
strong coordination of the complex with phosphate groups of nucleotide. The present 
observation is in agreement with preferential selectivity of the Cu(II) complex 
[C14H22N4O6CU] towards S'-GMP and Zn(II) complex [Ci4H22N406Zn] towards 5'-TMP 
revealing an electrostatic binding mode of complex with the nucleotide. 
Fluorescence spectroscopy 
The fluorescence emission titration of [C14H22N4O6CU], [Ci4H22N406Zn], [C22H38N4O6CU] 
and [C22H38N406Zn] were carried out with CT DNA under identical experimental conditions 
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(Figure 72). In the absence of CT DNA, all the complexes [C14H22N4O6CU], [Ci4H22N406Zn], 
[C22H38N4O6CU] and [C22H38N406Zn] emit weak luminescence in Tris-HCl buffer at ambient 
temperatures with a maxima appearing at 510 nm (excited at 260 nm). However, the 
subsequent addition of CT DNA from 0.66-4.0 x 10~^  M causes a gradual enhancement in the 
fluorescence intensity of the complexes with no apparent change in the shape and position of 
the emission bands. 
500 SSO 
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Figure 72. Emission spectra of complexes (a) [C14H22N4O6CU], (b) [Ci4H22N406Zn], (c) 
[C22H3SN4O6CU] and (d) [C22H3sN40(Zn] with increasing concentration of complexes in the 
absence and presence of CT DNA in Tris HCl buffer (pH 7.2). Arrows indicate change in 
intensity upon increasing concentration ofCTDNA. Inset: Plots ofr vs. r/Cpfor the titration 
ofCTDNA with complexes. [Complex] 6.66 x 10'^ M, [DNA] 0.66-4.0 x lO'^ M. 
This implies that the complexes [C14H22N4O6CU], [Ci4H22N406Zn], [C22H38N4O6CU] and 
[C22H38N406Zn] strongly interact with CT DNA probably due to the change in the 
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environment of the metal complex and also related to the extent to which the complex gets 
into the hydrophobic environment inside the DNA [233]. The inaccessibility of the solvent 
water molecules to reach the hydrophobic environment inside the DNA helix and the 
restricted mobility of the complexes at the binding site uhimately lead to the decrease in 
vibrational mode of relaxation. The binding constant, K values of [C14H22N4O6CU], 
[Ci4H22N406Zn], [C22H38N4O6CU] and [C22H38N406Zn] were calculated from the plots of r/cf 
vs. r, and were found to be 3.2 x 10^ 2.6 x 10^ 1.6 x 10^  and 3.9 x IO^'M"', respectively. 
Steady-state emission quenching experiments were performed by using anionic quencher, 
K4[Fe(CN)6] which has been found to be able to distinguish between the binding modes of the 
complex with DNA. [Fe(CN)6] ~ is a dynamic fluorescence quencher and provides a sensitive 
tool to examine nature of the interaction of probe with DNA [234]. Upon addition increasing 
CT DNA, the quenching of the fluorescence intensity was observed for [C14H22N4O6CU], 
[C,4H22N406Zn], [C22H38N4O6CU] and [C22H38N406Zn]. Figure 73 shows a typical Stem-
Volmer plot of lo/I vs. [Fe(CN)6]^ for [C,4H22N406Cu], [Ci4H22N406Zn], [C22H38N4O6CU] 
and [C22H38N406Zn]. The plots for [C14H22N4O6CU], [C,4H22N406Zn], [C22H38N4O6CU] and 
[C22H38N406Zn] in absence of DNA gave Ksvof 9.7 x 10^ 4.7 x 10\ 3.6 x lO' and 1.6 x 10^ 
respectively. 
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Figure 73. Stern-Volmer quenching plots with K^fFefCNJeJ of complex (a) [C14H22N4O6CU] 
(•/o) andlCuHiiN^OiZn] (m/a), (h) [C22H38N4O6CUJ (•/o) and [CiiHisN^OeZn] (m/u) in the 
absence (u/o) and presence (m/») ofCTDNA. 
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In presence of DMA the quenching curves were depressed reflecting the protection of 
complexes by the DNA helix and the Ksv values of [C14H22N4O6CU], [Ci4H22N406Zn], 
[C22H3gN406Cu] and [C22H38N406Zn] decreased to 1.3 xlO^ 1.6 x 10^ 1.3 x 10^  and 1.0 x 
10^ , respectively. The greater the decrease in Ksv value of complex indicates its higher DNA 
binding ability. 
Viscosity measurements 
To clarify the mode of interaction between the complexes [C14H22N4O6CU], [Ci4H22N406Zn], 
[C22H38N4O6CU] and [C22H3gN406Zn] and CT DNA, viscosity measurements were performed. 
Since DNA is a poly anion, the repulsion between the negative charges makes the DNA 
molecule more extended in solution. The negative charges of DNA are partially neutralized 
when the cations of complexes bind to DNA through electrostatic interaction to the phosphate 
group of DNA backbone leading to contraction of the DNA helix, shortening of DNA 
molecule and decrease in viscosity of DNA. The plots of relative viscosity vs. 1/R 
(=[complex]/[DNA]) are shown in Figure 74. 
^ 
p 
' I ' I ' I ' I ' I 
0.0 0.2 0.4 0.6 0.8 1.0 
|Complex|/|DNA| 
Figure 74. Effect of viscosity of complexes [Cj4H22N40eCuJ (red), [Cj4H22N406Zn] (blue), 
[C22H38N4O6CUJ (green) and [C22Hi8N40drt] (black) on the viscosity of CT DNA. Relative 
viscosity rj/tjo vs. [complex]/[DNA]. [Complex] 0.2-1 x 10^ M, [DNA] 10^ M in Tris-HCl 
buffer (pH = 7.2). 
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The decrease in the viscosity of these complexes revealed an electrostatic non classical mode 
of binding of complexes with DNA [167]. This decrease in viscosity observed for the 
tetrapeptide metal complexes [C14H22N4O6CU], [Ci4H22N406Zn], [C22H38N4O6CU] and 
[C22H3sN406Zn] suggest that the hydrophobic interaction of the peptide with DNA surface, 
encouraged by the hydrogen bonding interactions leads to bending (kinking) of the DNA 
chain. However, a greater decrease in the case of Cu(II) complexes than the Zn(II) complexes 
supported their strong binding. 
Circular dichroic studies 
As described earlier, that simple groove binding and electrostatic interaction of a small 
molecules with DNA show less or no perturbations on the base stacking and helicity bands, 
while intercalation enhances the intensities of both the bands stabilizing the right-handed B 
conformation of CT DNA as observed for the classical intercalator methylene blue. When the 
tetrapeptide complexes [C]4H22N406Cu] and [Ci4H22N406Zn] were incubated with CT DNA, 
the CD spectrum of DNA undergoes changes in both positive and negative bands (Figure 75). 
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Figure 75. CD spectra ofCTDNA alone (red), in presence of[Ci4H22N406Cu] (blue) and in 
presence of[Ci4H22N406Zn] (green). [Complex] KT" M, [DNA] KF' M. 
The complexes [C14H22N4O6CU] and [Ci4H22N406Zn] exhibited an increase in intensities of 
negative (ellipticity) while a decrease in intensities of positive (helicity) bands which indicate 
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strong conformational changes. The decrease in the positive band by these complexes 
suggests that the complex can unwind the DNA helix and lead to loss of helicity [174] and 
upon the interaction with the complexes, the B-DNA transforms into an A-like conformation 
[235]. These changes are in accordance with the above spectroscopic studies revealing the 
binding of complexes via non-intercalative mode of binding i.e. groove binding. 
DNA cleavage assay 
The chemical nuclease activity of the complexes [C14H22N4O6CU] and [Ci4H22N406Zn] was 
studied using supercoiled pBR322 plasmid DNA as a substrate in a medium of 50 mM Tris-
HCl/NaCl buffer (pH 7.2) in the absence and presence of external agents under physiological 
conditions. Firstly, the concentration dependent DNA cleavage by [C14H22N4O6CU] and 
[Ci4H22N406Zn] were performed. Incubating plasmid pBR322 DNA with these complexes 
under physiological conditions produced the outcome shown in Figure 76. 
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Figure 76. The cleavage patterns of the agarose Gel electrophoresis diagram showing 
cleavage of pBR322 supercoiled DNA (50 f.iM) by complex (a) [Ci4H22N^06Cu] and (b) 
[Ci4H22N406Zn] at 310 K after 45 min of incubation; Lane 1, DNA control; Lane 2, JO juMof 
complex + DNA; Lane 3: 20 /iM of complex + DNA; Lane 4: 30 ^ iM of complex + DNA; Lane 
5: 40 ji^M of complex + DNA; Lane 6: 50 ^ M of complex + DNA. 
Upon increasing the concentrations of [C14H22N4O6CU], Form I plasmid DNA was gradually 
converted into Form II along with the appearance of Form III (Lanes 5 and 6) at higher 
concentration. While in the case of the Zn(ll) complex [Ci4H22N406Zn], there is no 
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conversion to Form III but the DNA cleavage activity is enhanced upon increasing the 
concentration. It is suggested that the Cu(II) complex [C14H22N4O6CU] may cut the DNA 
strand at two positions (double strand cleavage) while Zn(II) complex [Ci4H22N406Zn] 
exhibited single strand cleavage. 
The nuclease efficiency of the metal complexes is known to depend on the activators used for 
initiating the DNA cleavage. The DNA cleavage activity of complexes [C14H22N4O6CU] and 
[Ci4H22N406Zn] in presence of H2O2, MPA, GSH and Asc was evaluated and the cleavage 
pattern is depicted in Figure 77 (Lanes 2-5). The cleavage activity of complex 
[C14H22N4O6CU] was significantly enhanced by these activators as shown in Figure 77a where 
the activity followed the order MPA > H2O2 > GSH == Asc. While in the case of Zn(II) 
complex [Ci4H22N406Zn], complete inhibition was found in the case of H2O2 (Lane 2, Figure 
77b) and conversion to Form III in the presence of MPA (Lane 3, Figure 77b) The cleavage 
activity of complex [Ci4H22N406Zn] followed the order H202» MPA > GSH ~ Asc. 
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Figure 77. Agarose Gel electrophoresis pattern for the cleavage ofpBR322 supercoiled DNA 
(50 f.iM) by complex (a) [C14H22N4O6CU] and (b) [Ci4H22N406Zn] in presence of different 
activating agents at 310 K after incubation for 45 min. Lane 1: DNA Control; Lane 2: 50 /.iM 
of complex + H2O2 (0.4 M) + DNA; Lane 3: 50 fiM of complex + MPA (0.4 M) + DNA; Lane 
4: 50 ^iM of complex + GSH (0.4 M) + DNA; Lane 5: 50 fiM of complex + ASc (0.4 M) + 
DNA; Lane 6: 50 fiM of complex + DMSO (04 M) + DNA; Lane 7: 50 fiM of complex + 
EtOH (0.4 M) + DNA; Lane 8: 50 ^ M of complex + sodium azide (0.4 M) + DNA; Lane 9: 50 
^iM of complex + SOD (15 units) + DNA; Lane 10: 50 ^M of complex + DNA + DAPl (8 
jjM); Lane 11: 50 fiM of complex + DNA + methyl green (2.5 juL of a 0.0 Img/ml solution). 
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To probe the groove binding preferences of complexes [C14H22N4O6CU] and [Ci4H22N406Zn], 
the minor groove binding agent (DAPI) and major groove binding agent (methyl green) were 
used with supercoiled plasmid pBR322 DNA. Prior to the addition of complexes 
[C14H22N4O6CU] and [Ci4H22N406Zn], DNA was incubated with groove binding agents. The 
electrophoresis results with DAPI (Lane 10, Figure 77) showed inhibition in the case of both 
the complexes. However, no apparent inhibition of DNA damage was observed in presence of 
major groove binder (Lane 11, Figure 77). This suggests minor groove preference for both the 
complexes. These results are of significance as majority of the oxidative cleavage reagents 
(Cu(ll) complex [C14H22N4O6CU] in this case) generally bind in the minor groove rather than 
the major groove [236]. 
Reactive oxygen species generated during the interaction between metal complexes and 
dioxygen or redox reagents are the major cause of DNA damage. In general, oxidative 
cleavage of plasmid DNAs may lead to the formation of reactive singlet oxygen ('O2), 
hydrogen peroxide (H2O2) and/or hydroxyl radical ('OH) species. These species contain a 
photo or a redox active center, which causes damage to the sugar and/or base [237]. In order 
to obtain information about the active chemical species that was responsible for the DNA 
damage, we investigated the DNA cleavage in the presence of hydroxyl radical scavengers 
(DMSO and EtOH), singlet oxygen quenchers (NaNs) and SOD as superoxide radical 
scavenger under identical conditions. In the case of complex [C14H22N4O6CU], the cleavage 
experiments revealed that the hydroxy radical inhibitors can prevent the DNA damage but not 
completely (Lanes 6-7 Figure 77a) as little inhibiton was exhibited by DMSO and no obvious 
inhibition was shown by EtOH. While in the presence of sodium azide, (Lane 8 Figure 77a) 
there is efficient inhibition of DNA scission. The inhibitoiy effect of sodium azide can be 
ascribed to the affinity of the azide anion for transition metals [183]. The Cu(II) complex 
[C14H22N4O6CU] may be capable of cleaving the DNA through an oxidative DNA damage 
\ ft " 
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pathway involving the hydroxyl radicals and singlet oxygen species. Many research groups 
have proposed the possible reaction mechanisms of DNA damage by Cu(II) complexes in the 
presence of hydrogen peroxide [133]. The initial step is the interaction of Cu(II) complex with 
the outer sphere of DNA strand. The second step is the reduction of Cu(ll) complex to Cu(I) 
complex by reducing agent, then the Cu(I)-DNA adduct further reacts with H2O2 via the 
Fenton mechanism to generate a hydroxyl radical species that can bind to the metal ion [118]: 
Cu(II) complex + DNA -^ Cu(II)-DNA 
Cu(II)-DNA ~> Cu(l)-DNA 
Cu(l)-DNA + H2O2 -^ Cu(ll) (•OH)-DNA + 'OH 
In the case of [Ci4H22N406Zn], no inhibition of DNA cleavage in the presence of scavengers 
of hydroxyl radical DMSO and EtOH (Lane 6-7 Figure 77b), ruling out the possibility of 
DNA cleavage by hydroxyl radicals. While in the presence of singlet oxygen (sodium azide) 
and superoxide radical scavenger (SOD), there is considerable DNA cleavage, DNA 
converted to Form III in presence of SOD suggesting the non-involvement of the superoxide 
radical in the cleavage pathway. This indicates that the cleavage of DNA probably follows a 
discernable hydrolytic cleavage mechanism (Scheme 9). 
iase 
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Scheme 9: Proposed intermediate in the hydrolysis of DNA cleavage promoted by 
[C,4H22N406ZnJ. 
129 
Since, complex [Ci4H22N406Zn] contains coordinated water molecule, which facilitates the 
nucleophilic attack of water oxygen to phosphorus to give a five-coordinate phosphate 
intermediate and subsequent rearrangement of the phosphate, which allows the DNA to be 
cleaved readily. This hypothesis is supported by previous literature which reveals that Zn(Il) 
complexes generally cleave the DNA by hydrolytic pathway. 
Direct evidence in support of hydrolytic cleavage mechanism of exhibited by [Ci4H22N406Zn] 
was obtained by the religation assays in which supercoiled pBR322 DNA was treated with T4 
DNA ligase enzyme and subjected to gel electrophoresis. 
T4 DNA ligase assay 
The [Ci4H22N406Zn] yielded linearized DNA which was reHgated by using T4 DNA ligase 
enzyme (Figure 78). In our case, DNA religation was complete and after ligation there was 
complete repair which was quantitatively ascertained by comparison of complex treated DNA 
and with the control DNA alone in SC form. 
Figure 78. Agarose Gel electrophoresis pattern for the ligation pBR322 plasmid DNA 
linearized by Zn(II) complex [Ci4H22N40f,Zn]: Lane 1: DNA control; Lane 2: pBR322 
plasmid DNA cleaved by [Ci4H22N406Zn]; Lane 3: ligation of linearized pBR322 plasmid 
DNA by T4 DNA ligase. 
Hence, these results implied that the process of DNA cleavage by [Ci4H22N406Zn] occurs via 
a hydrolytic pathway. 
DNA cleavage promoted by H2O2 
In addition, the control experiments on DNA cleavage were also performed using H2O2 and 
metal ions alone as depicted in Figure 79. It was observed that metal ion and H2O2 alone 
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induced little influence on DNA damage, followed by conversion of Form I to Form II. 
However Cu(II) metal ion induced by H2O2 caused extensive DNA damage due to reduction 
of Cu(Il) to Cu(I) has an important role in the production of active species causing DNA 
damage. Similarly in presence of Zn(II)-H202 system DNA cleavage was observed due to the 
enhanced nucleophilicity but depressed electrophilicity of the peroxide ion coordinated to the 
zinc(II) ion. 
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Figure 79. The cleavage patterns of the agarose Gel electrophoresis diagram showing 
cleavage of pBR322 siipercoiled DNA (50 juM) by free Cu(II) and Zn(II) ions at 310 K after 
45 min of incubation; Lane I: DNA control; Lane 2: DNA + H2O2 (0.4 M); Lane 5: DNA + 
50 ^MofCii(IL) metal ion; Lane 4: DNA + 50 juMofCu(II) metal ion + H2O2 (0.4 M); Lane 
5: DNA + 50nMofZn(lI) metal ion; Lane 6: DNA + 50^MofZu(ll) metal ion + H2O2 (0.4 
M). 
In vitro MTT cytotoxic assay 
The MTT cell proliferation assay has been widely accepted as a reliable way to measure the 
cell proliferation rate. As from the results of in vitro DNA binding studies it was evident that 
complexes [C14H22N4O6CU] and [Ci4H22N406Zn] exhibited greater binding propensity as 
compared to other complexes, cytotoxic activity was evaluated for complexes 
[C14H22N4O6CU] and [Ci4H22N406Zn]. In vitro cytotoxic activity of [C14H22N4O6CU] and 
[Ci4H22N406Zn] in terms of IC50 values were screened against three human carcinoma cell 
lines of different histological origin by MTT assay: MDA-MB 231 (breast adenocarcinoma), 
A375 (malignant melanoma) and HCT116 (colon carcinoma) with cisplatin as control. The 
results in terms of IC50 values are given in the Table 11. The Cu(II) complex [C14H22N4O6CU] 
exhibited good cytotoxicity against A375 and HCTl 16 cancer cell lines as compared to Zn(II) 
complex [Ci4H22N406Zn]. 
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Table 11. In vitro cytotoxic activity of complexes [C14H22N4O6CU] and [Ci4H22N406Zn] 
against different cancer cell lines. 
Cell lines (IC50 fiM) 
Complex MDA-MB231 A375 HCT116 
[C14H22N406CU] 
95% CI. 
[C,4H22N406Zn] 
95% C.I. 
Cisplatin 
95% C.I. 
13,54 
10.33 to 17.74 
18,24 
13.40 to 24.84 
6.9 
5.633 to 7.4 
25,04 
17.41 to 36.02 
18,94 
13.68 to 26.23 
0.71 
0.563 to 0.904 
54,26 
44.51 to 66.13 
33,00 
25.85 to 42.11 
8.728 
8.030 to 9.486 
The ICso value is the concentration of compound that affords a 50% reduction in cell growth 
(after 72 h of incubation). MDA-MB 231= human breast adenocarcinoma cell line. A375 = 
human malignant melanoma cell line. HCT116 = human colon carcinoma cell line. 
C.I. = confidence interval 
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Conclusion 
The synthesis, structural characterization and comparative DNA binding and cleavage studies 
of Cu(II) and Zn(II) complexes of tetrapeptide ligands (Pro-Gly-Pro-Gly, [C20H32N4O7] and 
Pro-Leu-Pro-Leu, [C28H48N4O7]) have been carried out. Solution stability studies revealed 
stable nature of peptides in solution. In vitro DNA binding studies of ligands and complexes 
were carried out by employing various optical methods, revealed that the metal complexes 
bind more avidly to the DNA as compared to free ligands preferentially via groove binding. 
The observed Kb values revealed that both Cu(II) complexes [C14H22N4O6CU] and 
[C22H38N4O6CU] exhibit greater binding propensity than Zn(II) complexes [Ci4H22N406Zn] 
and [C22H38N406Zn], however, steric constraints in [C22H38N4O6CU] and [C22H38N406Zn] 
accounted for lower DNA binding affinity than [C14H22N4O6CU] and [Ci4H22N406Zn]. The 
artificial nuclease activity was ascertained by gel electrophoretic mobility assay; 
[C14H22N4O6CU] and [Ci4H22N406Zn] displayed efficient cleavage activity of plasmid 
pBR322 DNA. Both the complexes bind to the minor groove of the DNA. The results of gel 
electrophoresis revealed that the complex [C14H22N4O6CU] cleaved plasmid DNA via 
oxidative mechanism while the DNA cleavage by [C]4H22N406Zn] proceeds via hydrolytic 
pathway which was further confirmed by T4 DNA religation experiment. In vitro cytotoxic 
activity of [C14H22N4O6CU] and [Ci4H22N406Zn] in terms of IC50 values were screened against 
three human carcinoma cell lines of different histological origin by MTT assay: MDA-MB 
231 (breast adenocarcinoma), A375 (malignant melanoma) and HCT116 (colon carcinoma) 
and compared to cisplatin revealing that complexes [C14H22N4O6CU], [Ci4H22N406Zn] 
exhibited good cytotoxic activity. Hence, we could say that the tethering of DNA recognition 
peptide moiety to metals provides a viable strategy for the construction of small, synthetic 
repressors for the detailed, systematic study of peptide-DNA recognition. 
CHAPTER V 
Enantiomeric recognition of chiral L- and D-
penicillamine Zinc(II) complexes: DNA binding 
behavior and cleavage studies 
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Synthesis 
Synthesis of complexes 
(L)-[Ci9H2iN304SZn] 
The complex (L)-fCi9H2iN30^SZnJ was synthesized following a general procedure: 
To the methanolic solution of 1,10-phenanthroline monohydrate (0.79 g, 4 mmol) was added 
20 ml methanolic solution of Zn(CH3COO)2 (0.87 g, 4 mmol) and to this reaction a 
methanolic mixture of L-penicillamine (0.59 g, 4 mmol), pretreated with KOH (0.22 g, 4 
mmol) was added drop wise and kept on reflux for 4-5h. After refluxing the reaction mixture 
was filtered to remove any unreacted L-penicillamine and the resulting solution was kept on 
slow evaporation at room temperature yielding a white product which was filtered, washed 
with diethyl ether and dried in vacuo (Scheme 10). 
Yield; 52%, m.p.: 236 °C (d), Anal. Calc. for C|9H2,N304SZn (%): C, 50.39; H, 4.67; N, 9.28; 
Found: C, 50.89; H, 4.92; N, 9.98. Selected IR data (KBr, cm'', v): 3282 Vas(NH2); 2595 v(S-
H)pen; 1622 Vas(COO); 1566 8(NH2); 1345 Vs(COO); 854 5(S-H). ' H N M R (DMSO-de, 400 
MHz, 5, ppm): 8.65 (2H, aromatic Hphen); 7.6-8.14 (6H, aromatic Hphen+2H, NH2pen); 3.5 (s, 
chiral -CHpen); 2.09 (s, IH, -SHpen); 1.40 (s, 6H, -CHspen). '^ C NMR (100 MHz, 5, ppm): 181 
(C=Open); 148.3, 140, 127.2, 125.25 (IOC, aromatic); 61.84 (IC, chiral Cpe„); 49.95 (IC, - C -
SHpen); 26.75 (2C, -CH3 Cpen). Molar conductance (10"^ M, MeOH, 25°C, ^"'cm^mor'): 87 
(1:1 electrolyte). UV-vis (lO"* M, MeOH, nm): 271, 290. [ajo (MeOH, 25 °C): -52. ESI-MS 
{m/zy. 458 [C,9H2iN304SZn+5H^]. 
(D>-[Ci9H2iN304SZn] 
The complex (D)-[Ci9H2iN304SZn] was synthesized according to the procedure outlined 
above for (L)-[Ci9H2iN304SZn] from D-penicillamine (0.59 g, 4 mmol) instead of L-
penicillamine. 
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Yield: 58%, m.p.: 235 °C (d). Anal. Calc. for C,9H2iN304SZn (%): C, 50.39; H, 4.67; N, 9.28; 
Found: C, 50.79; H, 4.86; N, 9.77. Selected IR data (KBr, cm~', v): 3292 Va,(NH2); 2591 v(S-
H)pen; 1620 Vas(COO); 1516 5(NH2); 1375 v,(COO); 853 5(S-H). ' H N M R (DMSO-de, 300 
MHz, 5, ppm): 8.68 (2H, aromatic Hphen); 7.6-8.1 (6H, aromatic Hphen+2H, NH2pen); 3.19 (s, 
chiral -CHpen); 2.08 (s, IH, -SHpen); 1.42 (s, 6H, -CHspen). "C NMR (100 MHz, 5, ppm): 
181.48 (C=0 pen); 148.46, 140.38, 125.15 (IOC, aromatic Cphen); 62.91 (IC, chiral Cpen); 
49.95 (IC, -C-SHpen); 26.75 (2C, -CH3 Cpe„). Molar conductance (10"^ M, MeOH, 25°C, QT 
'cm-mof'): 92 (1:1 electrolyte). UV-vis (10^ M, MeOH, nm): 271, 291. [ajo (MeOH, 25 
°C): +31. ESI-MS (m/2^): 455 [Ci9H2iN304SZn+3H^]. 
SH 
OH 
H,N 
Zn(CH3COO)2 
• 
MeOH, 70 "C 
4-5 h 
CH.COO 
1,10-phenanthroline L-/D-penicillamine (LH(D)-[C,9H2,N304SZn] 
Scheme 10. Synthesis of complexes (L)~[Ci9H2!N30^SZnJ and (D)-[Cj9H2iN30^SZnJ. 
Results and discussion 
Penicillamine-derived enantiomeric (L- and D-) Zn(II) complexes (L)-[Ci9H2iN304SZn] and 
(D)-[Ci9H2iN304SZn] of 1,10-phenanthroline were synthesized and characterized from 
analytical and physicochemical data. The 1:1 electrolytic complexes showed good solubility 
in MeOH and DMSO, and were insoluble in hydrocarbons. They were stable in solid and 
solution phases. Because of the presence of chiral auxiliaries (L- and D-penicillamine) both 
the complexes (L)- and (D)-[Ci9H2iN304SZn] exhibited optical rotation, [a]^ values of-52 
and +31, respectively indicated that the complexes were optically active. The energy 
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minimized 3-dimensionaI molecular structures of complexes (L>- and (D>-[Ci9H2iN304SZn] 
are represented in Figure 80. 
Figure 80. The energy minimized cylindrical bonded 3~dimensional molecular structures of 
complexes (a) (L)-[Ci9H2iN}04SZn] and (b) (D)-[CigH2iN304SZn]. Color scheme: Nitrogen 
(blue), oxygen (red) Zn(II) (dark grey), sulfur (yellow) and carbon (grey). Hydrogen atoms 
and non-coordinated acetate ions have been omitted for clarity. 
Infrared spectroscopy 
Coordination by amino group: The IR -NH2 stretching frequencies were used to distinguish 
coordinated from non-coordinated amino groups. The position and intensity of vCN-H) bands 
are influenced by hydrogen bonding and by coordination of nitrogen to metal. The most 
important bands in the spectra of free L/D-penicillamine were assigned to v(NH3*) at 3174-
2967 cm"' and Vas(COO") at 1595 cm"' corresponding to the Zwitterionic form of 
penicillamine [127]. The free L/D-penicillamine exhibit absorption frequency band at 3250 
cm"' corresponding to Vas(NH2) which was shifted towards higher frequencies in the 
complexes indicating coordination to metal through NH2 group [238]. Also confirmed by the 
changes in the 5(NH2) bands from 1650 cm"' in free L/D-penicillamine to 1566 and 1516 
cm"' in (L)- and (D)-[Ci9H2iN304SZn], respectively [239]. 
Coordination by carboxylate group: The IR -0-C=0 stretching frequencies distinguish 
coordinated from the uncoordinated carboxyl group. The absorption bands of Vas(COO) 
exhibited by the complexes (1622 and 1620 cm"' for (L)- and (DHC]9H2iN304SZn], 
respectively) was subsequently higher than the free L/D-penicillamine (1590 cm"') [128]. 
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The Vs(COO) frequency in complexes (L)- and (D)-[Ci9H2iN304SZn] were shifted to lower 
frequencies (1345 cm ' and 1375 cm"' for (L)- and (D)-[Ci9H2iN304SZn], respectively) as 
compared to the free penicillamine (1397 cm"'), which indicated that the terminal 
coordination mode of the carboxylate group of penicillamine to metal ion is via deprotonation 
[153]. The Av value which represents the coordination modes of the carboxylate group was 
greater than 200 cm"' indicating unidentate carboxylate ligation. 
Further, the v(S-H) absorption bands at 2600-2400 cm"' in free L/D-penicillamine [127] did 
not undergo any significant shift in the IR frequency (2595 and 2591 cm"' in (L)- and (D)-
[Ci9H2iN304SZn], respectively) which suggested non-involvement of -SH group in 
coordination. The bands assigned to v(C-H) of phenanthroline moiety at 843 and 724 cm"' in 
(L)-[Ci9H2|N304SZn] and 842 and 723 cm"' in (D)-[C,9H2iN304SZn] were shifted to lower 
frequencies as compared to the free phenanthroline (853 and 737 cm"') indicating the 
formation of coordinate covalent bond between the metal and phenanthroline N atoms [240]. 
Nuclear magnetic resonance spectroscopy 
The ' H N M R spectra of the complexes (L)- and (D)-[Ci9H2iN304SZn] were recorded in 
DMS0-d6 and is represented in Figure 81. 
(a) 
J 
(b) 
JL .LL 
Figure 81. 'H NMR spectra of complexes (a) (L)~[Ci9H2iN304SZnJ and (b) (D)-
[Ci9H2iNsO,SZnJ. 
The -NH2 resonance of free L/D-penicillamine (5 6.10 ppm [241]) was shifted downfield (5 
-7.6 ppm) which merged with the aromatic proton resonances in the complexes (L)- and (D)-
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[Ci9H2iN304SZn] upon coordination of the -NH2 group to the metal. However, there was no 
chemical shift in the resonance signal corresponding to -SH proton (5 1.0-2.0 ppm in free 
L/D-penicillamine) in the complexes (5 -2.09 ppm), which indicated non-involvement of-
SH group in coordination. The -COOH resonance of free L/D-penicillamine (5 12.0-13.0 
ppm) was absent in the complexes suggesting the replacement of carboxylic proton and 
coordination through zinc metal. While the other peaks at 8 1.4 and 5 3.5 ppm corresponded 
to the methyl protons and the proton attached to the chiral carbon of L/D-penicillamine 
moiety, respectively, confirming the presence of L/D-penicillamine moiety in the Zn(II) 
complexes. The protons in the aromatic region of the phenanthroline moiety exhibited 
resonance peaks in the region 5 7.60-8.14 ppm in the complexes confirming the presence of 
phenanthroline moiety. 
The characteristic resonance peaks in '^ C NMR spectra of complexes (L)-[Ci9H2iN304SZn] 
and (D)-[Ci9H2iN304SZn] were recorded in DMSO-de (Figure 82). 
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Figure 82. "C NMR spectra of complexes (a) (LHCifHiiNsO^SZn] and (b) (D)-
[Ci9H2iNs04SZn]. 
The resonance of carboxylic carbon (-COOH) were shifted downfield (5 180 ppm) in the 
complexes (L)- and (D)-[Ci9H2iN304SZn] as compared to the free penicillamine (5 169 ppm 
[241]), which was suggestive of the coordination of penicillamine to zinc through carboxylic 
moiety via deprotonation [131]. Other resonance peaks at around 5 61.8, 49.9 and 26.7 ppm in 
complexes (L)- and (D)-[Ci9H2iN304SZn], could be attributed to the chiral carbon, C-SH 
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and methyl carbons of penicillamine moiety, respectively, confirming its presence in the 
complexes. The signals corresponding to chiral carbon of penicillamine (-CH-NH2) also 
shifted downfield as a consequence of zinc coordination to NH2 group. The phenyl carbons (8 
127-147 ppm) of phenanthroline appeared at 8 125-140 ppm in the complexes [242]. 
Mass spectrometry 
ESI mass spectra of the complexes (L)- and (D)-[Ci9H2iN304SZn] recorded in DMSO 
displayed prominent peaks corresponding to the molecular ion fragment at mJz at 458 and 455 
which could be attributed to (LHCi9H2iN304SZn + SlT] and (DHCi9H2iN304SZn + StT], 
respectively. Other peaks observed in complexes (L)-[Ci9H2iN304SZn] and (D)-
[Ci9H2iN304SZn] at m/z 319 corresponded to the fragments obtained by the expulsion of -
CH3COO and -C(CH3)2SH moiety of penicillamine, at m/z 244 after removal of penicillamine 
moiety and at m/z 180 by the successive expulsion zinc metal corresponding to the 
phenanthroline moiety. 
Electronic spectra 
Both the enantiomeric complexes (L)- and (D)-[C]9H2iN304SZn] exhibited strong bands in 
the UV region at -270 nm which may be attributed to ligand based charge transfer transitions 
and other low energy bands at around 290 nm corresponding to ;t-*rt* transitions of 
coordinated phenanthroline ligand [243,244]. The electronic spectra of complexes (L)- and 
(D)-[Ci9H2iN304SZn] also displayed transitions around 270 nm characteristic of tetrahedral 
environment around Zn(ll) metal center [39]. 
DNA binding studies 
DNA is the primary cellular target for numerous antitumor drugs. Reversible or irreversible 
modifications of the nucleic acids can lead to disruption of the transcription and/or 
replication, initiating ultimately the death of cancerous cells. Significant efforts have been 
focused on developing new synthetic molecules that bind to DNA, influence its activity with 
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the goals of controlling DNA processing, creating new therapeutics or diagnostics and to 
enhance the fundamental understanding of DNA molecular recognition. 
Electronic absorption titration 
With an aim to distinguish between the DNA binding propensities of different enantiomeric 
forms, the electronic absorption titrations of complexes (L)- and (D)-[Ci9H2iN304SZn] with 
CT DNA were carried out. Upon adding increasing amounts of CT DNA (0.00-3.33 x 10"' M) 
to complexes (L>- and (D)-[Ci9H2iN304SZn] (6.66 x 10"^  M), the ligand based charge 
transfer spectral band at -273 nm exhibited hyperchromism with a significant blue shift of 
~4-7 nm in the band position (Figure 83). 
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Figure 83. Absorption spectra of complexes (a) (L)-[Ci9H2iNs04SZn] and (b) (D)-
[CigH2iNs04SZn] in Tris-HCl buffer (pH = 7.2) in the absence and presence of increasing 
amounts ofCTDNA. Inset: Plots of [DNA]/(£a-£j) vs. [DNA] for the titration ofCTDNA with 
complexes. Arrow indicates the increase in absorbance upon increasing DNA concentration. 
m, experimental data points; full lines, linear fitting of the data. [Complex] 6.66 x IGT M, 
[DNA] 0-3.33 X10'M. 
This concomitant blue shift in the spectral band rules out the groove binding nature of the 
complexes suggesting an intimate association of the complexes with CT DNA and is likely 
that these complexes bind to CT DNA electrostatically via external contact (surface binding) 
with the DNA duplex [245]. Although there are subtle differences in binding ability of 
different enantiomers, nevertheless, we can discriminate between the two enantiomeric forms 
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by observing their spectral titration profiles. The differences in binding of two enantiomeric 
L- and D- forms are quite evident as there is greater increase in molar extinction coefficient 
values attributed to hyperchromism, 39% in case of L-enantiomer, complex (L)-
[Ci9H2iN304SZn] with blue shift of 7 nm in comparison to D-enantiomer complex (D)-
[Ci9H2iN304SZn] which exhibited a relatively lower hyperchromism of 26% and a blue shift 
of 4 nm. 
In order to compare quantitatively the binding strength of complexes (L)- and (D)-
[Ci9H2iN304SZn] with CT DNA, the intrinsic binding constant, Kj, values were calculated 
and are represented in Table 12. 
Table 12. The intrinsic binding constant (Kb) values of complexes with CT DNA (mean 
standard deviation of± 0.12). 
Complex Kb(]Vr') Monitored % Blue shift 
at (nm) hyperchromism (nm) 
(L)-[C,9H2iN304SZn] 6.7 xlO' 273 39 7 
(D)-[Ci9H2iN304SZn] 2.6x10'' 273 26 4 
The observed values revealed that the L-enantiomer complex possess higher propensity for 
DNA binding in comparison with the D-enantiomer. Furthermore, it implicates that the 
different conformational features are processed differently by cellular machinery. L-form of 
the Zn(II) complex interacts with right handed B-DNA forming a two-pole complementary 
complex compatible to its molecular symmetry and therefore, exhibits strong electrostatic 
interactions additionally via hydrogen bonding [246]. Nevertheless, due to the presence of 
aromatic phenanthroline moiety, partial intercalative mode of binding cannot be ruled out 
[158]. The binding mode needs to be proved through some more experiments. 
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Interaction with mononucleotides (5'-GMP and 5'-TMP) 
To further examine the mode of binding and to provide a concrete evidence for electrostatic 
binding, the interaction of complexes (L)- and (D)-[Ci9H2iN304SZn] were carried out with 
5'-GMP and 5'-TMP. The absorption spectra of the complexes (L)- and (D)-
[Ci9H2iN304SZn] in presence of 5'-GMP and 5'-TMP are shown in Figures 84 and 85. 
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Figure 84. Absorption spectral traces of complex (a) (L)-[Ci9H2iN304SZn] and (b) (D)-
[C,9H2iN304SZn]in Tris-HCl upon the addition of 5'-GMP.[Complex] 6.66x 10'^M, [5-
GMPJ 0-2.0xJOr^M. 
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Figure 85. Absorption spectral traces of complex (a) (L)-[Ci9H2iN304SZn] and (b) (D)-
[Ci9H2iN304SZn] in Tris-HCl upon the addition of5'-TMP. [Complex] 6.66x 10^M, [5-
TMP] 0-2.0X 10'M. 
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Upon addition of the nucleotides the absorption spectra of the complexes exhibited 
hyperchromism without any shift in the absorption band indicating electrostatic mode of 
binding with the oxygen of the negatively charged surface phosphate group of the DNA helix 
[247]. Kb values calculated for complexes (L)- and (D)-[Ci9H2iN304SZn] are shown in Table 
13. The Kb values calculated suggested greater binding of Zn(II) complexes with 5'-TMP 
rather than 5'-GMP clearly indicating that zinc specifically binds to 5'-TMP through its N3 
nitrogen as consistent with earlier observations. 
Table 13. The intrinsic binding constant (Kh) values of complexes [C27H26NHOiiZn2] and 
[C22H27N70iiZn2] with nucleotides (mean standard deviation of± 0.14). 
Complex Kb(]Vr') Monitored % Blue 
at (nm) hyperchromism shift 
(nm) 
5'-GMP 5'-TMP 
(LHCi9H2iN304SZn] 2.11x10" 
(DHCi9H2iN304SZn] 1.18 xlO" 
3.29x10" 
2.82 X 10" 
271 
271 
272 
272 
24 
19 
32 
26 
1 
2 
1 
2 
Since, L-enantiomeric form of the complex exhibited greater binding propensity, the 
interaction of complex (L)-[Ci9H2iN304SZn] was also validated by ' H and ' ' ? NMR 
spectroscopy. Relative shifts in the ' H and "'P NMR signal of 5'-GMP and 5'-TMP in 
presence of complex (L)~[Ci9H2iN304SZn] provides infonnation about the binding mode of 
this complex. The free 5'-GMP exhibited H8 signal at 5 8.07 ppm and Hi—H5' ribose proton 
signals at 5 3.85-5.80 ppm. Complex (LHCi9H2iN304SZn] + 5'-GMP showed no significant 
shifts of the H8 signal of the purine base, strongly suggesting negligible interaction of the 
Zn(Il) atom with theN7 of the nucleotide (Figure 86) [248]. 
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Figure 86. 'H NMR spectrum of (a) 5'~GMP (5 mmol) alone and (b) 5'-GMP with (L)-
[CisHsiNsO^SZnJ (2.5 mmol) (c) 5'-TMP (5 mmol) alone and (d) 5'~TMP with (L)-
[C,9H2iN304SZn] (2.5 mmol) at 25 °C. 
On the other hand, upon addition of 5'-TMP to (L)-[Ci9H2iN304SZn], the signal of N3 atom 
of free 5-TMP (5 7.64 ppm) undergoes a substantial shift to 5 7.80 ppm while other 
resonances at 5 6.2 and 1.98 ppm (C6-H and CH3 of thymine group T-CH3, respectively) in 
free 5'-TMP shifted to 5 6.16 and 1.76 ppm, respectively suggestive of interaction of complex 
with 5'-TMP. The ^'P NMR spectra of complex (L)-[C|9H2iN304SZn] in presence of 5'-
GMP revealed a shift of 5 3.55 (8 3.76 ppm in free 5'-GMP) while, in the presence of 5'-
TMP, complete disappearance of signal (5 3.18 ppm in free 5'-TMP) was observed which 
suggesting the electrostatic mode of interaction between phosphate groups (06 of phosphate 
group) with Zn(Il) centre (Figure 87). 
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*S—:j? ; 
i / j Figure 87. "P NMR spectrum of (a) 5'-GMP (5 mmol) alone and (b) 5'-GMP with (L)-
[Cj9H2iN30^SZnJ (2.5 mmol) (c) 5'~TMP (5 mmol) alone and (d) 5'~TMP with (L)-
[Ci9H2iNi04SZn] (2.5 mmol) at 25 °C. 
Fluorescence spectral studies 
To further confirm the interaction between (L)- and (D)-[Ci9H2iN304SZn] and CT DNA, 
emission experiments were carried out. Complexes (L)- and (D)-[Ci9H2iN304SZn] exhibited 
luminescence in Tris-HCl buffer with a maximum wavelength at 370nm (excited at 260 nm). 
The results of emission titration for (L)- and (D)-[Ci9H2iN304SZn] with CT DNA are 
illustrated in Figure 88. An increase in DNA concentration increased the emission intensity of 
(L)- and (D)-[Ci9H2iN304SZn]. The observed enhancement could be due to relatively non-
polar environment of the bound metal complex in the presence of DNA, such that the 
complexes were less deeply inserted inside the hydrophobic pockets or grooves of CT DNA 
[233]. The binding constant value, K for the (L)- and (D)-[Ci9H2iN304SZn] determined from 
the Scatchard equation were calculated to be 5.9 x 10"* and 3.1 x lO"* M"', respectively. On the 
basis of K values, we can evaluate the extent and mode of binding of different enantiomers 
showing enantiospecific discrimination. 
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Figure 88. Emission spectra of the complexes (a) (L)-[Ci9H2iN304SZnJ and (b) (D)~ 
[Ci9H2iN304SZn] in Tris-HCl buffer (pH = 7.2) with increasing concentration of complexes 
in presence of fixed concentration ofEB-DNA. Arrow indicates the change in intensity upon 
increasing concentration of complexes. Inset: Plots ofr vs. r/Cpfor the titration ofCTDNA 
with complexes m, experimental data points; full lines, linear fitting of the data. [Complex] 
6.66x 10^M, [DNAJ 0.66-4.0x Ja^M. 
To evaluate the interacting strength of enantiomer complexes (L)- and (D)-[Ci9H2iN304SZn], 
emission quenching experiments using [Fe(CN)6]''~ as a quencher were also performed. 
[Fe(CN)6] poorly quench fluorescence of complexes which are strongly bound to the DNA 
whereas the complexes which are free in solution are quenched efficiently due to ion pairing 
[249]. 
The quenching efficiency was evaluated from the Stem-Volmer equation. The emission 
intensity of the complexes (L)- and (D)-[Ci9H2iN304SZn] was greatly affected by the 
addition of anionic quencher. The decrease in emission intensity of the complex was due to 
the repulsion of highly negative charged [Fe(CN)6]''" from the DNA polyanion backbone, 
which hinders access of [Fe(CN)6]'* to the DNA-bound complexes [250]. The plot of free 
complexes (L)- and (DHCi9H2iN304SZn] gave a Ksv value of 8.23 x lO'' and 6.96 x lO" M~\ 
respectively (Figure 89). In the presence of DNA the quenching curve was depressed 
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reflecting the protection of complex by the DNA helix and the Ksv value of (L)- and (D)-
[Ci9H2iN304SZn] decreased to 4.22 x 10'* and 3.76 x 10^  M~\ respectively. 
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Figure 89. Stern-Volmer quenching plots with K^FefCNJsJ of (L)-[Ci9H2iN304SZnJ in the 
absence (u) and presence (m) ofCTDNA and (D)-fC]<)H2]Ns04SZnJ in the absence (o) and 
presence (•) ofCTDNA. 
Viscosity measurements 
The effects of the complexes (L)- and (D)-[Ci9H2iN304SZn] on the relative viscosity of CT 
DNA are shown in Figure 90. The results clearly indicated that in presence of the complexes 
(L)- and (D)-[Ci9H2iN304SZn], the viscosity of CT DNA first decreased followed by a 
substantial increase. The initial decrease was observed due to the interaction of complexes 
with DNA producing kinks or bends in the DNA strand, thereby diminishing its effective 
length suggesting non-intercalative presumably electrostatic interactions. While, on the other 
hand, the further increase in the viscosity supports partial intercalation of the aromatic 
phenanthroline moieties into the DNA helix base pairs. These results indicated the dual 
binding nature of these Zn(II) complexes [245]. A higher reduction and higher enhancement 
in the viscosity of CT DNA of complex (L)-[Ci9H2iN304SZn] compared to complex (D)-
[Ci9H2iN304SZn], suggesting a greater binding propensity of L-enantiomer, which was 
consistent with the results, obtained from other spectral titration studies. 
147 
|Coniplexl/|DNAl 
Figure 90. Effect of increasing amounts of complexes (L)-fCi9H2jNs04SZnJ (black) and (D)-
[Ci9H2iNi04SZn] (red) on the viscosity ofCTDNA in Tris-HCl buffer (pH = 7.2). Relative 
viscosity fj/rio vs. [complex]/[DNA]. [Complex] 0.2-1 x KT^M, [DNAJ lO^M. 
Circular dichroic studies 
The CD of unbound CT DNA is characterized by a positive band at 275 nm and a negative 
band near 240 nm with a zero-cross over around 258 nm. These two bands are the net result 
of exciton coupling interactions of the bases which depend on the skewed orientation on the 
DNA backbone [251]. Figure 91 displays the CD spectra of CT DNA in absence and presence 
of complexes (L)- and (D)-[Ci9H2iN304SZn]. 
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Figure 91. CD spectrum of CT DNA alone (green), in presence of (L)-[Ci9H2iNs04SZn] 
(blue) and (D)~[Cj9H2iNs04SZn] (red). [Complex]=1 (T^ M, [DNA]= 10^ M. 
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Upon the addition of complex (L)-[Ci9H2iN304SZn] to CT DNA, both the positive and 
negative bands exhibited a decrease in intensity in comparison with free CT DNA in the CD 
spectrum. While the complex (D)-[Ci9H2iN304SZn] presented inverse CD spectra in which 
the intensities of both positive and negative bands increased, suggesting that complex may 
interact in an electrostatic mode. The nucleobases in the deep major groove of DNA double 
helix are preferably accessible to the positively charged transition metal complexes and 
neutralize the two closely associated negatively charged sugar phosphate backbone along the 
major groove and results in B-+A conformational transitions [235]. Both the enantiomers 
upon binding to CT DNA showed opposite spectral changes in CD spectrum, attributed to the 
different matching between the enantiomers and the DNA or to the different binding sites of 
the enantiomers. 
DNA cleavage assay 
The DNA cleavage ability of enantiomers of complexes (L)- and (D)-[Ci9H2iN304SZn] was 
studied by agarose gel electrophoresis using supercoiled plasmid pBR322 DNA as a substrate. 
The activity of complexes (L)- and (D)-[Ci9H2iN304SZn] was assessed by the conversion of 
DNA from Form I to Form II or Form III. A concentration-dependent DNA cleavage by (L)-
and (D)-[Ci9H2iN304SZn] was first performed. Briefly, pBR322 DNA was mixed with 
different concentration of ((L)- and (D)-[Ci9H2iN304SZn] and the mixture were incubated at 
310 K for 45 min as shown in Figure 92. With the increase of concentration of (L)- and (D)-
[Ci9H2iN304SZn] (20-35 |iM) intensified nicked form (Form II, NC) was observed and the 
amounts of Form I diminishes gradually whereas those of Form II progressively increased 
(Lane 2-5) without the formation of Form III, suggesting single strand DNA cleavage. This 
distinct pattern of gel electrophoresis discriminates clearly DNA cleavage activity by L- and 
D-enantiomers of the complex; D-enantiomer reveals less efficient DNA cleavage whereas 
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L-enantiomer cleaves DNA with higher efficiency to convert SC form into NC form 
completely at higher concentration. 
(a) 
Form II 
Form! 
(b) 
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Figure 92. The cleavage patterns of the agarose gel electrophoresis for pBR322 plasmid 
DNA (300 ng) at 310 K after 45 min of incubation in buffer (5mM Tris-HCl/50 mM NaCl, 
pH= 7.2) by (a) (LHCigHiiNiO^SIn]; Lane 1, DNA control; Lane 2, DNA + (L)-
[Ci9H2!N30,SZnJ (20 nM); Lane 3, DNA + (L)-[Ci9H2iN30^SZnJ (25 nM); Lane 4, DNA + 
(L)-[Ci9H2iNsO,SZn] (30 ^M); Lane 5, DNA + (LHCgHiiNiO^SZn] (35 nM); (b) (D)-
[CigHiiNsO^SZn]; Lane 1, DNA control; Lane 2, DNA + (D)-[C,9H2,N304SZn] (20 ixM); 
Lane 3, DNA + (DyiCigHjiNiO^SZn] (25 ^M); Lane 4, DNA + (D)-fC!9H2iN30,SZnJ (30 
fiM); Lane 5, DNA + (D)-[Ci9H2iN304SZn] (35 ^ iM). 
Since the nuclease efficiency of complexes is usually dependent on activators. Therefore, 
DNA cleavage activity of (L>- and (D)-[Ci9H2iN304SZn] in presence of H2O2, ascorbate, 3 -
mercaptopropionic acid and glutathione was evaluated (Figure 93). The cleavage activity of 
(L)- and (D)-[Ci9H2iN304SZn]were significantly enhanced by these activators and follows 
the order MPA > H2O2 > Asc > GSH for (LHCi9H2iN304SZn], while (D)-[Ci9H2iN304SZn] 
follows the order MPA > Asc > GSH > H2O2. 
To explore the mechanistic pathway of the cleavage activity, comparative DNA cleavage 
experiments of complexes (L)- and (D)-[Ci9H2iN304SZn] were carried out in presence of 
some standard radical scavengers such as DMSO and ethyl alcohol as hydroxyl radical 
scavenger (OH'), sodium azide (NaNa) as singlet oxygen ('O2) quencher and superoxide 
dismutase as superoxide anion radical {0{~) scavenger and were used prior to the addition of 
metal complexes to DNA solution (Figure 93). 
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Figure 93. Agarose gel electrophoresis pattern for the cleavage pattern of pBR322 plasmid 
DNA (300 ng) in the presence of different activating agents, ROS and groove binders at 310 K 
after 45 min of incubation in buffer (5mM Tris-HCl/50 mMNaCl, pH= 7.2) by (a) (a) (L)-
[Ci9H2iN30^SZnJ (35 ^iM) and (b) (D)-[Ci9H2jN304SZnJ (35 nM); Lane 1, DNA control; 
Lane 2, DNA + complex + H2O2 (0.4 M); Lane 3, DNA + complex + MPA (0.4 M); Lane 4, 
DNA + complex + GSH (0.4 M); Lane 5, DNA + complex + ASc (0.4 M); Lane 6, DNA + 
complex + DMSO (0.4 ^iM); Lane 7, DNA + complex + EtOH (0.4 ^iM); Lane 8, DNA + 
complex + NaN} (0.4 nM); Lane 9. DNA + complex + SOD (15 Units); Lane 10, DNA + 
complex + DAPI (8 /uM); Lane 11: DNA + complex + methyl green (2.5 //Z of a O.Olmg/ml 
solution). 
Upon addition of DMSO and ethyl alcohol (Lanes 6 and 7) to (L)- and (D)-
[Ci9H2iN304SZn], DNA cleavage was inhibited suggesting the possibility of hydroxyl radical 
as one of the active species. Thus, free radicals participate in the oxidation of the deoxyribose 
moiety, followed by hydrolytic cleavage of the sugar phosphate back bone in the absence of 
the scavengers [236]. On the other hand, addition of NaNs (Lane 8) did not attenuate the DNA 
strand scission indicative of non-involvement of singlet oxygen for DNA cleavage. However, 
superoxide dismutase SOD (lane 9) enhances the cleavage efficiency in both the complexes, 
displayed concomitant conversion of Form II to Form III. Therefore, an oxidative cleavage 
pathway of DNA by complexes (L)- and (D)-[Ci9H2iN304SZn] has been excluded and 
evidently the cleavage proceeds by a hydrolytic mechanism. 
The potential interacting site of complexes (L)- and (D)-[Ci9H2iN304SZn] was further 
explored in presence of the minor groove binder, DAPI and the major groove binder, methyl 
green. The DNA cleavage activity of (L)- and (D)-[Ci9H2iN304SZn] was inhibited in 
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presence of DAPI while it remained unaffected in the presence of methyl green (Figure 93, 
Lanes 10 and 11), indicating minor groove-binding preference of the complexes. 
T4 DNA ligase assay 
To ascertain the discernible hydrolytic DNA cleavage pathway mediated by complexes (L)-
and (D)-[Ci9H2iN304SZn], DNA religation experiment was further performed in which 
supercoiled pBR322 DNA was treated with T4 DNA ligase enzyme and subjected to gel 
electrophoresis [187] (Figure 94). 
Form l( 
Form I 
Figure 94. Agarose Gel electrophoresis pattern for the ligation pBR322 plasmid DNA 
linearized by complexes (L)~ and (D)-[Ci<jH2jN304SZnj: Lane 1, DNA control; Lane 2, 
pBR322 plasmid DNA cleaved by (L)-[CigHjiNsO^SZn] and; Lane 3, ligation of linearized 
pBR322 plasmid DNA by T4 DNA ligase, Lane 4, pBR322 plasmid DNA cleaved by (D)-
[C/()H2/N30^SZnJ, Lane 5, ligation of linearized pBR322 plasmid DNA by T4 DNA ligase. 
The complexes (L)- and (D)-[Ci9H2iN304SZn] yielded linearized DNA which was religated 
by using T4 DNA ligase enzyme. In our case, the nicked form (Form II) was relegated to a 
large extent in comparison to control DNA alone in supercoiled form, providing a direct 
evidence in favor of hydrolytic mechanism. 
Molecular Docking 
Molecular docking techniques are well-documented computational tool to understand the 
Drug-DNA interactions for the structure-based drug design and discovery, as well as in the 
mechanistic study by placing a small molecule into the binding site of the target specific 
region of the DNA mainly in a non-covalent fashion [209]. The enantiomers of chiral metal 
complexes (L)- and (D)-[Ci9H2iN304SZn] having different complementary shape that 
complements the groove curvature (isohelicity) and functional group placement and H-
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bonding groups acts as critical components for binding affinity and molecular recognition 
[252]. Herein, molecular docking studies of complexes (L)- and (D)-[Ci9H2iN304SZn] with 
DNA duplex of sequence d(CGCGAATTCGCG)2 dodecamer (PDB ID:1BNA) were 
performed in order to predict the chosen binding site along with preferred orientation of the 
molecules inside the DNA minor groove. The complexes adopted a characteristic shape and 
flexible enough to adopt a conformation which is complementary to the minor groove. The 
energetically most favorable conformation of the docked pose (Figure 95) revealed that (L)-
and (D)-[Ci9H2iN304SZn] located within central A-T (-10.8 A) rich regions of DNA in the 
minor groove compared to peripheral G-C (-13.2 A) ones, due to enantioselectivity and site-
specificity of complexes towards A-T region and leads to van der Waals interaction and 
hydrophobic contacts with DNA functional groups which define the stability of groove [210]. 
It is well known that the interactions of chemical species with the minor groove of B-DNA 
differ from those occurring in the major groove, both in terms of electrostatic potential and 
steric effects, because of the narrow shape of the former. In contrast to major groove small 
molecules preferentially interact with the minor groove due to little steric interference [211]. 
Moreover, minor groove-binding molecules generally have aromatic rings connected by 
single bonds that allow for torsional rotation in order to fit into the helical curvature of the 
groove [253]. There are H-bonds (2.8-3.0 A) between the -SH groups of penicillamine and 
C-2 carbonyl oxygen of T8 at a distance of 3.71 A. The resulting binding energy of docked 
metal complexes (L)- and (D)-[Ci9H2iN304SZn] were found to be -306.4, and -289.1 
KJmof', respectively, correlating well with the experimental DNA binding values. The more 
negative the relative binding energy, greatest the DNA binding propensity. Because, right 
handed chiral DNA being complimentary to L-form of the complex exhibits strong 
interactions via hydrogen bonding complimentary to its molecular symmetry [153]. Thus, we 
can conclude that there is a mutual complement between spectroscopic techniques and 
153 
molecular docked model, which can be substantiate our spectroscopic results and at the same 
time provides further evidence of groove binding. 
(a) (b) 
Figure 95. Molecular docked model of complexes (a) (L)-[CigH2iNsOS2n] and (h) (D)-
[Ci9H2iNs04SZnJ with DNA dodecamer duplex of sequence d(CGCGAATTCGCG)2 (PDB ID: 
IBNA). 
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Conclusion 
Two enantiomeric pairs of Zn(II) complexes of L/D-penicillamine and 1,10-phenanthroline 
(L)-[Ci9H2iN304SZn] and (D)-[Ci9H2iN304SZn] were synthesized and thoroughly 
characterized. Their in vitro DNA binding abilities were investigated by absorption, 
fluorescence, viscosity and CD measurements. The results supported the fact that both the 
enantiomeric forms of complexes (L)- and (D)-[Ci9H2iN304SZn], bind to CT DNA via 
electrostatic mode of interaction. The binding constant values clearly indicated the 
enantiopreferential binding of complex, (L)-[Ci9H2iN304SZn] over the (D)-
[Ci9H2iN304SZn]. The interaction studies of both the pairs of the complexes with 
mononucleotides suggested that the complexes prefer relatively facile A-T sequence to the 
G-C one exhibiting slight base pair specificity in binding to DNA. Both the complexes (L)-
and (D)-[Ci9H2iN304SZn] were able to promote DNA cleavage via hydrolytic mechanistic 
pathway with greater cleavage ability of L-form than the D-form in which the free radicals 
participate in the oxidation of the deoxyribose moiety, followed by hydrolytic cleavage of the 
sugar phosphate back bone in the absence of the scavengers; further supported by T4 DNA 
religation assay. Both the enantiomeric pairs of Zn(ll) complexes preferred the minor groove 
of the DNA helix. These findings were further supported by molecular docking experiments. 
CHAPTER VI 
Synthesis of enantiomeric Cu(II)/Ni(II) complexes of 
L/D-histidine and picolinic acid: in vitro DNA 
binding, PBR322 DNA cleavage and antimicrobial 
activity 
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Synthesis 
Synthesis of complexes 
(L)-[Ci2Hi4N40sCu] 
10 ml aqueous solution of picolinic acid (1.23 g, 10 mmol) was added to a methanolic 
solution (20 ml) of copper chloride dihydrate (1.70 g, 10 mmol). The mixture was stirred for 
10-15 min. To the resulting solution was added a methanolic solution (10 ml) of L-histidine 
(1.55 g, 10 mmol) pretreated with KOH (0.56 g, 10 mmol) and the resulting solution was 
stirred at room temperature for 2h. Blue colored solid was obtained which was filtered, 
washed with diethyl ether and dried in vacuo (Scheme 11). 
Yield: 73%, m.p. 192 °C. Anal. Calc. for Ci2H,4N405Cu (%): C, 40.28; H, 3.94; N, 15.66. 
Found: C, 40.92; H, 4.02; N, 15.89. Selected IR data (KBr, cm"', v): 3382 v(0-H)water, 3033 
v(N-H)His,idine, 1602 V(C=C)p,e„li„ic acid, 1 5 7 0 Vas(COO), 1 4 4 7 Vs(COO) , 1 3 3 8 v(C-N)pjeolin,c acid, 
850 5(H20). Molar Conductance, AM (DMSO); 13 i^'cm-moP' (non-electrolyte). UV-vis 
(MeOH, nm, e, Lmol'cm"'): 264 (11700), 636 (203) (d-d). ESI-MS {m/z^), 358 
[C,2H,4N405CU+H^]. 
(L)-[Ci2Hi4N40sNi] 
The complex (L)-[Ci2Hi4N405Ni] was synthesized following the procedure as outlined above 
for (L)-[Ci2Hi4N405Cu] from nickel chloride hexahydrate (2.37 g, 10 mmol) instead of 
CUCI2.2H2O. Green solid obtained which was filtered, washed with diethyl ether and dried />? 
vacuo. 
Yield: 59%, m.p. 183 °C. Anal. Calc. for C,2H,4N405Ni (%): C, 40.83; H, 4.00; N, 15.87. 
Found: C, 40.99; H, 3.92; N, 14.01. Selected IR data (KBr, cm"', v): 3386 v(0-H)water, 3035 
v(N-H)Hist,d,ne, 1 6 0 8 V(C=C)p,eol,n,c acd, 1571 Vas(COO), 1 4 4 9 V s ( C O O ) , 1 3 3 2 v(C-N)pi,o,in,c acd, 
847 5(H20). ' H N M R (400 MHz, DMSO-dg, 6, ppm): 9.01 (s,lH, -NH)Hist,dme, 8.29-7.98 (m, 
4H, aromafic H)picoiinic acid, 8.05 (d, IH, -CH)Hist,dine, 3.84 (t, IH, chiral -CH + -NH2)Histidine, 
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3.11 (d, 2H, -CH2)Histidine. '^ C NMR (100 MHz, DMSO-ds, 8, ppm): 181.8 (2C, carbonyl C), 
149.2 (IC, -C=N)picoiinic acd, 137.9-127.3 (5C, aromatic C)picoiinic add, 134.8 (IC, -CHWidine, 
120.2 (IC, -CH attached to chiral C)Histidine, 63 (IC, chiral C)Histidine, 34 (IC, -CH2)Histidine-
Molar Conductance, Au (DMSO): 11 Q~'cm^mor' (non-electrolyte). UV-vis (MeOH, nm, s, 
Lmor'cm"'): 257 (12300), 598 (126) (d-d). ESI-MS (m/z'), 354 [Ci2Hi4N405Ni+2ir]. 
(D)-[C,2Hl4N405Cu] 
The complex (D)-[Ci2Hi4N405Cu] was synthesized according to the procedure outlined 
above for the (L)-[Ci2Hi4N405Cu] with D-histidine (1.55 g, 10 mmol) instead of L-histidine. 
Blue colored soHd was obtained which was filtered, washed with diethyl ether and dried in 
vacuo. 
Yield: 61%, m.p. 197 °C. Anal. Calc. for C12H14N4O5CU (%): C, 40.28; H, 3.94; N, 15.66. 
Found: C, 40.56; H, 3.88; N, 15.76. Selected IR data (KBr, cm"', v): 3398 v(0-H)water, 3030 
v(N-H)Histidine, 1606 V(C=C)picolinic acid, 1572 Vas(COO), 1 4 8 8 V s ( C O O ) , 1 3 4 2 v(C-N)picolinic acid, 
842 5(H20). Molar Conductance, Au (DMSO): 17 Q'cm^moP' (non-electrolyte). UV-vis 
(MeOH, nm, s, Lmor'cm''): 262 (18300), 542 (223) (d-d). ESI-MS (m/z^), 360 
[Ci2H,4N405Cu+3H^]. 
(D)-[Ci2Hi4N405Ni] 
The complex (D)-[Ci2Hi4N405Ni] was synthesized according to the procedure outlined above 
for the (D)-[Ci2Hi4N405Cu] from nicicel chloride hexahydrate (2.37 g, 10 mmol) instead of 
CUCI2.2H2O. Green solid obtained which was filtered, washed with diethyl ether and dried in 
vacuo. 
Yield: 63%, m.p. 191 °C. Anal. Calc. for Ci2H,4N405Ni (%): C, 40.83; H, 4.00; N, 15.87. 
Found: C, 40.79; H, 4.23; N, 15.93. Selected IR data (KBr, cm"', v): 3395 v(0-H)water, 3027 
v(N-H)HisMne , 1604 v(C=C)p,colimc acid, 1 5 7 8 Vas(COO), 1 4 9 6 V s ( C 0 0 ) , 1 3 4 7 v(C-N)picol,nic acid, 
842 5(H20). ' H NMR (400 MHz, DMSO-dg, 8, ppm): 8.42 (s, IH, -NH)Histidine, 8.28-7.97 (m. 
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4H, aromatic H)picoiinic add, 8.18 (d, IH, -CH)Histidine, 3.81 (t, IH, chiral -CH + -NH2)HistKjine, 
3.09 (d, 2H, -CH2)Histidine. '^ C NMR (100 MHz, DMSO-dg, 5, ppm): 172.4 (2C, carbonyl C), 
146.6 (IC, -C=N>,coii„ic aod, 133.8-127.8 (5C, aromatic C)pjcoii„ic acid, 142.1 (IC, -CHWidine, 
117.5 (IC, -€H attached to chiral C)Histidine, 53.4 (IC, chiral C)Hisiid,„e, 25.6 (IC, -CH2)H,stid.ne. 
Molar Conductance, AM (DMSO): 15 Q"'cm^mor' (non-electrolyte). UV-vis (MeOH, nm, e, 
Lmol'cm"'): 259 (14200), 602 (142) (d-d). ESI-MS (w//), 353 [C,2H,4N405Ni+H^]. 
o. 
NH + 
OH MCI2.XH2O 
M= Cu/Ni 
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L/D-histidine Picolinic acid ^^ 
M=Cu, L-His (L)-(C,2H,4N405Cu] 
=Ni, L-His (L)-[C,2H,4N40sNi] 
=Cu, D-His (D)-[Ci2H,4N405Cu] 
=Ni, D-His (D)-[Ci2H,4N405Ni] 
Scheme 11: Synthetic route to complexes (L)-~fCi2HiJ^40sCuJ, (L)-[Ci2Hi4N405Ni], (D)-
[Ci2H,4N405Cu] and (DHCnHiiNiOsNiJ. 
Results and discussion 
The synthetic route of L/D-histidine enantiomeric Cu(II) and Ni(II) complexes (L)-
[C,2H,4N405Cu], (L)-[C,2H,4N405Ni], (DHC12HMN4O5CU] and (D)-[Ci2H,4N405Ni] is 
represented in Scheme 11. The complexes (L)-[Ci2Hi4N405Cu], (L)-[Ci2Hi4N405Ni], (D)-
[C12H14N4O5CU] and (D)-[Ci2Hi4N405Ni] were obtained as amorphous solids. The proposed 
structures were formulated on the basis of their elemental analysis, spectroscopic data (IR, 
NMR, ESI-MS, UV-vis and EPR) and molar conductance measurements. Complexes (L)-
[C,2H,4N405Cu], (L)-[C,2H,4N405Ni], (D)-[C,2Hi4N405Cu] and (D)-[Ci2H,4N405Ni] were 
soluble in DMSO and methanol. The molar conductance values for complexes (L)-
[C,2H,4N405Cu], (L)-[C,2H,4N405Ni], (D)-[C,2H,4N405Cu] and (D)-[C,2H,4N405Ni] in 
DMSO were observed in the range of 11-17 ^"'cm^mol"', suggesting their non-electrolytic 
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behavior. The energy minimized 3-dimensionai molecular structures of enantiomeric Cu(ll) 
complexes (L)- and (DHC12H14N4O5CU] are represented in Figure 96. 
(a) (b) 
Figure 96. The energy minimized cylindrical bonded 3-dimensional molecular structures of 
complex (a) (Lf[Ci2Hi4N40sCu] and (b) {D)-[Ci2Hi4N405Cu]. Color scheme: Nitrogen 
(blue), oxygen (red) Cu(II) (dark grey) and carbon (grey). Hydrogen atoms have been omitted 
for clarity. 
Infrared spectroscopy 
The IR spectra of the complexes (L>-[C,2H,4N405Cu], (LHCi2Hi4N405Ni], (D)-
[C|2Hi4N405Cu] and (DHC,2Hi4N405Ni] recorded in KBr at 400-4000 cm"'. The presence 
of L/D-histidine in complexes (LHC12H14N4O5CU], (L)-[Ci2Hi4N40sNi], (D)-
[C12H14N4O5CU] and (D)-[Ci2Hi4N405Ni] was manifested by the IR band of medium 
intensity at -3035 cm"', assigned to v(N-H) stretching vibrations. The broadness and 
relatively lower frequency from free L/D-histidine (3088 cm"') was indicative of the 
involvement of histidine -NH2 group in the formation of the complexes [254]. The 
asymmetric and symmetric -COO stretches in the complexes (L)-[Ci2Hi4N405Cu], (L)-
[Ci2Hi4N405Ni], (DHC12H14N4O5CU] and (DHCi2Hi4N405Ni] were observed at -1572 and 
-1447-1488 cm"', respectively and the Av value indicated monodendate carboxylation. The 
coordination of the N atom of picolinic acid was confirmed by the appearance of the 
absorption band at -1332-1347 cm"' characteristic of -€-N stretch in complexes (L)-
[C,2H,4N405Cu], (L>-[Ci2H,4N405Ni], (DHC,2Hi4N405Cu] and (D)-[C,2H,4N405Ni], 
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whereas in the in free picolinic acid the same vibrations appear at 1324 cm~' [255]. Further, 
the presence of v(0-H) stretching vibrations and the rocking mode of water at -3382-3398 
cm^ and -850 cm"', respectively, suggested the presence of the coordinated H2O in these 
complexes [256]. Other stretching vibrations of the ring v(C=C) is usually located at 1595 
cm"' in free picolinic acid which was shifted to 1602-1608 cm"' in the complexes [257]. 
NMR spectroscopy 
The assignment of the proton resonances was made by their peak multiplicity, intensity 
pattern and comparison of the integration values of the protons with the expected 
composition. The ' H NMR spectra of Ni(ll) complexes (L)- and (D)-[C|2Hi4N405Ni] 
recorded in D2O, exhibited a sharp singlet centered at 5 9.01 and 8.42 ppm, respectively 
which could be attributed to the -NH group of L/D-histidine (Figure 97) [258]. The presence 
of multiplet peaks at 8 8.29-7.97 ppm, indicates the presence of aromatic protons of picolinic 
acid. Other resonance signals at 5 -8.05 and -3.11 ppm corresponds to the -CH and -CH2 
proton of histidine moiety. The signal corresponding to the chiral -CH of histidine at 6 -3.84 
ppm merged with the -NH2 proton. The absence of-COOH signal at 5 12.0-13.0 ppm in the 
complexes (L)- and (D)-[C]2Hi4N405Ni], indicated the coordination of carboxylic group of 
both picolinic acid and L/D-histidine to Ni(II) through deprotonation [219]. 
(a) 
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Figure 97. 'H NMR spectra of complexes (a) (L)-[Ci2Hj4N405NiJ and (b) (D)-
[CnHuN.OsNi]. 
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The '^C NMR spectra of complexes (L)- and (D)-[Ci2Hi4N405Ni], exhibited characteristic 
signals of carbonyl group of at 5 181.8 and 172.47 ppm, respectively (Figure 98). Other peaks 
at 8 -149.2 ppm could be attributed to the -C=N carbon of picolinic acid moiety. Both the 
enantiomers of complexes exhibited aromatic carbon signals in the range of 5 137.9-127.3 
ppm. The appearance of signals at 8 -134.8, -120.2, -63 and -34 ppm which could be 
attributable to -CH, -CH attached to chiral carbon, chiral C and -CH2, respectively, 
confirming the presence of L/D-histidine moiety in the complexes. 
(a) (b) 
IWMilpMNM^ 
III 111 III 111 141 1 ] | U l l i t 111 II i l IB ID SI 41 31 JB ppm 
13 Figure 98. "C NMR spectra of complexes (a) (LJ-fCisHnN^OsNiJ arid (b) (D)-
[CuHuN.OsNi]. 
Mass spectrometry 
The formation of enantiomeric Cu(lI)/Ni(II)-histidine-picolinic acid complexes and the 
speciation of various ionic forms in water were studied by ESl-MS. The complexes (L)-
[C,2H,4N405Cu], (LHCi2Hi4N405Ni], (DHCi2H,4N405Cu] and (DHCi2Hi4N405Ni] 
exhibited molecular ion peak of significant intensity at m/z 358, 354, 360 and 353 
corresponding to [Ci2H,4N405Cu + H^], [Ci2H,4N405Ni + IYC], [C,2HI4N405CU + 'iW] and 
[Ci2Hi4N405Ni + H^], respectively. These complexes also exhibited other fragmentation 
peaks. Complex (L)-[Ci2Hi4N405Cu] exhibited peaks at m/z 335, 220 and 158 attributable to 
the fragments [C12H14N4O5CU - H2O - 4H^], [C12H14N4O5CU - H2O - picolinic acid + A\^] 
after the loss of picolinic acid moiety and [C12H14N4O5CU - H2O - picolinic acid - Cu + 3H^] 
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after the loss of Cu atom, respectively. The initial fi-agmentation is due to the loss of non-
coordinated water molecule. The complex (L)-[Ci2Hi4N405Ni] exhibited fi-agmentation peaks 
at m/z 335, 214 and 156 corresponding to [Ci2Hi4N405Ni - H2O - 2 l f ], [Ci2Hi4N405Ni -
H2O - picolinic acid + 2H^] and [Ci2Hi4N405Ni - H2O - picolinic acid - Ni + Pf], 
respectively following the same fi-agmentation pattern. Similarly I>-histidine Cu(II) and Ni(II) 
complexes (D)-[Ci2Hi4N405Cu] and (D)-[Ci2Hi4N405Ni], exhibited fragmentation peaks at 
m/z 336, 220 and 156 corresponding to fragments [C12H14N4O5CU - H2O - 3H^], 
[C12H14N4O5CU - H2O - picolinic acid + 4H^] and [C12H14N4O5CU - H2O - picolinic acid -
Cu + I f ] , respectively {for (D)-[Ci2Hi4N405Cu]} and at m/z 2\% and 156 which could be 
attributed to [Ci2Hi4N405Ni - H2O - picolinic acid + 6H^] and [Ci2Hi4N405Ni - H2O -
picolinic acid-Ni + H^], respectively {for(D)-[Ci2Hi4N405Ni]}. 
EPR spectroscopy 
The EPR spectra of Cu(II) complexes (L)- and (D)-[Ci2Hi4N405Cu] were recorded at room 
temperature and LNT under the magnetic field strength of 3000±1000G with 
tetracyanoethylene (TCNE) as a field marker (g = 0.0027). 
:iA (<j) 
/ 
Figure 99. X-band EPR spectra of complexes (L)-[Ci2Hi4N40}Cu] and (D)-[Ci2Hi4N40sCu] 
at room temperature (a and c) and LNT (b and d). 
The X-band EPR spectra of complex (L)-[Ci2Hi4N405Cu] consisted of a broad axial 
symmetrical signal with g\\ = 2.18, g i = 2.048 and gavg= 2.092 computed from the formula gav 
= 1/3 (g|| + 2g±). Similarly complex (D)-[Ci2Hi4N405Cu] also exhibited these values at g\\ = 
2.21, gi = 2.U and gavg = 2.16. These parameters are consistent with the octahedral geometry 
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of the Cu(II) complexes and are represented in Figure 99. The trend gy > g± > ge (2.0023) 
further confirmed that the ground state of the Cu(II) is predominantly dx%^ orbital. 
Electronic absorption spectroscopy 
The electronic spectra of the complexes (L)-[Ci2Hi4N405Cu], (L)-[Ci2Hi4N405Ni], (D)-
[Ci2H]4N405Cu] and (D)-[Ci2H)4N405Ni] in DMSO recorded an intense absorption band at 
264-257 nm attributed to n—>n*/7i—>7C* intraligand transitions associated to the amino acid 
(L/D-histidine) moiety [256]. The visible spectra of Cu(Il) complexes (L)- and (D)-
[C12H14N4O5CU] revealed d-d bands at 636 and 642 nm, respectively suggesting an octahedral 
geometry around Cu(II) metal ion [226]. While the visible spectra of Ni(Il) complexes (L)-
and (D)-[Ci2H]4N405Ni] exhibited peak with maximum ca. at 598 and 602 nm, respectively 
which may be assigned to ^A2g-^ ^Tig (F) (v )^ transition of nickel(II) ion in an octahedral 
environment [259]. 
DNA binding studies 
Absorption spectral titration 
The UV-vis spectra of Cu(Il) complexes (L)- and (D)-[Ci2Hi4N405Cu] exhibited an intense 
absorption band centered at 269 nm, attributable to intra-ligand n-^n* transition; on addition 
of increasing amounts of CT DNA (0.00-0.2 x 10"^  M) to a fixed concentration of complex 
(0.66 X 10 M), a significant hyperchromism and a blue shift was observed which suggested 
strong binding to CT DNA electrostatically via external contact (surface binding) with the 
DNA duplex [245]. Figure 100 shows the spectral changes in the electronic bands of the 
complexes (L)- and (D)-[Ci2Hi4N405Cu] upon addition of increasing amounts of CT DNA. 
The 'hyperchromic effect' is typical of cationic complexes involving ligands with the non-
covalent DNA interactions which include electrostatic and groove (surface) binding of 
cationic metal complexes outside of DNA helix, along major or minor groove [19,260]. 
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Figure 100. UV-vis absorption spectra of complexes (a) (LJ-fCuHi^N^OsCuJ and (b) (D)-
[C12H14N4O5CU] in Tris-HCl buffer (pH=7.2) upon addition ofCTDNA. Arrow indicates the 
change in absorbance upon increasing DNA concentration. Inset: Plots of [DNA] vs. 
[DNA]/Sa-£ffor the titration ofCTDNA with complexes. ([Complex] 0.66 x ICT^ M, [DNA] 
0.00-0.2 xJO-^M). 
In order to compare the binding strength of the complexes with CT DNA, the intrinsic binding 
constants, Kb were obtained by monitoring the changes in the absorbance for the complexes 
with increasing concentration of DNA. Kb is obtained from the ratio of slope to the intercept 
from the plot of [DNA]/(ea-Sf) vs. [DNA]. The Kb values for complexes (L)- and (D)-
[C12H14N4O5CU], are reported in Table 14. 
Table 14. The intrinsic binding constant (Kb) values of complexes with CT DNA (mean 
standard deviation of± 0.18). 
Complex Kb(]Vr') Monitored at % Blue shift 
(om) hyperchromism (nm) 
(LHC12H14N4O5CU] 5.6x10'' 
(DHCi2H,4N405Cu] 9.8x10^ 
269 
269 
42 
26 
4 
6 
The Kb values suggested that the L-enantiomeric Cu(II) complex possess greater propensity 
for binding to CT DNA than the D-enantiomeric form. The L-conformation of Cu(II) 
complex fits well with the right handed B-DNA due to their compatible molecular 
symmetry and therefore interacts intimately with it forming a two-pole complementary 
complex [246]. 
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Interaction studies with mononucleotide (5'-GMP) 
In order to evaluate the binding preference of enantiomeric Cu(II) complexes (L)- and (D)-
[C12H14N4O5CU], the interaction studies with 5'-GMP by UV-vis absorption titrations were 
carried out as Cu(II) complexes show preference specificity to bind to the N7 of the guanine 
of the DNA double helix. Intrinsic binding constant, Kb values were calculated and are 
reported in Table 15. As shown in Figure 101, the absorption spectra of complexes upon the 
addition of 5'-GMP exhibited 'hyperchromism' which is consistent with the predominantly 
electrostatic interactions. 
Table 15. The intrinsic binding constant (K/,) values of complexes with the 5'-GMP (mean 
standard deviation of± 0.16). 
Complex Kb(]vr') Monitored at (nm) Blue shift (nm) 
(LHCi2H,4N405Cu] 1.92x10' 
(DHCi2H,4N405Cu] 8.79 X 10^  
272 
272 
3 
2 
Wavi'lenglh (nm) Wavekngth (nm) 
Figure 101. Absorption spectral traces of complexes (a) (L)-[Ci2Hi4N40iCu] and (b) (D)-
[Ci2Hi4N40iCu] in Tris-HCl upon the addition of 5'-GMP. [Complex] 6.66 x 10~^ M, [5-
GMPJ 0-2.0X 10'M. 
To further validate our hypothesis of specific recognition, the interaction of complexes (L)-
and (D)-[Ci2Hi4N405Cu] with 5'-GMP was obtained by ' H and "'? NMR spectroscopy. 
Upon the addition of complex (LHC!2Hi4N405Cu], the guanine H8 signal observed at 5 8.1 
ppm in free 5'-GMP shifted to a broad peak at 5 8.23 ppm, also it recorded a decrease in the 
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intensity as compared to the of D-enantiomeric complex [C12H14N4O5CU] where the guanine 
H8 signal shifted slightly to 5 8.05 ppm (Figure 102a). Similarly, in the ^'P NMR spectra of 
5'-GMP upon addition of complex (L)-[Ci2Hi4N405Cu], the signal at 5 3.73 ppm in free 5 '-
GMP shifted to 8 4.16 ppm, while upon the addition of complex (D)-[C]2Hi4N405Cu] this 
signal shifted downfield to 6 3.91 ppm (Figure 102b).The differences in chemical shift values 
for two enantiomeric forms clearly highlight the biological preference of the (L)-enantiomeric 
Cu(ll) complex as compared to (D)-enantiomer. 
Marzilli et al. stated that the phosphate group interaction dominates the formation constant of 
metai-nucleotide complexes and the base portion plays a secondary role [261]. The changes 
in O-P-0 bond angles after its coordination with the complexes (L)- and (D)-
[C12H14N4O5CU] exhibit pronounced changes in ^'P chemical shift values revealing a strong 
coordination of the complexes with phosphate groups of nucleotide. 
(a) 
HO-P-O—I N 
o- py 
OH OH 
Figure 102. 'HNMR spectrum of (a) 5'-GMP (5 mmol), 5'~GMP with (LHC12H14N4O5CU], 
5'-GMP with (D)-[Ci2Hi4N405Cu] (2.5 mmol) (b) ^'P NMR spectrum ofS'-GMP (5 mmol), 
S'-GMP with (L)-[C,2Hi4N405CuJ, S'-GMP with (D)-fCi2Hi4N405CuJ (2.5 mmol) at 25 °C. 
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Fluorescence spectral studies 
Fluorescence spectral technique is an effective method to study metal interaction with DNA. 
Since, the enantiomeric Cu(II) complexes (L)- and (D)-[Ci2Hi4N405Cu] exhibited 
fluorescence at 370 nm in 0.01 Tris-HCl/50mM NaCl buffer when excited at 260 nm at 
physiological pH, fixed amounts of complexes (L)- and (D)-[Ci2Hi4N405Cu] were titrated 
with increasing amounts of CT DNA. The addition of CT DNA exhibited a gradual increase 
in fluorescence emission intensity which implied that complexes reveal strong interaction 
with DNA as illustrated in Figure 103. 
Wivei«igth (am) Wavdeogtli (omf 
Figure 103. Emission enhancement spectra of the complexes (a) (L)-[C 12H14N4O5CU] and (b) 
(D)-[Ci2Hi4N40iCu] with increasing concentration ofCTDNA in Tris-HCl buffer (pH=7.2). 
Arrow indicates change in intensity upon increasing concentration of complexes. Inset: Plots 
of r vs. r/Cp for the titration of CT DNA with complexes m, experimental data points; full 
lines, linear fitting of the data. [Complex] 6.66 x 10 M, [DNA] 0.66-4.0 x KT^ M. 
This increase in the emission intensity implies that both the enantiomeric forms of Cu(ll) 
complexes strongly interact with CT DNA probably due to the change in the environment of 
the metal complex and also related to the extent to which the complex gets into the 
hydrophobic environment inside the DNA [233]. Since the environment inside the DNA helix 
is hydrophobic it reduces the accessibility of solvent molecules at the binding site and thus 
preventing the quenching effect. Thus, it is evident that complexes were protected efficiently 
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by the DNA helix, leading to decrease in the vibrational modes of relaxation, and higher 
emission intensity. The binding constant, K values of the complexes (L)- and (D)-
[C12H14N4O5CU] were calculated from the plots of r/cfvs. r, were found to be 6.2 x 10"* and 1.1 
x lO'' IVr', respectively. 
Fluorescence quenching refers to any process, which is a decrease of the fluorescence 
intensity from a fluorophore due to a variety of molecular interaction. These include excited-
state reactions, molecular rearrangements, energy transfer ground-state complex formation, 
and collisional quenching. Quenching can occur by different mechanisms, which usually 
classified as dynamic quenching and static quenching; dynamic quenching refers to a process 
that the fluorophore and the quencher come into contact during the transient existence of the 
exited state. A steady-state competitive binding experiment of complexes (L)- and (D)-
[C12H14N4O5CU] using [Fe(CN)6] as an anionic quencher was carried out as the quencher 
may afford further information about the binding of the complex to DNA. In the absence and 
presence of DNA complexes (L)- and (D)-[Ci2Hi4N405Cu] were efficiently quenched by 
[Fe(CN)6] . But the emission intensity of complexes in the absence of DNA was lower than 
that in the presence of CT DNA under the same concentration of K4[Fe(CN)6]. This could be 
explained by the fact that the positively charged complex ions are readily quenched by 
[Fe(CN)6]''^, whereas the complex bound to CT DNA can be protected from the quencher due 
to the high repulsion between the negatively charged DNA phosphate backbone and highly 
anionic [Fe(CN)6]''~, thus hindering the emission of the bound complex [279]. Stem-Volmer 
plot of lo/I vs. [Fe(CN)6]'*~ for the complexes (L)- and (D)-[Ci2Hi4N405Cu] are illustrated in 
Figure 104. The Ksv values of enantiomeric complexes (L)- and (D)-[Ci2Hi4N405Cu] in 
absence of DNA were calculated to be 2.8 x lO'' and 9.2 x 10 ,^ respectively. While in the 
presence of DNA, Ksv values of complexes (L)- and (D)-[Ci2Hi4N405Cu] were found to be 
1.4 X lO'' and 7.9 x 10^ respectively. The greater decrease in Ksv value of L-enantiomeric 
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form of Cu(II) complex indicated its liigher DNA binding ability as compared to D-
enantiomeric form of Cu(]]) complex. 
|Fe(CN)j'' M 
Figure 104. Stern-Volmer quenching plots with K4fFe(CN)6] of (L)~[Ci2Hi4N40sCu] in the 
absence (u) and presence (m) ofCTDNA and (D)-[Ci2H,4N405Cu] in the absence (A) and 
presence (k) ofCTDNA. 
Viscosity measurements 
To order to depict the binding mode of the Cu(ll) complexes (L)- and (DHC12H14N4O5CU], 
viscosity measurements on the solutions of the CT DNA incubated with complexes have been 
carried out. In the case of classic intercalation, DNA base pairs are separated in order to host 
the bound compound, resulting in the lengthening of the DNA helix and subsequently 
increased viscosity. On the other hand, the binding of a compound exclusively in DNA 
grooves by means of partial and/or non-classic intercalation, under same conditions, causes a 
bend or kink in the DNA helix, reducing its effective length and, as a result, the DNA 
solutions viscosity is decreased or remains unchanged, i.e. groove binders and electrostatic 
1 n 
interaction do not lengthen the DNA molecules [262]. The plot of relative viscosity (r|/r|o) ' 
vs. 1/R is represented in Figure 105. Complexes (L)- and (DHC12H14N4O5CU] exhibited a 
decrease in the viscosity of DNA on increasing concentration of complexes suggesting an 
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electrostatic binding mode to DNA. These results were well corroborated with the UV-vis 
and luminescence spectroscopic studies. 
l/R = [Complexj/[DNA] 
Figure 105. Effect of viscosity of complexes (L)~[Ci2Hi4N405Cu] (red) and (D)-
[C12H14N4O5CU] (hlack) on the viscosity of CT DNA. Relative viscosity rj/tjo vs. l/R. 
[Complex] 0.2-1 x KT^M, [DNA] 10^M. 
Circular dichroic studies 
Circular dichroism is a spectroscopic technique widely used to study the binding mode and 
interaction affinity of small molecules, like metal compounds, with biomolecules, particularly 
with DNA [263]. The heterocyclic bases of DNA become chiral when placed within the 
framework of the chiral sugar-phosphate backbone, leading to a characteristic CD spectrum 
in the 200-300 nm range. Modifications of the CD signals in this spectral range have shown 
to be useful to detect and follow DNA conformational changes, damage and/or cleavage upon 
interaction with metal complexes. CT DNA shows the typical spectrum of a right-handed B-
form DNA that consists of two bands: a positive one at 275 nm due to the base stacking and a 
negative one at 245 nm due to the right-handed helicity. Usually, it is described that classical 
intercalation leads to changes in intensities of both bands due to enhancement of base stacking 
and stabilization of helicity, whereas simple groove binding and electrostatic interaction of 
small molecules produce low or no perturbation on the base stacking and helicity bands 
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[264.265]. The CD spectra of free and DNA bound complexes (L)- and (DHC12H14N4O5CU] 
are shown in Figure 106. Addition of CT DNA causes significant changes in the intensity of 
both the bands. The CD spectra of CT DNA in the presence of complex (LHC12H14N4O5CU] 
at 1:1 molar ratio showed a decrease in ellipticity of both the positive and negative bands 
While upon the addition of I>-form of the complex, the CD spectra of CT DNA exhibited an 
increase in both the bands. The circular dichroism pattern of two enantiomeric forms of the 
complex reveals different behavior on interaction with CT DNA and more pronounced 
changes were observed for L-enantiomeric form of the complex, consequently supporting its 
greater binding affinity. 
Figure 106. CD spectrum of CT DNA alone (black), in presence of complex (L)~ 
[C,2H,4N405Cu] (red) and (D)-[Ci2Hi4N40sCuJ (green). [Complex] 10"' M, [DNA] 10^" M. 
DNA cleavage assay 
To evaluate the DNA cleavage ability of L-enantiomeric Cu(il) complex (L)-
[C12H14N4O5CU], the supercoiled pBR322 plasmid DNA as a substrate was incubated with 
complex in a medium of 50mM Tris-HCl/NaCl buffer (pH=7.2) under physiological 
conditions for 30 min in the absence of any external agents. Figure 107 (Lanes 1-6) shows the 
treatment of pBR322 DNA with different concentrations of the complex (L>-[Ci2Hi4N405Cu] 
(Control, 20, 40, 60, 80 and 100 nM, respectively). The results showed that the L-
enantiomeric Cu(Il) complex cleaved the DNA on single strand. 
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Figure 107. The cleavage patterns of the agarose Gel electrophoresis diagram showing 
cleavage of pBR322 supercoiled DNA (300ng) by complex (L)-[Ci2Hu^40iCu] at 310 K 
after 30 min of incubation; Lane 1, DNA control; Lane 2, 20 fiM of (L)~[Ci2Hi4N405CuJ + 
DNA; Lane 3: 40 fiMoffLJ-fCuHi^.O^CuJ + DNA; Lane 4: 60 nMofiLHCuHi^N^OsCu] 
+ DNA; Lane 5: 80 fiM of (L)~[C,2H,4N405Cu] + DNA; Lane 6: 100 nM of (L)-
fCj2H!4N40iCuJ + DNA. 
The DNA cleavage activity of Cu(II) complex (LHC12H14N4O5CU] in presence of H2O2, 3 -
mercaptopropionic acid (MPA), ascorbate (Asc) and glutathione (GSH) was evaluated and the 
cleavage activity of complex (LHC12H14N4O5CU] was significantly enhanced by these 
activators where the activity followed the order GSH ~ MPA > Asc » H2O2 (Figure 108, 
Lanes 2-5), 
Formll 
FormlO 
Form I 
Figure 108. Agarose Gel electrophoresis pattern for the cleavage of pBR322 supercoiled 
DNA (300ng) by (L)-[Ct2Hi4N405Cu] in presence of different activating agents at 310 K after 
incubation for 30 min. Lane 1: DNA Control; Lane 2: 80 fjM of complex + GSH (0.4 M) + 
DNA; Lane 3: 80 nM of complex + MPA (0.4 M) + DNA; Lane 4: 80 nM of complex + ASc 
(0.4 M) + DNA; Lane 5: 80 jiiM of complex + H2O2 (0.4 M) + DNA; Lane 6: 80 fiM of 
complex + DMSO (0.4 M) + DNA; Lane 7: 80 ^ M of complex + EtOH (0.4 M) + DNA; Lane 
8: 80 /uM of complex + sodium azide (0.4 M) + DNA; Lane 9: 80 fiM of complex + SOD (15 
units) + DNA. 
In order to diagnose whether the cleavage mechanism followed a hydrolytic or oxidative 
pathway, DNA cleavage in the presence of different reactive oxygen species viz., singlet 
oxygen scavenger (NaNs), hydroxyl radical scavenger (DMSO and EtOH) and superoxide 
anion radical scavenger (SOD) was carried out. The experiments revealed that the hydroxyl 
radical inhibitor, DMSO and EtOH do not prevent DNA degradation (Figure 108, Lanes 6 and 
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7). In the presence SOD (Figure 108, Lane 8), no inhibition was observed and Form III was 
formed, ruling out the possibility of cleavage by superoxide [266]. While the presence of 
NaNa efficiently inhibited the DNA cleavage (Figure 108, Lane 9), suggesting the 
involvement of 'O2 (singlet oxygen) species in the DNA cleavage mechanism. These results 
suggested an oxidative pathway for DNA cleavage. 
To clarify other aspects of mechanism, groove binders such as methyl green and DAPl were 
used (Figure 109). The cleavage was inhibited in the presence of DAPI, suggesting that the L-
enantiomeric Cu(U) complex (L)-[Ci2Hi4N405Cu] prefers the minor groove of the DNA. 
These results are of significance as majority of oxidative cleavage reagents generally bind in 
the minor groove of the DNA than the major groove [236]. 
F&iittn 
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Figure 109. Agarose Gel electrophoresis pattern for the cleavage of pBR322 supercoiled 
DNA (300ng) by (L)-[Ci2Hi4N^05CuJ in presence of groove recognition elements. Lane 1: 
DNA control; Lane 2: 80 ^M of (LHCiiHi^N.OsCu] + DNA + methyl green (2.5 pL of a 
0.0Img/mlsolution), Lane 3: 80 fjMof(L)~fC!2Hi^405CuJ + DNA + DAPI(8 fiM). 
Molecular docking 
Molecular docking studies with DNA 
There has been increasing interest in docking methods to study binding of drug molecules to 
DNA. In our experiment, molecular docking studies of complex (L)-[Ci2Hi4N405Cu] with 
DNA duplex of sequence d(CGCGAATTCGCG)2 dodecamer (PDB ID: IBNA) was 
performed in order to predict the chosen binding site along with preferred orientation of the 
molecules inside the DNA groove. It is well known that the interactions of chemical species 
with the minor groove of B-DNA differ from those occurring in the major groove, both in 
terms of electrostatic potential and steric-hindrance, because of the narrow shape of the 
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former. In contrast to major groove small molecules preferentially interact with the minor 
groove due to little steric interference. Additionally, minor-groove binding molecules have 
aromatic rings connected by single bonds that allow for torsional rotation in order to facilitate 
into the curvature of groove with displacement of water molecules. The energetically most 
favorable conformation of the docked pose. Figure 110 revealed that (L)-[Ci2Hi4N405Cu] fits 
snugly into the curved contour of the targeted DNA in the minor groove and is situated within 
narrower A-T (-10.8 A) regions compared to G-C (-13.2 A) ones and slightly bends the 
DNA in such a way that a part of the planar aromatic rings of picolinic acid and the histidine 
moiety makes favorable stacking interactions between DNA base pairs and lead to van der 
Waals interaction and hydrophobic contacts with DNA functional groups that define the 
groove. The resulting binding energy of docked metal complex (L)-[Ci2Hi4N405Cu] was 
found to be -213.3 KJmor'. Thus, we can conclude that there is a mutual complement 
between spectroscopic techniques and molecular docked model, which can be substantiate our 
spectroscopic results and at the same time provides further evidence of groove binding. 
Figure 110. Molecular docked model of complex (Lj-[Ci2Hi4N40sCu] with DNA dodecamer 
duplex of sequence d(CGCGAATTCGCG)2 (PDB ID: J SNA). 
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Antimicrobial activity 
Several metal complexes have already shown their worth as antibacterial agents however, the 
role of chirality in this aspect is less explored. Therefore, in an attempt to clarify the 
relationship between the absolute configuration and the biological activities, the efficiencies 
of the L/D-enantiomeric Cu(II) complexes (L)- and (D)-[Ci2Hi4N405Cu] have been tested 
for antibacterial and antifungal activity. When the antimicrobial activity of metal complexes is 
investigated, the following principal factors [267] should be considered: (i) the chelate effect 
of the ligands; (ii) the nature of the N-donor ligands; (iii) the total charge of the complex; (iv) 
the nuclearity of the metal center in the complex. 
The antibacterial activity of these complexes were tested against two Gram-positive [S. 
aureus (ATCC 25923), B. subtilis (MTCC 121)] and two Gram-negative [E .coli (ATCC 
25922), P. aeruginosa (ATCC 27853)] and compared with reference drug (doxycycline). The 
agar well-diffusion method was used in these assays and each experiment was performed in 
triplicate (Figure 111) [268]. Readings of the zone of inhibition (mm) represents the mean 
value of three readings. The data shown in Figure 112 revealed that, the activity of complexes 
(L)- and (D)-[Ci2Hi4N405Cu] increase with the increase in the concentration of the 
complexes. The activity of complex (L)-[Ci2Hi4N405Cu], was comparable to the reference 
drug at the concentration of 1000 ^ig/mL. Such increase in the activity of the complexes can 
be explained on the basis of Overtone's concept [260] and chelation theory [270]. According 
to which, the lipid membrane that surrounds the cell favors the passage of only the lipid-
soluble materials which makes liposolubility as an important factor that controls the 
antibacterial activity. On chelation, the polarity of copper ion will be reduced to a greater 
extent due to the overlap of the ligand orbital and partial sharing of the positive charge of the 
copper ion with donor groups. Furthermore, the chelation increases the delocalization of TI-
electrons over the whole chelate ring and enhances the lipophilicity of the Cu(Il) complexes. 
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The results reveal that Cu(Il) complex (LHC12H14N4O5CU] exhibited greater antibacterial 
activity as compared to Cu(II) complex (DHC12H14N4O5CU], suggesting that the L-
enantiomer of the complex showed higher antibacterial activity than its D-counterpart. These 
results are in agreement with the literature reports that one enantiomeric form of the compelx 
exhibits greater antimicrobial activity than other enantiomeric form [271,272]. 
Figure 111. Antibacterial activity of complexes (a) (L)-[Ci2Hi4N40sCu] and (b) (D)-
fC;2H/^40sCuJ against S. aureus at different concentrations. The maximum zone is 
represented by reference drug (doxycycline). 
The enantiomeric Cu(II) complexes (L)- and (DHC12H14N4O5CU] were also screened for 
their antifungal activity against C. albicans and compared with reference drug (nystatin). The 
results given in Figure 112 demonstrated that both the enantiomeric Cu(Il) complexes (L)-
and (DHC12H14N4O5CU] exhibited good antifungal activity. 
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Figure 112. The antimicrobial activity of complexes (L)- and (D)-[Ci2Hi4N405CuJ at 
different concentrations (250, 500 and 1000 /jg/ml) as compared to the reference drug. 
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Conclusion 
This work describes tiie synthesis and characterization of asymmetric (L)- and (D)-
[C12H14N4O5CU] and (L)- and (D)-[Ci2Hi4N405Ni] complexes, derived from L/D-histidine 
and ancillary ligand-picolinic acid. Copper-histidine ternary complexes are a prominent class 
of therapeutic agents which show a different mechanism of action as compared to platinum 
metal ion (copper is an essential bio-element and histidine is present in the active centers of 
many enzymes in the living systems). De novo synthetic strategy of new chemical entities 
from histidine imidazolyl groups tethered with biologically significant organic scaffold-
picolinic acid can be explored for designing robust chemotherapeutic agents. Since 
enantiomeric compounds have proven their superior efficacy as drugs than the racemate forms 
in the pharmaceutical industry; therefore two enantiomeric forms of the complexes were 
synthesized to evaluate their enantiomeric discrimination on the DNA binding ability. The 
present study demonstrates that studying the enantiomeric forms of biologically active Cu(Il) 
complexes can provide a rationale for potent, safe and efficacious drug design therapy The 
comparative in vitro DNA binding studies of Cu(ll) complexes (L)- and (DHC12H14N4O5CU] 
was investigated by absorption, fluorescence, viscosity and CD measurements and the results 
revealed enantiopreferential binding of the complexes via electrostatic binding mode to the 
DNA double helix. Discernible differences were observed in the interaction of the different 
enantiomers of Cu(ll) complex with DNA; notably, (L)-form of complex exhibited higher 
binding affinity than the (D)-fonn towards CT DNA, clearly attenuating the profound 
influence of chirality of the complexes on the DNA. 
Interaction between the complex (L)-[Ci2Hi4N405Cu] with pBR322 plasmid DNA evaluated 
by agarose gel electrophoresis revealed that the Cu(ll) complex binds to double-stranded 
pBR322 DNA possibly in the minor groove and displays efficient cleavage of supercoiled 
DNA. The involvement of 'O2 (singlet oxygen) species in the DNA cleavage mechanism 
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suggested that the DNA cleavage followed an oxidative pathway. Further the molecular 
docking studies confirmed the binding of (L)-[Ci2Hi4N405Cu] in the minor groove of the 
DNA. These enantiomeric Cu(II) complexes were evaluated for their use as antimicrobials 
and the antimicrobial activity results revealed that the L-form of Cu(II) complex exhibited 
higher activity as compared to the D-form of Cu(II) complex. The L-form of Cu(II) complex 
was found to exhibit distinctive features viz., i) displayed outstanding DNA binding 
capability, ii) exhibit target-specificity (binding to N7 of guanine), iii) exhibited efficient 
oxidative cleavage activity involving 'O2 (singlet oxygen) species, iv) displayed good 
antimicrobial acfivity. 
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